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Abstract
Human hypertension is a multifactorial disorder affecting up to 20% of the 
population of developed countries. The hypertensive phenotype varies between 
individual s and both environmental and genetic factors may be important in 
determining an individuals blood pressure. Although the majority of cases of 
hypertension are labelled as primary (or essential) implying that the aetiology of the 
hypertension is unknown, a genetically inherited form of hypertension, 
glucocorticoid-suppressible hyperaldosteronism (GSH), has been characterised 
and studied in detail in this thesis.
GSH is an inherited form of hypertension characterised by elevated plasma 
aldosterone concentrations with suppression of plasma renin activity, hypertension, 
hypokalaemia, and an autosomal dominant mode of inheritance. A chimeric 116- 
hydroxylase/aldosterone synthase gene has been described in patients with GSH. 
This gene, presumably a result of unequal crossing-over at meiosis, has ACTH- 
inducible aldosterone synthase activity demonstrable in vivo which explains the 
observed clinical and biochemical phenotype of GSH.
A technique for detection of individuals with GSH was devised based on the 
detection of the chimeric gene by probing of a Southern blot of Bam HI digested 
genomic DNA. Normal individuals possess two hybridising species, a 8.4 kb band 
(110-hydroxylase, CYP11B1) and a 4.4 kb band (aldosterone synthase, CYP11B2) 
when probed with a 32P-labelled CYP11B1 exon 2-5 probe . Affected individuals 
possess the two normal bands and a third 6.3 kb band corresponding to the 
chimeric gene. This method was used to screen five kindreds affected by GSH and 
to detect 19 affected individuals.
Treatment of affected individuals with the oral glucocorticoid dexamethasone 0.5 
mg q.d.s. resulted in a fall in blood pressure and plasma aldosterone 
concentrations, and a normalisation of plasma renin concentration and statistically 
significant rise in plasma potassium concentration. Further evaluation of kindreds 
with GSH revealed a wide variation in the clinical phenotype of GSH, particularly in 
terms of blood pressure.
A novel observation on the role of parental origin of the disease gene was made. 
Patients inheriting the chimeric gene from their mother had higher blood pressures 
and higher plasma aldosterone concentrations than those inheriting the condition 
from their father.
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The exact nucleotide sequence of the chimeric genes in the 5 kindreds was 
determined by the dideoxy- chain termination method. Three kindreds possessed 
chimeric genes indistinguishable by sequencing, whilst the other two kindreds had 
unique crossovers. All crossover events occurred within the exon 3 - intron 4 
region of the chimeric genes, in keeping with previously published observations. 
The structure of the chimeric gene, i.e. the position of the crossover site, has no 
effect on the clinical phenotype.
In addition to determining the site of the crossover region in the kindreds, a diallelic 
polymorphism in the promoter region of the aldosterone synthase gene was 
identified. The C/T single nucleotide polymorphism lies within the Steroidogencic 
Factor-1 binding region of the promoter at position -340. One allele of this 
polymorphism was shown to be in linkage disequilibrium with GSH suggesting a 
degree of allelic bias in the origin of the chimeric genes causing GSH.
Individuals with GSH show impaired basal and ACTH-stimulated 11 3-hydroxylation 
ability compared with normal controls. Basal molar plasma ratios of DOC:B and 
S:F are raised in patients with GSH, but ACTH-stimulation results in differential 
effects on the 17-hydroxy- and 17-deoxy- pathways. In the 17-hydroxy- pathway 
(cortisol synthesis) the impaired 113-hydroxylation is exacerbated by ACTH, 
whereas in the 17-deoxy- pathway (aldosterone synthesis) ACTH stimulation acts 
to rectify the abnormality. Basal molar plasma B:ALDO ratio (an index of 
aldosterone synthase activity) was lower in patients with GSH than controls. ACTH 
stimulation resulted in a rise in B:ALDO ratio in patients with GSH and a fall in 
normal controls. The reasons for the observed differences are unclear but may 
arise as a result of pseudosubstrate inhibition of 113-hydroxylation by compounds 
such as 18-hydroxycortisol, or as a result of altered gene expression in the adrenal 
cortex in GSH.
Finally, a study of the effect of lifelong hyperaldosteronism on 
echocardiographically determined left ventricular mass index was performed. The 
study revealed that GSH did not predispose to premature or excessive left 
ventricular hypertrophy despite evidence that aldosterone can produce myocardial 
fibrosis. However, a significant positive correlation between left ventricular mass 
and plasma aldosterone concentration in patients with GSH was noted.
The study of GSH provides a framework for assessing the possible factors involved 
in the development of human essential hypertension. The observations contained 
in this thesis shed light on how a single gene disorder may cause hypertension and 
how other factors such as intrauterine influences may modulate the genetic
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component of hypertension. Further studies of GSH may reveal the mechanisms 
underlying altered corticosteroidogenesis in essential hypertension.
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Chapter 1
Introduction
1.1 Blood Pressure: Overview
It is over 300 years since William Harvey first correctly described the circulation of 
blood (Harvey, 1949) and some 250 years since the Reverend Stephen Hales 
made the first quantitative measure of blood pressure by inserting a brass tube in 
to the crural artery of a horse and connecting this to a vertical glass tube to 
observe that the value was 8 feet 3 inches (Hales, 1733). Important as the 
observation of Hales was, it was clearly not a practical method for application to 
the study of the blood pressure in man and it was another 172 years before 
Korotkoff reported a reliable, simple and reproducible method of measuring systolic 
and diastolic blood pressure in man using an inflatable cuff to compress an upper 
limb artery and listening to the sounds created by the arterial flow on release of the 
compression (Korotkoff, 1905).
Ninety years on from Korotkoff's initial observations, his is still the principal method 
of measuring blood pressure in man. However, almost every other aspect of our 
understanding of the circulation and its pathology has advanced by a considerable 
degree. Advances, initially in the clinical description of the effects of untreated high 
blood pressure, then in its physiology and biochemistry and most recently in the 
molecular biology and genetics of the cardiovascular system have led to a 
revolution in our understanding of high blood pressure. Observations in large 
populations of the effects of high blood pressure have identified hypertension as a 
major health problem in the developed world and have highlighted the importance 
of treating high blood pressure to minimise its consequences.
1.2 The Importance of Human Hypertension
In the majority of developed countries the leading cause of death is cardiovascular 
disease (Whelton, 1984). In addition, cardiovascular disease is a principal cause of 
major morbidity, loss of income and social disruption (Stamler et al., 1986). There 
are many "risk factors" for cardiovascular disease, i.e. factors affecting an 
individual which can influence his or her chance of developing cardiovascular 
disease, one of the most important of which is blood pressure. Blood pressure is of 
particular importance because it is one risk factor which can be modified with 
relative ease by the use of medication with consequent benefits for the individual 
(Stamler et al, 1986).
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1.2.1 Prevalence of Hypertension
There has always been controversy surrounding the definition of hypertension, 
particularly in regard to the distribution of blood pressure in the population. Platt 
argued that hypertension was an entity distinct from normotension whilst Pickering 
argued that blood pressure was a continuous spectrum and hypertension was a 
quantitative deviation from the norm (Pickering, 1961, Platt, 1959). Time has borne 
out Pickering's arguments. Therefore, when examining the blood pressure 
spectrum it has been difficult to decide where hypertension begins.
Any distinction between hypertension and normotension is therefore arbitrary and 
one disadvantage of labelling the remainder of the population as normotensive is 
that the normotensive group are assumed to be at no risk from cardiovascular 
disease which is not true since the risk of blood pressure-related cardiovascular 
disease increases throughout the range of normal blood pressure (Working Group 
on Primary Prevention, 1994). In the United States the prevalence of hypertension, 
as defined by the Fifth Report of the Joint National Committee on Detection, 
Evaluation, and Treatment of High Blood Pressure, has been reported by the Third 
Health and Nutritional Examination Survey of the National Centre for Health 
Statistics (Joint National Committee, 1993) (Table 1.2 a). This group defined an 
individual as hypertensive if his or her systolic blood pressure is >= 140 mmHg and 
diastolic blood pressure is >= 90 mmHg, the readings being the mean of three 
readings taken on a single visit. Using the cut-off points in this study the 
prevalence of hypertension rises dramatically from 4% at 18-29 years to 65% at 
>80 years. These blood pressure measurements could represent a considerable 
overestimate of the prevalence of hypertension because they are taken on a single 
visit, but it has been shown that even a single measurement of blood pressure has 
prognostic significance (Stamler et al, 1986).
Table 1.2 b lists the prevalence of hypertension in the United States when a more 
conservative definition of hypertension (systolic blood pressure >=160 mmHg, or 
diastolic blood pressure >=95 mmHg) similar to that used in the United Kingdom 
(Gordon, 1964). The estimates of overall prevalence from this survey are less than 
the corresponding age-specific estimates in Table 1.2 a, but in both cases there 
was a clear association between age and prevalence of hypertension. Of particular 
interest in this regard is the change in nature of the hypertension in the different 
age groups. Young hypertensives tend to have raised diastolic blood pressures 
whilst elderly hypertensives have raised systolic blood pressures with little or no 
elevation in diastolic pressures.
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Indeed, by the end of the seventh decade, isolated systolic hypertension accounts 
for more than 60% and 70% of the hypertension seen in men and women, 
respectively (Whelton et al., 1994).
Age in Years 1 Percentage Hypertensive
i "  ................... ......... ............................................................................
18-29 _ . . . . « 4
30-39 l 11
40-49 I 21
50-59 l 44
60-60 54
70-79 11.... 64
>80 II 65
Table 1.2 a Prevalence of hypertension a by age in the general population of the United 
States, 1988-91. Adapted from (Joint National Committee, 1993)
Age (years) Male | Female
I
18-24 1.6 n i 1.2
25-34 4.8 | 3.1
35-44 13.4 I 8.3
45-54 19.0 | 17.9
55-64 23.4 || 30.4
65-74 30.3 49.8
75-79 41.7 || 46.0
Table 1.2 b Prevalence (%) of adult male and female residents of the United States with 
definite hypertension b as classified before the wide spread use of antihypertensive 
medications. Adapted from (Gordon, 1964)
1.2.2 Incidence of Hypertension
There are relatively few studies which provide information on the incidence of 
hypertension in the general population. However, these studies do suggest a 
consistent tendency for incidence to rise with age (Andre et al., 1982, Buck and 
Donner, 1987, Dannenberg et al., 1988, Dunn et al., 1970, Garrison et al., 1987, 
Paffenberger et al., 1983). Typically, the annual incidence of hypertension has 
been less than 1-2% in the second and third decades rising to 4-8% in the sixth 
and seventh decades (Andre et al, 1982, Buck and Donner, 1987, Dannenberg et 
al, 1988, Garrison et al, 1987, Paffenberger et al, 1983). This incidence is affected 
by other factors such as body weight, gender, alcohol intake and physical activity
a Average of three blood pressure measurements, at a single visit, >=140 mmHg systolic, or 90 
mmHg diastolic, or current treatment with antihypertensive drugs. 
b Systolic BP >= 160 mmHg or diastolic >=95 mmHg
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and accruing evidence suggests that weight reduction, increased physical activity 
and reduction of alcohol intake can reduce the incidence of hypertension 
(Dannenberg et al., 1987, Working Group on Primary Prevention, 1994).
1.2.3 Morbidity and Mortality from Hypertension
As stated previously, hypertension is a major cause of morbidity and mortality in 
the developed countries of the world (Whelton, 1984). Blood pressure has been 
identified as the major reversible risk factor for cerebrovascular accidents (CVA) 
and as an important modifiable risk factor in the genesis of myocardial infarction 
(Kannel and Stokes, 1985). In addition, elevated blood pressure leads to a variety 
of so-called "end-organ" effects, i.e. the presence of hypertension has deleterious 
effects on a number of important tissue in the body exposed to the elevated 
pressure. Organs susceptible to the effects of hypertension include the heart, 
kidney, retinal vessels, the cerebral circulation and the systemic arterial circulation 
in general. Table 1.2 c lists the potential effects of hypertension on various organs. 
The effect of prolonged elevation of blood pressure on the primary incidence of 
stroke and has been estimated from the pooled data of 9 prospective observational 
studies (MacMahon, 1994). These studies have shown that the association 
between blood pressure and stroke is relatively constant throughout the full range 
of blood pressures, i.e. the risk of stroke at a given level of blood pressure rises in 
proportion to the level of blood pressure studied. In addition, these studies 
suggested that there was no lower limit of blood pressure associated with a 
reduced risk of stroke and that even in individuals with blood pressure levels 
regarded as normotensive there was a direct relationship between blood pressure 
level and stroke risk (MacMahon, 1994). If an individual has a 5mm Hg lower 
diastolic blood pressure accompanied by a 9mm Hg lower systolic pressure the 
risk of stroke is 34% lower whereas a 10mm Hg lower diastolic pressure 
accompanied by an 18-19mm Hg lower systolic pressure confers a 56% reduction 
in the risk of stroke (Table 1.2 d).
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Organ Effect
Brain Microaneurysm formation in arterioles resulting in
small areas of cerebral infarction, major areas of 
cerebral haemorrhage leading to disability and death, 
hypertensive encephalopathy 
Heart Left ventricular hypertrophy, ventricular
dysrhythmmias, heart failure 
Kidney sclerosis of arterioles with no clinical sequelae,
progressive renal impairment, acute renal failure 
in malignant phase hypertension 
Retinal Vessels Minor thickening of arterioles with narrowing of
vessel lumen, leakage of plasma and ischaemia 
of retina, vascular occlusion (arterial and venous) 
with loss of sight
Arterial Circulation Generalised arteriosclerosis, thickening of arterial
media, dissection of aorta.
Table 1.2 c Effects of hypertension on end-organ tissues in man.
A similar analysis of the effect of blood pressure on the incidence of coronary heart 
disease (CHD) revealed a trend in the incidence of CHD events and blood 
pressure level similar to that observed for stroke disease, although the slope of the 
association was less steep and there was the same trend in risk of CHD events 
throughout the normotensive range of blood pressure.
Difference in Difference in risk of
SBP I DBP Stroke || CHD
l
9 I 5 34% 21%
14 I 7.5 46% II 29%
19 I 10 56% I 37%
Table 1.2 d Estimates of percentage differences in stroke and coronary event risk associated 
with prolonged differences in systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) adjusted for age, smoking and blood cholesterol. Adapted from (MacMahon, 1994).
The analysis of CHD events showed that if an individual has a 5mm Hg lower 
diastolic blood pressure accompanied by a 9mm Hg lower systolic pressure, the 
CHD event risk is 21% lower whereas a 10mm Hg lower diastolic pressure
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accompanied by an 18-19mm Hg lower systolic pressure confers a 37% reduction 
in the risk of CHD (Table 1.2 d).
The effect of prolonged hypertension on the incidence of heart failure is also 
considerable. A blood pressure in the hypertensive range (systolic BP >= 160, 
diastolic BP >= 95 mmHg) is associated with a six-fold increase in risk of heart 
failure compared to normotensive subjects (Stokes et al.f 1989). Similarly, an effect 
of blood pressure on the incidence of peripheral vascular disease (incidence in 
hypertensive group twice that in normotensive group) (Hughson et al., 1978) and 
renal impairment have been detected (Lindeman et al., 1984). These risks can 
perhaps be better appreciated in terms of the number of deaths due to stroke and 
CHD that could be avoided by a 9/5 mm Hg reduction in population (Table 1.2 e) 
(Wagner et al., 1991, World Health Organisation, 1991, World Health Organisation, 
1992).Any means of producing a significant reduction in the prevalence of 
hypertension and/or lowering the blood pressure of the general population should 
lead to a significant reduction in the incidence of stroke and coronary disease.
Deaths avoided by 
Annual mortality 9/5 mm Hg reduction
in population BP*
Country | Stroke ] CHD I Stroke || CHD
I
UK | || 76308 || 169481 26000 || 36000
USA || I 149972 509412 I 51000 || 107000
Table 1.2 e Annual mortality from stroke and coronary disease, and number of deaths likely 
to be avoided by a reduction in population blood pressure of 9/5 mm Hg (MacMahon, 1994). 
*Based on the risk reduction stated in Table 1.2 d. Adapted from (MacMahon, 1994)
1.2.4 Effect of Drug Treatment on Hypertension
There have been many trials of drug therapy in hypertension, initially in the 
treatment of so-called malignant phase hypertension, i.e. hypertension associated 
with end-organ damage, rapid deterioration in renal function and a high mortality (2 
year survival 8%), and subsequently severe hypertension, i.e. a systolic blood 
pressure >-180 mmHg and a diastolic blood pressure >=105 mmHg, associated 
with lesser degrees of end-organ damage and lesser mortality (Harrington et al., 
1959, Hodge et al., 1961, Sokolow and Perloff, 1960). These trials showed that 
drug therapy reduces the risk of death, stroke and to a lesser extent, coronary
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disease. The effect of drug treatment on the reduction of stroke and CHD event 
risk in individuals with less severe forms of hypertension has been less 
encouraging. Drug treatment of mild-moderate high blood pressure by a variety of 
treatments, principally diuretics and 13-blocker drugs, has been assessed by a 
number of trials. A meta-analysis of these trials has shown that lowering of diastolic 
blood pressure by an average of 6 mm Hg leads to a reduction in stroke incidence 
(fatal and non-fatal) of 38% and a reduction in CHD event incidence of 16%
(Collins and Peto, 1994, Collins et al., 1990).
From the above data it can be appreciated that the burden of disease attributable 
to blood pressure is considerable and the reduction of this burden by drug 
treatment is limited. An understanding of the cause of hypertension may lead to a 
more rational framework for the treatment and prevention of hypertension and its 
consequences.
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1.3 Causes and Classification of Hypertension
Hypertension is clearly a common and important problem. However, the underlying 
cause in the majority of cases of hypertension is unknown, so-called 'essential' or 
'primary' hypertension. This group constitutes the vast majority of all cases of 
hypertension and accounts for between 95-99% of all cases of hypertension. The 
remaining cases are classified as 'secondary' hypertension, i.e. hypertension is the 
consequence of some biochemical or mechanical pathology which is potentially 
reversible and the hypertension curable.
1.3.1 Secondary Hypertension
Secondary causes of hypertension are relatively uncommon and published series 
have reported a prevalence of 1.1-11.0% (Berglund et al., 1976, Gifford, 1969, 
Lewin et al., 1985, Sinclair et al., 1987). The wide variation in prevalence takes into 
account the different populations investigated (Table 1.3 a).
Screening those patients referred to a specialist clinic with refractory hypertension 
is likely to yield a greater number of secondary cases than screening the general 
population just as screening an entire population will involve screening many 
normotensive as well as hypertensive individuals and thus lessen the diagnostic 
yield of the procedure.
(Gifford, 1969) (Berglund et al, 
1976)
(Lewin et al, 
1985)
(Sinclair et al, 
... 1987)
Patients 4939 689 5485 3783
Source Referred Population
Screen
Population
Screen
Referred
Secondary HT 11 5.8 1.1 7.9
Renal 54 3.6 1.0 5.6
Renovascular 4.5 0.6 0.1 0.7
Aldosteronism 0.5 0.1 0.1 0.3
Pill - - 0.1 1.0
Table 1.3 a Prevalence (percentage) of secondary hypertension in four published series. HT - 
hypertension, Aldosteronism - Primary Hyperaldosteronism, Pill - Oral Contraceptive Pill.
Similarly, the form of the screening test will affect the estimation of the prevalence 
of a particular cause in the screened population, e.g. intravenous urography will fail 
to detect very few cases of renal artery stenosis but will over-estimate the
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incidence in a clinic population and underestimate the incidence in the general 
population (Sinclair et al, 1987). However, most estimates agree that secondary 
hypertension is uncommon although the causes are many. The majority of causes 
of secondary hypertension are due to hormone excess, renal disease or to some 
vascular disease such as renal artery stenosis or coarctation of the aorta (Table
1.3 b).
Many of these conditions illustrate the effects of the extremes of physiology with 
respect to the physiological system involved. For example, in cases of 
phaeochromocytoma excessive catecholamine secretion from the adrenal gland 
results in a constellation of signs and symptoms which are an exaggeration of the 
physiological effects of catecholamines in vivo (Hall and Ball, 1992).
Given the potential for these gross abnormalities of the mechanisms controlling 
blood pressure to give rise to hypertension, it is conceivable that less severe 
alterations in the physiology of those systems which regulate blood pressure might 
be responsible for causing the more common form of essential hypertension.
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Organ Example
Kidney Autosomal Dominant Polycystic Disease 
Renal Parenchymal Disease, 
e.g. chronic glomerulonephritis, chronic 
interstitial nephritis, reflux nephropathy, 
analgesic nephropathy, amyloidosis
Arteries Renal Artery Stenosis - either uni- or 
bilateral, e.g. atheromatous or secondary 
to fibromuscular dysplasia
Adrenal Medulla - Phaeochromocytoma
Cortex - Cortisol overproduction
i.e. ACTH producing pituitary tumour,
ectopic ACTH production, cortisol-secreting
adrenal tumour
Aldosterone overproduction
i.e. Adrenal adenoma (Conn's Syndrome),
idiopathic hyperaldosteronism, glucocorticoid
suppressible hyperaldosteronism
Inborn errors of metabolism, i.e. 1113-hydroxylase
deficiency, 17a-hydroxylase deficiency, apparent
mineralocorticoid excess
Drugs Oral contraceptive pill,
glucocorticoids, e.g. prednisolone, dexamethasone, 
mineralocorticoids, e.g. 9a-fludrocortisone, 
cyclosporine, non-steroidal anti-inflammatory drugs, 
erythropoietin, Liquorice and carbenoxolone
Others Acromegaly, Hyperthyroidism, Acute intermittent 
porphyria, Raised intracranial pressure 
Rare tumours - renin, angiotensin, endothelin and 
medullolipin-secreting tumours have hypertension as 
a feature of the syndrome
Table 1.3b Secondary causes of hypertension
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1.3.2 Essential Hypertension
Essential hypertension (Primary hypertension) is the name given to the most 
common form of hypertension. This accounts for >95% of all cases of hypertension 
and excludes all those forms where a remediable cause can be found (Table 1.3 
b). Thus, diagnosis is a negative process. In an attempt to provide a positive basis 
for diagnosis the physiology of virtually every human biological system described 
has been studied in hypertensive patients. Many have been found to be deranged 
when compared with normal subjects. Indeed, many types of secondary 
hypertension represent extremes of the physiological norm and similar but milder 
abnormalities can be demonstrated in patients with essential hypertension, e.g. 
steroid 11 B-hydroxylase deficiency in children with hypertension and impaired 116- 
hydroxylase activity in patients with essential hypertension. A complex interaction 
of environment, in particular dietary electrolyte intake, genetic background and 
lifestyle appear to determine the lifetime risk of hypertension.
Below is a brief account of some of the factors thought to be important in the 
pathogenesis of hypertension. Evidence of genetic influences is summarised in 
1.4.
1.3.3 Overview of essential hypertension
Essential hypertension is a multifactorial disorder thought to be caused by the 
interaction of an individual's genetically determined risk of developing hypertension 
with his or hers environment, including diet, intrauterine environment and other 
modifiable factors (Swales, 1994).
Environmental influences have been assessed in detail in hypertensive populations 
and factors such as high dietary sodium intake, obesity, excessive alcohol intake, 
lack of exercise and psychosocial stress have all been implicated as potentially 
reversible risk factors in the development and maintenance of hypertension 
(Swales, 1994). These may account for some of the population-dependant 
variations in blood pressure observed. For example, the high sodium intake of 
Japanese populations results in a high proportion of hypertensive subjects 
whereas in the USA where salt intake is lower, other factors such as obesity may 
play a greater role in the development of hypertension (Swales, 1994). These 
factors together with certain genetic factors (See 1.4) may be considered as 
primary determinants, i.e. they are directly responsible for the elevation of blood 
pressure, in contradistinction to secondary phenomena. Secondary phenomena 
are those abnormalities of physiology, biochemistry and molecular biology found in
30
hypertensive but not in normotensive people which may be a consequence the 
hypertensive state and which may amplify the blood pressure response, e.g. 
vascular hypertrophy.
An example of a consequence of hypertension is left ventricular hypertrophy, whilst 
other examples of secondary phenomena include enhanced activity of the 
sympathetic nervous system, and increased lipid membrane viscosity. In addition, 
chronic elevation of arterial pressure also leads to hypertrophy of arterial 
resistance vessels in hypertension (Folkow, 1978, Folkow, 1982).
It is not easy in some cases to distinguish primary and secondary roles and some 
systems may contribute in both capacities. For example, a case has been made for 
vascular hypertrophy as the primary cause of hypertension (Folkow, 1978, Folkow, 
1982).There is strong evidence of both primary and secondary effects on blood 
pressure by the adrenal gland. A number of studies (See 1.3.4-5, 1.4) have hinted 
at the possibility of primary genetic lesions predisposing to the development of 
essential hypertension but observed changes of regulation of adrenal steroid 
secretion may reflect secondary adaptation.
1.3.4 Adrenal corticosteroids in essential hypertension
As long ago as 1956, functional abnormalities of the adrenal cortex were 
suggested as a cause of essential hypertension (Genest et al., 1956). A number of 
abnormalities of urinary excretion rate, measured secretion rate, plasma levels and 
clearance of several adrenal steroids were noted in hypertensive patients (Brown 
et al., 1972a, Nowaczynski et al., 1971, Nowaczynski et al., 1975). However, no 
single defect in steroid biosynthesis has so far been detected in patients with 
essential hypertension to account for the development of essential hypertension. 
The possibility of other unconventional steroids (e.g. 168- 
hydroxydehydroepiandrosterone, 18-hydroxyDOC, 18-hydroxycorticosterone, 19- 
nor-aldosterone) having an important role in the causation of essential 
hypertension, particularly in the 'low-renin' forms of essential hypertension, has 
been suggested but has not yet been substantiated (Bennett et al., 1975, Tan and 
Mulrow, 1979).
Two studies have indicated that impaired activity of the enzyme steroid 118- 
hydroxylase (see 1.5.2) may be an important feature of patients with essential 
hypertension. In the first study of 10 patients with hypertension classified on the 
basis of their plasma renin as having either low- or normal-renin hypertension 
(Honda et al., 1977). Patients were given intravenous ACTH and the plasma
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concentrations of a variety of steroid hormones measured. Patients with essential 
hypertension had higher post-ACTH plasma aldosterone, DOC and 11 - 
deoxycortisol (S) concentrations, and lower plasma corticosterone (B) 
concentrations than a normotensive control group (Table 1.3 c). Calculation of 
molar plasma ratios of DOC:B and S:F serve a an index of adrenal cortex 116- 
hydroxylation ability. High ratios imply impaired conversion of DOC and S to B or F 
respectively. In patients with essential hypertension, the DOC:B ratio following 
ACTH was higher than in normotensive controls.
Secondly, a study of 15 patients with essential hypertension and 15 normotensive 
controls demonstrated significant differences in basal and ACTH-stimulated 
plasma steroid concentrations between the two groups (De Simone et al., 1985). 
Hypertensive subjects had significantly higher basal plasma DOC and S 
concentrations than normotensive controls. In addition, basal DOC:B and S:F 
ratios were also higher in the hypertensive group and ACTH-stimulation resulted in 
higher DOC:B and S:F ratios in hypertensive than normotensive patients (Table 1.3 
c).
In both of these studies, no abnormality of aldosterone synthesis was detected 
suggesting the defect lay within the zona fasciculata region of the adrenal cortex 
(See 1.5).
DOC:B S:F
Basal Basal Post-
ACTH
Post-
ACTH
Basal Basal Post-
ACTH
Post-
ACTH
NT HT NT HT NT HT NT HT
Honda 0.018 0.015 0.02 0.06£ N/A N/A N/A N/A
De
Simone
0.013 0.04f 13.1* 37.4*t 0.003 0.011 f 3.4* 10.2*t
t  p<0.001, $ p<0.05
*ACTH stimulation areas, N/A - not available
Table 1.3 c Impaired 118-hydroxylation ability in essential hypertension
Both studies provide evidence of alteration in adrenal cortex 116-hydroxylase 
activity in essential hypertension. The exact nature of the abnormality is not clear 
and previous authors have suggested that these differences may arise from 
unknown, genetically-determined partial deficiency of steroid-116-hydroxylase (De 
Simone et al, 1985, Honda et al, 1977). A syndrome of complete steroid 116- 
hydroxylase deficiency has been described, one feature of which is hypertension 
(See 1.8.2), but heterozygotes for mutations giving rise to clinical 116-hydroxylase
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deficiency are not hypertensive nor do they have abnormalities of their basal 
steroid profiles similar to those in patients with essential hypertension (Pang et al., 
1980). Therefore, in patients with essential hypertension the genetic mutation is 
unlikely to be similar to that giving rise to clinical 118-hydroxylase deficiency.
Abnormal regulation of the expression of 118-hydroxylase in the adrenal cortex is 
one possibility (See chapter 5). Evidence that this apparent deficiency may not 
merely be a mild classical form has been reported (R Fraser, Personal 
communication). In a large population of hypertensive subjects, 118-hydroxylase 
activity was impaired in the 17a-hydroxy pathway (cortisol synthesis) but not in the 
17-deoxy pathway (corticosterone synthesis).
A further abnormality relating to corticosteroids in hypertensive patients has been 
the demonstration of possible alterations in the activity of the enzyme 118- 
hydroxysteroid dehydrogenase (118-OHSD, see 1.5.6) in hypertensive patients. 
Studies in hypertensive patients have shown that there is reduced cortisol 
clearance and increased vascular sensitivity to cortisol compared with normal 
subjects (Walker et al., 1991a, Walker et al., 1991b) suggesting that 1180HSD 
activity is reduced and that cortisol is able to exert mineralocorticoid effects in 
target tissues (1.5.6). More recently clear evidence of impaired 118-OHSD activity 
in hypertensive patients has been demonstrated by examining their urinary steroid 
excretion patterns (Soro et al., 1995). Patients with essential hypertension have higher 
ratios of 118-hydroxy metabolites to 11-dehydro metabolites of cortisol (tetrahydro- 
+ allotetrahydrocortisol / tetrahydrocortisone), consistent with impairment of 
1180HSD activity, but also higher ratios of 5a- to 58- reduced metabolites 
(allotetrahydrocortisol/tetrahydrocortisol), consistent with impairment of 58- 
reductase activity, than normotensive subjects. This may point to a possible 
common link between 1180HSD and the enzyme 58-reductase in vivo. The rare 
syndrome of apparent mineralocorticoid excess (SAME) is due to the congenital 
absence of 1180HSD function. The urinary steroid abnormalities in essential 
hypertension are similar to, but much less profound than those found in SAME but 
do not exclude a role for a partial deficiency of 1180HSD in essential 
hypertension.
1.3.5 Abnormalities of aldosterone secretion in essential hypertension
The aldosterone secretory and pressor response to Angll infusion are abnormal in 
patients with essential hypertension (Chinn and Dusterdieck, 1972, Kaplan and 
Silah, 1964, Kisch et al., 1976). Angiotensin II is a key regulator of aldosterone 
secretion in man (Fraser et al., 1979), and has an important pressor effect.
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Patients with essential hypertension have enhanced pressor and aldosterone 
secretory responses to intravenous Angll infusion (Kisch et al, 1976, Oelkers et al., 
1974), both when assessed as the dose necessary to raise systolic blood pressure 
by 20mmHg or as the absolute rise in blood pressure in response to a fixed 
amount of infused Angll (Chinn and Dusterdieck, 1972, Zoccali et al., 1983).
Both the pressor response and aldosterone-secretory response to Ang II are 
sodium dependent, i.e. manipulation of body sodium content can alter the 
relationship. Sodium restriction results in both increased basal plasma aldosterone 
concentrations and enhanced Angll-induced aldosterone secretion in both normal 
and hypertensive subjects (Hollenberg et al., 1974, Kisch et al, 1976, Oelkers et al, 
1974, Zoccali et al, 1983); hypertensive subjects have a somewhat greater 
response to sodium depletion than normotensive subjects but this response and 
the response to Ang II may be inconsistent (Zoccali et al, 1983). Those patients 
with a below average rise in plasma aldosterone in response to sodium restriction 
have also been shown to have a reduced aldosterone secretory response to Angll 
infusion when salt-deplete and have been termed 'non-modulators' (Williams et al., 
1982).
Hypertensive patients can be defined as modulators or non-modulators on the 
basis of their change in plasma aldosterone concentration in response to sodium 
restriction and change in p-amminohippurate clearance following Angll infusion in 
the salt-loaded state (Williams et al., 1992). Using this classification gives a 
bimodal distribution in the hypertensive population of modulators and non­
modulators. Non-modulators tend to be older than modulators and there is 
evidence to suggest that non-modulation has a genetic basis. In one study of 
patients with a positive family history (FH+) of hypertension, 81% of FH+ 
hypertensive patients were non-modulators (Lifton et al., 1989). In another study of 
hypertensive sibling-pairs, non-modulation was shown to aggregate within families 
and was independent of sodium intake (Dluhy et al., 1988).
Therefore, there are clearly abnormalities in the control of aldosterone secretion in 
essential hypertension which may have a heritable component although the 
physiological differences giving rise to these abnormalities is unclear.
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1.4 Genetic Factors in Human Hypertension
Since the discussions of Platt and Pickering in the 1950's and 60's, there has been 
a general awareness of the role of inheritance in hypertension (Pickering, 1961, 
Platt, 1959). Most clinicians will observe aggregation of hypertension within a 
family, but this does not prove or disprove a genetic role in its causation as 
environmental influences may readily explain such observations. In order to study 
the genetic contribution to hypertension, one starting point is to find evidence of 
familial aggregation of blood pressure. If such aggregation occurs, it must be 
determined if there is a genetic component, a shared environment or both. If there 
is a genetic component present, does it arise from a minor effect of many 
contributory genes or are there a few genes with a major effect? Subsequently, the 
effect of environmental influences on a major gene and blood pressure should be 
determined and individuals within a family with differing genotypes studied to 
identify the specific environmental influences altering the blood pressure response.
1.4.1 Blood pressure phenotype
A positive family history is commonly used as a measure of familial aggregation of 
blood pressure and as a surrogate measure of undefined risk in family members. 
Significant associations between a family history of hypertension and the 
development of hypertension in a family member have been demonstrated (Hunt 
and Williams, 1994). The strength of the association varies depending on the 
definition of 'family history' and the risk attributable to a positive family history of 
hypertension can be detected after 13 years of follow-up (Hunt and Williams,
1994). Table 1.4 a outlines the effect of sex and number of affected family 
members on an individuals relative risk of developing hypertension. Similar findings 
have been reported in children with a positive family history of hypertension. Young 
adults with a systolic blood pressure over the age- and gender-specific 90th 
percentile had a greater prevalence of positive family histories of hypertension and 
more ischaemic heart disease and strokes (Hunt and Williams, 1994). Taken 
together, the majority of evidence suggests that a positive family history of 
hypertension, properly defined, is a significant indicator of hypertension risk in an 
individual. Even in two families where the cause of hypertension is very different, 
for example adult polycystic kidney disease and glucocorticoid-suppressible 
hyperaldosteronism, this will hold true despite the genetic basis being very 
different.
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Aqe
Defn of FH %with +FH 20-39 40-49 50-59 60-69 >70
Males
1+Affected 53 2.5 1.8 1.7 1.2 0.9
1 + age<55 32 2.8 2.1 1.8 1.1 0.8
2+Affected 24 3.8 2.4 2.3 1.2 0.6
2 + age<55 11 4.1 2.5 2.4 1.0 0.8
FHS > 1.0 14 3.9 2.5 2.9 1.4 1.2
FHS > 2.0 7 4.0 3.2 3.3 1.4 2.8
Females
1-i-Affected 2.8 2.0 1.5 1.2 1.0
1 + age<55 3.2 2.3 1.5 1.0 0.8
2+Affected 3.8 2.4 2.3 1.2 0.6
2 + age<55 5.0 3.5 1.5 0.7 0.8
FHS > 1.0 4.4 3.3 2.0 1.0 1.2
FHS > 2.0 4.4 3.9 2.0 1.0 1.3
Defn of FH - definition of family history of hypertension, % with FH - percentage of patients with a 
positive family history. FHS - family history score as defined by FHS= (observed number of 
hypertensives - expected number)/Vexpected, with a 0.5 correction in the numerator
Table 1.4 a Relative risks of hypertension for different definitions of a positive family history 
of hypertension for males and females based upon 13 years of follow-up in 15200 families. 
Adapted from (Hunt and Williams, 1994)
Location Systolic Blood Pressure Diastolic Blood Pressure
Michigan, USA 0.17 0.12
GeorgiaLUSA 0.20 0.17
Framingham, USA 0.18 0.17
Utah, USA 0.16 0.21
United Kingdom 0.33 0.20
Turkmenistan 0.27 0.11
Norway 0.22 0.23
Brazil 0.27 0.32
Tokelau 0.17 0.13
Table 1.4 b Sib-sib blood pressure correlations. Adapted from (Hunt and Williams, 1994)
SBP I DBP II
II II
•Ymzl •Ydz) h2 r(mz) r(dz) H/^
II
0.61 0.29 0.63 0.61 II 0.32 | 0.66
r - correlation between twins, mz - monozygotic, dz - dizygotic, h2 - heritability
Table 1.4 c Intraclass blood pressure correlations and heritability estimates. 
Adapted from (Hunt and Williams, 1994).
36
Many large population studies have shown familial correlations of blood pressure 
(Table 1.4 b). These correlations are generally in the 0.1-0.3 range and are broadly 
similar amongst the various sib-sib pairings. Sib-sib correlations are in turn 
generally slightly higher than parent-offspring correlations (Hunt and Williams, 
1994). There is also data which suggest that mother-offspring correlations are 
stronger than those of father-offspring and that this maternal effect is present from 
the first year of life (Levine et al., 1982). Estimates of polygenic heritability can be 
obtained from familial correlations These estimates cluster around 20% for family 
studies (Hunt and Williams, 1994), but are much higher in twin studies at around 
60%(Table 1.4 c). In particular, monozygous twins show a higher correlation in 
blood pressure and blood pressure heritability than dizygous twins and both were 
higher than siblings (Hunt and Williams, 1994). The effect of a common 
environment in these groups has also been examined and has revealed that 
monozygous twins have a much more similar environment than dizygous twins or 
common sibs but correction for this still leaves the twin groups with a much higher 
blood pressure correlation suggesting a definite component derived from 
inheritance (Hunt and Williams, 1994).
Adoption studies have shown that in families with both adoptive and natural 
children, the correlation in blood pressure between parent and natural child was 
greater than that between parent and adoptive child and the correlation between 
natural sibs was greater than that between adoptive and natural sibs (Hunt and 
Williams, 1994).
The factors determining the inherited tendency to hypertension may be determined 
either directly from the genes inherited from the patients parents. However, the 
possibility that adverse conditions during intrauterine life may programme 
subsequent adult blood pressure has been raised. The potential role of in utero 
influences has been reviewed recently (Law and Barker, 1994) and references 
therein.
A number of studies have demonstrated an association between low fetal growth 
rate and increased death rate from coronary heart disease and stroke. Similarly, 
blood pressure shows an inverse relationship with birthweight across the range of 
blood pressures in both sexes (Law and Barker, 1994).
A number of studies have demonstrated 'tracking' of blood pressure from early 
childhood, suggesting that hypertension is programmed into an individual from an 
early age. In addition, it has been noted that those children born thin and 
undernourished have higher blood pressure at age 4 years than those with normal
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body proportions, as have those adults who had large placentas at delivery (a sign 
of adaptation to fetal undernutrition) (Law et al., 1991), and the association is found 
in children who are 'light for dates' rather than premature. Finally, studies of the 
growth of children from birth have shown that it is the degree of undernutrition at 
birth rather than the accelerated growth (catch-up growth) after birth which 
determines subsequent blood pressure suggesting that the individuals blood 
pressure is programmed in utero (Law et al, 1991, Lever and Harrap, 1992).
Such programming of blood pressure has been demonstrated in protein deprived 
pregnant rats whose offspring had elevated systolic blood pressures compared 
with those receiving a normal protein diet (Law and Barker, 1994), and in the 
offspring of rats receiving glucocorticoids during pregnancy (Benedicktsson et al.,
1993). Human evidence is less prevalent but the study of the Dutch Hunger Winter 
showed that the women whose mothers were malnourished during pregnancy 
themselves had babies with retarded intra-uterine growth (Law and Barker, 1994).
The difference in blood pressure in people of low and high birthweight is small in 
childhood but increases progressively with age (Law and Barker, 1994). One 
interpretation is that the process started in utero is amplified throughout life, 
perhaps through effects on blood vessel structure and function (Folkow, 1978, 
Folkow, 1982). It may be the case therefore, that alterations in fetal arterial 
structure secondary to the effects of undernutrition may lead to changes in arterial 
compliance which in turn lead to changes in vessel structure which in turn alter 
arterial compliance. Thus, a vicious circle is set up to maintain and amplify the 
process started in utero.
Thus, it appears from studies of heritability that hypertension has an important 
genetic component in the region of 20-30%. In order to relate this variance to the 
setting of human physiology, a number of the factors regulating blood pressure in 
man have been examined to determine whether genetic variation occurs in these 
systems and if they influence blood pressure.
1.4.2 Renin-angiotensin-aldosterone system
The renin-angiotensin system is central to the control of blood pressure in normal 
man (Figure 1.4 a). Variations in the plasma concentrations of certain components 
of the system have been detected in normal populations and a genetic basis for 
these variations has been postulated. Differences have also been detected in 
hypertensive patients and in animal models of hypertension . The role of the renin-
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angiotensin system in the control of aldosterone secretion in man is reviewed in 
detail in 1.5.5.
The renin-angiotensin system is a good place to start looking for genetic variation 
resulting in hypertension because it contains many components central to the 
control of blood pressure in normal individuals and the actions of certain 
components, e.g. Angll, have been implicated in the mechanisms which sustain 
hypertension after the initial stimulus. The idea of a candidate gene, i.e. a gene for 
a protein or enzyme directly involved in a central physiological process, has been 
most readily studied in the renin-angiotensin system.
Angiotensinogen
Renin ►  ^
Angiotensin I
Angiotensin I-__
converting enzyme
Angiotensin II
A
Aldosterone Direct Pressor 
Secretion Effect
Figure 1.4 a Renin-angiotensin system
The renin gene has been cloned in man and mapped to chromosome 1. A number 
of studies have shown no evidence of linkage of the renin locus to human 
hypertension . This is not the case in rat hypertension where polymorphisms in the 
renin gene have been shown to co-segregate with the hypertensive phenotype 
(Hunt and Williams, 1994).
The gene for angiotensinogen (AGT) has been cloned in man, mapped to 
chromosome 1q42-43, and a number of polymorphic regions of this gene detected. 
Polymorphisms of this gene are associated with differences in plasma
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angiotensinogen levels and hypertension (Jeunemaitre et al., 1992b). Sib-pair 
analysis has shown that the certain alleles of the gene predispose to hypertension, 
particularly more severe hypertension (defined as those cases requiring >2 
antihypertensive drugs to control blood pressure), in males. No linkage was found 
in female subjects, perhaps due to the effects of oestrogen on plasma 
angiotensinogen levels. One marker polymorphism, M235T in exon 2 of the AGT 
locus has been associated with hypertension in both males and females in one 
study performed in Utah and France, where the frequency of M235T was 0.51 in 
severe hypertensives and 0.36 in controls (Jeunemaitre et al, 1992b), but not in a 
population studied in the United Kingdom (Caulfield et al., 1994). However, a 
second polymorphism, a GT-repeat in the 3' untranslated region of the gene, has 
been found to be in linkage with hypertension in both males and females in the 
British study (Caulfield et al, 1994).
A similar association between the GT-repeat and pre-eclampsia has been 
demonstrated in Scottish and Icelandic women (Angrimmson et al., 1993), and the 
M235T variant and pre-eclampsia in a study from Utah (Ward et al., 1993).
The gene for angiotensin-l converting enzyme (ACE) has been cloned, mapped to 
chromosome 17 and a polymorphism in intron 16 of the gene characterised 
(Hubert et al., 1991). This polymorphism consists of the presence or absence of an 
Alu repeat which can be detected by PCR amplification of intron 16 (insertion 
(l)/deletion (D) polymorphism). The I/D polymorphism accounts for approximately 
50% of the variance in plasma ACE levels in normal populations, with DD 
homozygotes having the highest plasma ACE levels, II homozygotes the lowest 
and heterozygotes intermediate levels (Rigat et al., 1990). However, a number of 
studies have shown that in man there is no association between the ACE I/D 
polymorphism and hypertension (Harrap et al., 1993, Jeunemaitre et al., 1992a, 
Schmidt et al., 1993), whilst only one suggest a possible role in the development of 
hypertension (Zee et al., 1992). There is however, one study that suggests that the 
ACE I/D polymorphism may be important in determining whether left ventricular 
hypertrophy develops in hypertensive subjects (Schunkert et al., 1994).
However, there is evidence that the ACE I/D polymorphism may be an important 
independent risk factor for the development of myocardial infarction, particularly in 
the absence of conventional risk factors (Cambien et al., 1992).
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1.4.3 Glucocorticoid receptor polymorphism
Steroid hormones are important regulators of blood pressure in man. One major 
class of steroid hormones is the glucocorticoids, excess of which can give rise to 
hypertension. The principal human glucocorticoid is cortisol which, like all other 
steroid hormones, binds to a nuclear receptor to produce its effect. Cortisol binds 
to the glucocorticoid receptor (GR)/n vivo and initiates a series of intracellular 
processes one of which is to alter vascular tone and ultimately raise blood pressure 
(Walker et al, 1991b) and 1.5.6. The gene for the GR has been cloned and 
mapped to chromosome 5 and a diallelic Bell RFLP in the region of the gene 
described (Murray et al., 1987). This polymorphism has been associated with a 
hypertensive tendency and abnormalities of steroid synthesis in the 'Ladywell 
Study' population (Watt et al., 1992). In this study the offspring of hypertensive and 
normotensive parents were studied and analysed by the '4-comers' method. The 
offspring were sub-divided into four groups on the basis of their parents blood 
pressure (high or low) and the offspring's blood pressure (high-normal or low- 
normal) thus deriving the four corners of the study group (Figure 1.4 b). When the 
two extremes of phenotype, the high-high and low-low groups, were compared it 
was found that there was an excess of homozygotes for the large allele of the 
RFLP in the high-high group compared with the low-low group (27% vs. 9%, 
p<0.01). Offspring of hypertensive parents with high normal blood pressures also 
had significantly higher plasma levels of cortisol, 18-hydroxycorticosterone and 
angiotensinogen compared with the low normal offspring.
Physiological studies have shown a trend towards increased affinity of 
dexamethasone for GR, reduced GR number, in vitro, and higher plasma cortisol 
concentrations in normal subjects homozygous for the large fragment of the Bell 
RFLP genotype (Panarelli and Fraser, 1994). It is not clear, however, if this is a 
direct effect of the polymorphism or is of relevance to the development of 
hypertension in man.
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Offspring 
Blood Pressure 
High
Parental 
Blood Pressure
High
Patient in the 4-corners of the study population 
All patient in study
Figure 1.4 b Four corners approach to analysis of 
inheritance of hypertension
Thus it would appear that the GR locus or a locus nearby may have exert an effect 
on blood pressure in man but further studies are required.
1.4.4 Sodium-lithium countertransport
In man the presence of an erythrocyte sodium transporter which promotes 
intracellular to extracellular transport of sodium ions has been described. This 
pump also transports lithium ions and a measure of the degree of sodium-lithium 
countertransport (SLC) has been studied and found to be raised in patients with 
essential hypertension when compared with normotensive controls (Canessa et al., 
1980).
Studies designed to test for the presence of a genetic effect on SLC have been 
reviewed in detail (Hunt and Williams, 1994). These studies demonstrate high 
parent-offspring (0.52) and sib-sib correlations (0.39) in SLC and twin studies 
estimate the polygenic heritability to be between 60-98%. Major gene segregation 
for SLC has also been demonstrated (Table 1.4 d)
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Study Gene
Frequency
Normal Mean High Mean
1 0.45 0.31 0.48 0.45
2 0.28 0.29 0.45 0.17
3 0.26 0.29 0.60 0.42
4 0.23 0.26 0.53 0.70
h2 - heritability
Table 1.4 d Comparison of genetic model estimates of Na-Li countertransport (adapted from 
(Hunt and Williams, 1994)
All four studies found evidence for a recessive major gene for high SLC levels 
along with a significant polygenic effect. However, the confounding effects of 
gender and plasma triglyceride levels on SLC results in a significant blunting of the 
bimodal distribution of SLC in the population. Further analysis of the pedigrees 
have shown that a subset of the all the kindreds studied show a high degree of 
segregation of SLC and hypertension and can reject a non-transmissible cause of 
the bimodality in SLC levels.
As yet no genetic marker for the SLC locus has been found and the in vivo function 
of the SLC mechanism is unknown. However, one study in sib-pairs has rejected 
the possibility that the SLC mechanism is in fact the Sodium-Hydrogen pump (gene 
on chromosome 1) with a LOD score of -5.91 for linkage between SLC and the 
Sodium-Hydrogen pump.
1.4.5 Kallikrein
Kallikrein is an enzyme which converts inactive kininogens to vasodilator kinins. 
The kallikrein-kinin system tends to counteract the renin-angiotensin system as 
ACE inactivates kinins as well as producing Angll. Therefore a defect in the 
kallikrein system leading to low production of active kinins may lead to the 
development of hypertension (Figure 1.4 c). The data relating to the genetics of 
kallikrein in human hypertension has been reviewed in detail (Hunt and Williams,
1994) and references therein. Urinary kallikrein levels are low in patients with 
essential hypertension and there is a strong familial aggregation in adults and 
children. Intrafamily correlations of urinary kallikrein excretion were high: adult 
siblings - 0.34, youth siblings - 0.55, and parent-offspring correlations for adults 
and youths were 0.43 and 0.50 respectively. Genetic modelling of the available 
data has shown that a recessive major gene effect with additional polygenic 
influences is the best fit. The major gene explained 51% of the variance in urinary 
kallikrein excretion with polygenes explaining another 27%.
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Figure 1.4 c Kallikrein-Kinin and Renin-Angiotensin systems
A study of monozygotic twins revealed that the strongest environmental 
determinant of urinary kallikrein excretion was urinary potassium excretion. 
Incorporation of the effects of environmental influences into the previous model 
allowed the model to be refined and clearly defined the effect of major genes and 
environment on urinary kallikrein excretion (Table 1.4 e).
A significant gene-environment interaction was found for the underlying variables 
represented by urinary kallikrein and potassium levels. Urinary potassium excretion 
reflects dietary potassium intake in the steady state whilst urinary kallikrein 
excretion is thought to reflect local renal kallikrein levels. The interaction suggested 
that subjects homozygous for the low kallikrein gene had low levels of renal 
kallikrein that are not modified by changes in potassium intake. Subjects 
homozygous for the high kallikrein gene may be protected from the development of 
hypertension by maintaining high kallikrein levels as a result of being more 
responsive to changing potassium levels or other alterations that might lower 
kallikrein levels. However heterozygotes, who account for 50% of the population 
studied, showed a very significant positive relationship between urinary kallikrein
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and potassium. A decrease in urinary potassium in this population of 1.3 standard 
deviations results in a fall in urinary kallikrein levels to that seen in the low 
homozygote group. Similarly a rise in dietary potassium leading to a rise in urinary 
potassium excretion of 0.8 standard deviations would be expected to raise 
kallikrein levels to those of the high homozygote group. This finding would seem to 
fit well with the epidemiological evidence that dietary potassium supplementation 
may reduce blood pressure.
Urinary Potassium
Source Low Average High
Major Gene 47 38 62
Polvqenes 0 0 0
Recent
Environment
12 14 9
Individual Variation 30 35 21
Table 1.4 e Sources of variation in urinary kallikrein levels by urinary potassium level (%). 
Adapted from (Hunt and Williams, 1994)
The human kallikrein gene has been cloned but as yet no studies in man have 
been published showing co-segregation or linkage of this locus to hypertension.
1.4.6 Abnormalities of steroid metabolism
Adrenal steroids can cause hypertension when present in excess and there are a 
number of well defined inherited abnormalities of steroid metabolism which have 
hypertension as a feature of the clinical syndrome (1.8.2-4, 1.9). Three of these 
disorders, steroid 110-hydroxylase deficiency, steroid 17a-hydroxylase deficiency 
and the syndrome of apparent mineralocorticoid excess have an autosomal 
recessive mode of inheritance and are rare causes of hypertension. Glucocorticoid- 
suppressible hyperaldosteronism is inherited as an autosomal dominant trait and 
although thought to be rare, its incidence may be greater than first thought (1.9). In 
addition, there have been reports of aldosterone-secreting adrenal adenomata 
occurring within families although the genetic basis for this is unknown (Stowasser 
et al., 1992).
Impairment of 110-hydroxylase activity in patients with essential hypertension has 
been noted previously (De Simone et al, 1985, Honda et al, 1977) and the steroid 
synthetic defect in these patients may be genetically determined in that 
polymorphisms have been described within the coding region of the gene for 110- 
hydroxylase (Lifton et al., 1992). The enhanced pressor and aldosterone secretory 
response to Angll infusion in hypertensive patients may also have a genetic basis
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because polymorphisms have been detected in the regulatory regions of the gene 
for aldosterone synthase which could affect the aldosterone secretory response to 
Ang II (Chapter 5), (Lifton et al, 1992).
In summary, there are clearly many ways in which hereditary influences may 
determine blood pressure.Three candidate genes appear to be linked to the 
hypertensive phenotype, angiotensinogen, sodium-lithium countertransport and 
urinary kallikrein excretion. Other loci, in particular the glucocorticoid receptor 
polymorphism and polymorphisms in the adrenal steroidogenic enzyme genes, 
may be of importance and further study will elucidate this.
The likelihood that a few genes exerting a small, additive effect on blood pressure 
in an individual would appear therefore to be the case in human hypertension, 
although the effects may vary on the combination of genes an individual has, the 
environmental influences encountered and other less well defined influences such 
as the in utero environment.
46
1.5 The Adrenal Gland
The first anatomical description of the adrenal gland was made in 1563 by 
Eustachius (Eustachius, 1774). The first differentiation of the adrenal gland into 
cortex and medulla was made by Huchke (Schoenwetter, 1968) and in the 19th 
century Arnold first described the concentric zones we now use to describe the 
adrenal cortex (Arnold, 1866). Ideas about the function of the adrenal cortex 
lagged behind the anatomical description of the gland. In 1716 the Academie des 
Sciences de Bordeaux offered a prize for the answer to the question, "What is the 
purpose of the suprarenal glands?" However the answers were so unsatisfactory 
that the prize was not awarded and the judge forced to say "Perhaps some day 
chance will reveal what all of this work was unable to do" (Gaunt, 1975). The first 
evidence of a physiological role for the adrenal glands came from the clinical 
observations of Thomas Addison in 1849 (Addison, 1849). It was six years later 
that Addison published his authoritative account of the effects of adrenal disease in 
man (Addison, 1855). Experimental confirmation of the clinical findings came the 
following year from Brown-Sequard who performed adrenalectomies on several 
species of animal and noted the detrimental effect (Brown-Sequard, 1856). It was 
not until 1930, however, that the efficacy of adrenal cortex extracts in maintaining 
the health and growth of adrenalectomised cats was noted (Swingle and Pfiffner, 
1931) and these extracts were then used to successfully treat patients with 
Addison's disease (Rowntree et al., 1930).
1.5.1 Anatomy of the Adrenal Gland
Each adrenal gland consists of two functionally distinct endocrine glands within a 
single fibrous capsule. The adrenal gland is situated on the superior pole of the 
kidney and weighs about 4 grams in healthy adults. The outer capsule consists of 
loose fibrous tissue and surrounds the outer cortex of the adrenal. The cortex 
accounts for 90% of the weight of the adult adrenal and is derived from the 
mesenchymal cells adjacent to the urogenital ridge. The inner adrenal medulla is 
derived from cells of the neural crest which migrate into the adrenal during the third 
month of fetal life. Its cells secrete the catecholamines, adrenaline, noradrenaline 
and dopamine; its function will not be discussed further.
The adrenal cortex is divided into three roughly concentric zones based on the light 
microscopic appearances of the cells (Arnold, 1866). The outer zone, the zona 
glomerulosa constitutes 15% of the cortex and consists of poorly demarcated 
islands of cells lying subjacent to the capsule of the gland. In the majority of
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Figure 1.5 a Microscopic anatomy of the Adrenal Cortex. 
After Gray's Anatomy, 36 Ed.
instances these islands do not form a continuous layer. The glomerulosa cells are 
small and have a low cytoplasrrr.nuclear ratio and an intermediate number of lipid 
inclusions. The adjacent zone is the zona fasciculata which constitutes 75% of the 
cortex. It is not well demarcated from the glomerulosa and cells from the 
fasciculata may penetrate the glomerulosa to contact the capsule. Cells in this 
zone have a high cytoplasminuclear ratio, are large and have a foamy, vacuolated 
cytoplasm because of the numerous lipid deposits. The innermost zone of the 
cortex is the zona reticularis, and is sharply demarcated from the fasciculata and 
medulla. Cells in this zone have a compact, lipid-poor cytoplasm and lie in 
anastamosing cords separated by sinusoidal spaces (Figure 1.5 a) (Orth et al., 
1992).
1.5.2 Steroid Synthesis in the Adrenal Cortex
The adrenal cortex is the site of synthesis of a number of important steroid 
hormones in man. Steroid hormones are derived from the 
cyclopentanophenanthrene ring structure consisting three cyclohexane rings and 
one cyclopentane ring (Figure 1.5 b).
Figure 1.5b Cyclopentanophenanthrene ring structure
The starting point for the synthesis of all adrenal corticosteroid hormones in man is 
cholesterol. Cholesterol can be synthesised de novo from acetate, mobilised from 
intracellular cholesteryl ester pools or imported from plasma lipoproteins by 
steroidogenic tissues. About 80% of cholesterol is provided by circulating 
lipoproteins, principally low density lipoprotein (LDL) which acts via a cell surface 
receptor (Gwynne and Strauss, 1982). The LDL particle undergoes receptor- 
mediated endocytosis to be internalised by the cell and cholesteryl esters are 
liberated for use as steroidogenic substrates (Goldstein et al., 1979). Under normal
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Figure 1.5 d Synthesis of aldosterone and cortisol in the adrenal cortex
conditions, a further 20% of cholesterol is synthesised de novo from acetyl 
coenzyme A (Gwynne and Strauss, 1982).
Three major groups of steroid hormones are synthesised in the adrenal cortex in 
man. The outer zona glomerulosa is the exclusive site of synthesis of aldosterone 
whilst the zonae fasciculata and reticularis synthesise cortisol and the adrenal 
androgens dehydroepiandrosterone (DHEA) and androstenedione. The most 
abundant product of the adrenal cortex, dehydroepiandrosterone sulphate 
(DHEAS), is formed exclusively in the zona reticularis (Orth et al, 1992). Synthesis 
of the various adrenal corticosteroids is compartmentalised within the cells of the 
adrenal cortex by virtue of the subcellular location of the enzymes involved (Figure
1.5 c). The biosynthetic pathways for conversion of cholesterol to aldosterone, 
cortisol and the adrenal androgens have been determined and are shown in Figure
1.5 d. The aldosterone biosynthetic pathway is discussed in detail in section 1.7.
The synthetic action of the steroidogenic enzymes is made possible by the 
existence of a coupled enzyme system which transfers electrons to the P-450 
enzymes as reducing equivalents and allows the final hydroxylation step to occur. 
Two such systems exist in man, coupled to the action of the steroidogenic P-450 
enzymes. The first is based on adrenodoxin, a non-haem iron-binding protein that 
exists in a soluble form in the mitochondrial matrix and in man is linked to the 
activity of P-450scc> P-450hb and P-450aido (Kimura and Suzuki, 1967). Man has a 
single gene for adrenodoxin and two pseudogenes (Morel et al., 1988). Linked to 
adrenodoxin is the enzyme adrenodoxin reductase which accepts electrons from 
NADPH in the first step of the reduction cascade. In man there is a single gene for 
adrenodoxin reductase but two forms of the enzyme are produced by alternative 
splicing of the DNA (Solish et al., 1988). This so-called 'electron shuttle' system is 
illustrated in Figure 1.5 e. NADPH donates electrons to an adrenodoxin reductase 
and converts it to its reduced state. This then acts to convert adrenodoxin to a 
reduced state which in turn transfers reducing equivalents to the P-450 enzyme.
A second system exists coupled to the activity of P-450C17 and P-450C21 (Kominami 
et al., 1980). This system utilises a flavoprotein distinct from adrenodoxin 
reductase. This enzyme, P-450 reductase, transfers two electrons from NADPH to 
P-450C17 and P-450C21- In addition, cytochrome bs may also donate electrons to P- 
450C17 and P-450C21 (Yanagibashi and Hall, 1986) (Figure 1.5 f).
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Figure 1.5 f Electron shuttle system for P-450c17 and P-450c21
Cholesterol is converted to pregnenolone by the enzyme P-450scc located on the 
inner mitochondrial membrane. This step is the rate-limiting step in steroidogenesis 
and involves two oxidations at the C20 and C22 positions followed by the removal 
of isocaproic acid from the C-20 position (Strott, 1990). This enzyme, the so-called 
'Side-Chain Cleavage' enzyme is encoded by a single gene found on chromosome 
15 and is found in all steroidogenic tissues (Chung et al., 1986a). The newly 
synthesised pregnenolone is returned to the cytosolic compartment where a series 
of microsomal enzymes convert it to 11-deoxycortisol. Pregnenolone is converted 
to progesterone by the enzyme 36-hydroxysteroid dehydrogenase/A5 -A4 
isomerase, a non P-450 enzyme encoded by a gene on chromosome 1 (Berube et 
al., 1989). A number of isoforms of this enzyme have been described with tissue- 
specific expression (Lachance et al., 1991).
The enzyme P-450C17 is encoded by a single gene, CYP17A, on chromosome 10 
(Matteson et al., 1986) which transcribes a single mRNA message and protein
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product (Chung et al., 1986b, Kagimoto et al., 1988). In the zonae fasciculata and 
reticularis both pregnenolone and progesterone may undergo hydroxylation at the 
C-17 position in addition to the cleavage of the residual two-carbon chain at C-17 
although this depends on which biosynthetic pathway they enter.
The degree of P-450C17 activity to some extent determines which pathway the 
reaction products take. In the zona glomerulosa P-450C17 activity is not present and 
therefore pregnenolone is converted to progesterone as a precursor in the 
formation of aldosterone. In the zona fasciculata pregnenolone undergoes 
hydroxylation of the C-17 position and the product, 17a-hydroxyprogesterone 
undergoes subsequent hydroxylation steps to become cortisol. However, some 
pregnenolone may be converted to progesterone before being converted to 17a- 
hydroxyprogesterone and subsequently cortisol. If the action of the enzyme is to 
cleave the two-carbon chain at C-21 in addition to the hydroxylation of 
pregnenolone (i.e. 17a-hydroxylase 17,20 lyase) the product is 
dehydroepiandrosterone a major adrenal androgen and the precursor of other 
adrenal androgens (Orth et al, 1992).
Whether 17-hydroxycorticosteroids are formed by this enzyme system is 
determined by the relative electron supply from the P-450 reductase system. This 
system donates electrons to P-450C17 in competition with P-450C2i and the relative 
excess or deficit of donated electrons can determine the degree of P-450C17 activity 
(Miller, 1988). In the zona glomerulosa there is no P-450C17 activity.
The next step in the sequence is the conversion of 17a-hydroxyprogesterone to 
11-deoxycortisol by the enzyme P-450C2i- This enzyme resides in the smooth 
endoplasmic reticulum of the cell and is encoded by the gene CYP21A which lies 
on chromosome 6 in the midst of the Major Histocompatibility Complex region. It 
lies in tandem with ia highly homologous pseudogene, CYP21P, which has no 
known function and can participate in gene conversion events to cause the clinical 
syndromes of steroid 21-hydroxylase deficiency (White et al., 1984, White et al., 
1984).
Once formed, 11-deoxycortisol is transported to the inner mitochondrial membrane 
where the final hydroxylation step to form cortisol occurs. This step is catalysed by 
the enzyme P-450n& whose gene, CYP11B1, is found on the long arm of 
chromosome 8 (8q22) (Mornet et al., 1989). In addition to the formation of cortisol, 
P-450iib  is also thought to catalyse the formation of corticosterone, 18-hydroxy- 
11-deoxycorticosterone and 19-hydroxy-11-deoxycorticosterone from 11- 
deoxycorticosterone in the zona fasciculata, underscoring the close relationship
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between this enzyme and P-450aido in their catalytic properties (Shizuta et al., 
1992).
The gene for P-450hq and its closely related homologue, CYP11B2 encoding P- 
450aido, are of central importance in the biosynthesis of aldosterone and in the 
pathogenesis of hypertensive disorders of adrenal metabolism and are discussed 
in detail in section 1.7.
1.5.3 Regulation of Steroid Secretion
The zonae fasciculata and reticularis are the site of synthesis of cortisol and the 
adrenal androgens in man. The control of the rate of synthesis of cortisol and the 
other secretory products of these zones is determined by factors outwith the 
adrenal gland, namely interactions between the hypothalamus, the anterior 
pituitary, neural and other influences such as stress. Figure 1.5 g outlines the 
normal regulation of cortisol secretion in man.
1.5.4 Adrenocorticotrophin
The principal secretory stimulus to the cortisol-producing cells of the adrenal cortex 
is ACTH. ACTH is synthesised as a part of a large precursor molecule (241 amino 
acids), pro-opiomelanocorticotropin (POMC), which also contains other peptides, 
including melanocyte-stimulating hormone. The gene for POMC is situated on 
chromosome 2 (Owerbach et al., 1982, Whitfield et al., 1982). The gene product of 
the POMC gene undergoes extensive post-translational processing, including 
cleavage to produce multiple peptides. In the anterior pituitary the products of this 
enzymatic cleavage are ACTH, B-lipotrophin and the joining (J) peptide. ACTH is a 
39 amino acid peptide, the first 24 of which are conserved in all species studied, 
and the first 18 NH2-terminal amino acids of this peptide confer its biological 
activity (Smith and Funder, 1988) (Figure 1.5 h).
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Figure 1.5 g Control of Cortisol secretion in man
The ACTH peptide also contains the precursor molecule for one of the melanocyte- 
stimulating hormones (a-MSH) whose effect can be seen when ACTH is present in 
gross excess in Nelson's syndrome, i.e. skin pigmentation secondary to chronically 
elevated plasma ACTH levels from an ACTH-secreting pituitary adenoma
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Figure 1.5 h Amino acid sequence of human ACTH.
Bold residues indicate those common to ACTH, alpha and beta
MSH
ACTH release from the pituitary gland is pulsatile, i.e. brief episodic bursts of 
ACTH release occur throughout the 24 hour period. In the early part of the day, the 
release of ACTH is greater due to pulses of greater amplitude (Veldhuis et al., 
1990). The increase in amplitude of the pulses occurs after 3-5 hours of sleep and 
reaches a maximum prior to waking and for 1 hour after waking, before declining 
during the day (Veldhuis et al, 1990). Plasma cortisol levels mirror these changes 
in ACTH secretion but the longer clearance time for cortisol results in a slower 
decline in plasma cortisol relative to plasma ACTH (Krieger et al., 1971). This so- 
called 'nyctothemeral' or 'diurnal' rhythm is maintained in the physiological state but 
is lost in disease states where cortisol or ACTH secretion becomes autonomous, 
e.g. Cushing's syndrome (ACTH-secreting pituitary adenoma) or a cortisol- 
secreting adrenal adenoma/carcinoma.
Under normal circumstances ACTH and cortisol regulate their own secretion by 
means of a negative feedback loop whereby high levels of cortisol inhibit the 
secretion of ACTH and corticotrophin releasing hormone (which regulates ACTH 
secretion). However, ACTH secretion and consequently plasma cortisol levels can 
be influenced by inputs from 'higher' centres, i.e. hypoglycaemia, fever and mental 
stress all raise ACTH and cortisol levels and are important sources of variation in 
day-to-day measurement of plasma levels.
The primary action of ACTH on the cells of the zona fasciculata is to increase 
cortisol secretion by increasing its synthesis; intra-adrenal storage of cortisol is 
minimal (Dickerman et al., 1984, Hall, 1985). ACTH depletes adrenal cholesterol 
content to an extent which corresponds with increased steroid synthesis (Long, 
1985, Peron and Koritz, 1960). ACTH acts by binding to a high-affinity cell-surface
54
receptor, and each adrenocortical cell is said to possess approximately 3600 
ACTH-binding sites (Orth et al, 1992). ACTH binding promotes the generation of 
cyclic AMP (cAMP) via adenylate cyclase, which in turn activates protein kinase A 
and leads to the phosphorylation of a number of proteins and increase in nuclear 
mRNA production (Simpson and Waterman, 1988).
The effects of ACTH on steroidogenesis can be divided into acute (within minutes) 
and chronic (after several hours) effects. The acute effect of ACTH is to increase 
conversion of cholesterol to pregnenolone, the rate-limiting step of cortisol 
synthesis, by activation of P450scc (Simpson and Waterman, 1988). Using 
polyclonal antibodies directed against the various steroidogenic enzymes it has 
been demonstrated that ACTH treatment of bovine adrenal cortex cells results in a 
4-5-fold increase in the rate of synthesis of P-450scc, P-450hg, P-450c2i. P- 
450i7a and adrenodoxin some 24-36 hours after ACTH treatment. ACTH and 
cAMP treatment lead to similar increases in the levels of translatable mRNA of all 
of these enzymes (Simpson and Waterman, 1988), thought to be due to an 
increase in transcription of the corresponding genes. These increases in mRNA 
synthesis can be detected as little as 4 hours after ACTH treatment. Similar results 
have been found when human fetal adrenal cells were studied (John et al., 1986).
The chronic effects of ACTH involve increased synthesis of most of the enzymes of 
the steroidogenic pathway as well as actions on cell growth (Hall, 1985, Simpson 
and Waterman, 1988). When there is prolonged deficiency of ACTH, such as 
following hypophysectomy, the level of steroidogenic enzymes and RNA synthesis 
fall in association with atrophy of the adrenal cortex. These changes are reversed 
by ACTH administration but may require several days to return to normal (Orth et 
al, 1992). Using nuclear run-on assays, it has been demonstrated that ACTH 
administration results in increased transcription of the various steroidogenic 
enzyme genes, and that the increased mRNA synthesis leads to chronically 
enhanced enzyme production (John et al, 1986). Also, the addition of 
cycloheximide, an inhibitor of RNA translation, to ACTH-stimulated bovine 
adrenocortical cells inhibits production of steroidogenic enzyme RNA species, but 
total mRNA levels remain normal. Therefore, it would appear that ACTH acting via 
cAMP generation, generates short-lived protein factor(s) which may interact 
directly with the steroidogenic genes to influence their expression. The factors 
responsible for this direct effect on gene expression have not been fully identified 
but are discussed more fully in 1.7.
55
1.5.5 Angiotensin II and Potassium
The zona glomerulosa of the adrenal cortex is the sole site of aldosterone 
synthesis and secretion in man. Recently however, aldosterone synthase gene 
expression has been detected in vascular endothelium and vascular smooth 
muscle cells in association with mineralocorticoid receptor gene expression by RT- 
PCR (Hatakeyama et al., 1994). In addition, local extra-adrenal aldosterone 
synthesis was demonstrated. Although the degree of aldosterone synthase gene 
expression was low (1/50 th that of the adrenal) this suggests that vascular 
aldosterone synthesis may be important in the control of vascular development.
Three major stimulants of aldosterone secretion have been identified in man, 
angiotensin II (Ang II), plasma [K+] and ACTH. Ang II is an octapeptide hormone 
generated by the renin-angiotensin system. This system consists of one precursor 
protein, angiotensinogen produced by the liver, and two enzymes, renin first 
described in the juxtaglomerular cells of the kidney, and angiotensin-l converting 
enzyme (ACE), widely distributed but found in large amounts in the pulmonary 
vascular endothelium. The components of this system are linked in the 'classical' 
renin-angiotensin system (RAS) (Figure 1.5 i).
Angiotensinogen
Renin
▼
Kidney
Angiotensin I
Angiotensin I- ^  
converting enzyme ^
Angiotensin II
Vascular
Endothelium
Aldosterone
Secretion
Direct Pressor 
Effect
Figure 1.5 i Classical renin-angiotensin system
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Renin (EC 3.4.23.15) is an aspartyl protease secreted by the juxtaglomerular cells 
of the kidney. It has only one substrate in vivo, angiotensinogen, and cleaves this 
protein to release angiotensin I (Ang I). Ang I is the converted into the octapeptide 
Ang II in the pulmonary circulation by ACE. Thus formed, Ang II has two major 
effects, firstly to stimulate aldosterone secretion by the adrenal cortex and 
secondly to produce a direct pressor response through increased resistance vessel 
tone (Swales, 1994). This classical pathway is important in acute cardiovascular 
homeostasis, i.e. the response to head-up tilt or blood loss (Dzau and Pratt, 1986) 
and in the regulation of aldosterone secretion in response to salt depletion (Zoccali 
et al, 1983).
In addition to the classical pathway, there is evidence that a paracrine renin- 
angiotensin system exists where all the components of the RAS are found or 
generated. Tissues such as vascular endothelial and smooth muscle cells, the 
brain and the adrenal cortex have all been shown to possess the elements 
necessary for in situ generation of Ang II (Ehlers and Riordan, 1990, Gould et al., 
1964, Racz et al., 1992, Samani, 1994) (Table 1.5 a).
Tissue Renin Angiotensinogen
Adrenal +++ +
Kidney +++++ ++
Liver +++++
Brain +++ +++
Aorta + +
Heart + ++
Testis ++ -
Table 1.5 a Distribution of renin and angiotensinogen mRNA in tissues (Samani, 1994)
Ang II is thought to produce its effect on aldosterone secretion via the type I 
angiotensin II receptor (ATI). On binding with the ATI receptor which is coupled to 
a G-protein, a number of post-receptor events occur. Phospholipase C activation 
occurs which leads to the hydrolysis of phosphatidyl inositol biphosphate , 
producing inositol triphosphate (IP3) and diacylglycerol (DAG) which leads to a 
rapid rise in intracellular calcium and activation of aldosterone synthesis (Farese et 
al., 1984). In tandem with this there is a decrease in membrane potassium 
permeability and resultant rapid depolarisation of the cell (Shepherd, 1989). 
Voltage-dependent calcium channels open and there is entry of extracellular 
calcium, a process which can be blocked by the dihydropyridine class of calcium
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channel blocking drugs (Kojima et al., 1985a). The rise in intracellular [Ca2+] 
results in opening of calcium-dependent potassium channels and repolarization of 
the membrane. This rise in intracellular [Ca2+] correlates well with aldosterone 
production (Braley et al., 1986). In addition, DAG activates protein kinase C which 
then acts on cellular proteins to alter gene expression, principally at the side-chain 
cleavage step (Aguilera and Catt, 1978) and the aldosterone synthase step 
(Curnow et al., 1991).
In man, studies have defined the sensitivity threshold to intravenous Ang II infusion 
(Oelkers et al, 1974). The threshold varies from 0.3 to 1.0 ng Angll/kg body weight 
min-1 in individuals consuming 100-200mEq of sodium. A low sodium diet 
increases this sensitivity and the magnitude of the response to Ang II rises by up to 
threefold. The threshold sensitivity is often reduced to 0.3 Angll/kg body weight 
min*1, an infusion rate that produces no measureable change in circulating Ang II 
levels (Hollenberg et al, 1974). Potassium loading also increases the maximum 
aldosterone response to Ang II infusion, but by a factor of 1/3 of those caused by 
changes in sodium restriction (Hollenberg et al., 1975). With prolonged Ang II 
infusion, aldosterone secretion decreases, perhaps secondary to whole body 
potassium depletion (Ames et al., 1965).
Potassium stimulates aldosterone secretion which in turn facilitate renal potassium 
excretion thereby forming a means of regulating body potassium balance. In man, 
a 25% increase in aldosterone secretion can be detected after infusion of 10 mEq 
of potassium, an amount which does not increase plasma [K+] (Hollenberg et al, 
1975). Changes in dietary potassium intake for as little as 24 hours can 
substantially modify the adrenal response to acute potassium administration: high 
dietary potassium intake enhances responsiveness, while low potassium reduces it 
(Dluhy et al., 1972). No such changes have been observed when dietary sodium 
intake is varied (Dluhy et al, 1972).
It is thought that potassium acts at the plasma membrane by modifying the 
membrane potential and that the zona glomerulosa cell is peculiarly sensitive to 
potassium-induced membrane depolarisation. Increasing potassium concentration 
leads to depolarisation of the cell membrane and activation of voltage-dependent 
calcium channels in the plasma membrane as the initial step (Kojima et al., 1985b). 
Calcium influx leads to a sustained rise in cytosolic [Ca2+], present for the duration 
of the stimulus, which correlates with aldosterone production (Braley et al, 1986).
ACTH may also increase aldosterone secretion but this is only temporary and after 
24 hours of continuous ACTH administration, the plasma aldosterone falls to
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normal or sub-normal levels in normal individuals (Connell et al., 1987). Some of 
this effect would appear to be due to the rapid sodium retention, and thus 
suppression of Ang II formation, caused by the ACTH-mediated elevation in 
plasma concentrations of intermediates such as 11-deoxycorticosterone, 
corticosterone and cortisol itself (Connell et al, 1987). However, this is not the 
whole reason as sodium restricted individuals given ACTH exhibit the same rise 
and fall in plasma aldosterone despite minimal sodium retention (Connell et al., 
1988). The mechanisms whereby ACTH increases aldosterone secretion are 
thought to be similar to those in the zona fasciculata (Aguilera and Catt, 1978). Of 
interest is the observation that removal of the pituitary gland does not result in any 
immediate change in aldosterone secretion (Orth et al, 1992).
It is clear that Ang II and K+ have important effects on aldosterone secretion and 
that changes in intracellular calcium are central to the action of both stimuli. Ang II 
has added effects mediated through the generation of IP3, which alters intracellular 
[Ca2+], and DAG. ACTH has a temporary effect on aldosterone secretion in normal 
man. How these changes might effect the synthesis of aldosterone via alterations 
in the expression of the steroidogenic enzymes involved in aldosterone secretion is 
not clear but is discussed further in 1.7.
There are a number of other factors which have been shown to influence 
physiological control of aldosterone secretion, namely atrial natriuretic peptide, 
dopamine and serotonin (Ferriss, 1992). These compounds play a minor role in the 
control of aldosterone secretion in man compared with Ang II, potassium and 
ACTH.
1.5.6 Glucocorticoids versus mineralocorticoids
The adrenal corticosteroids which play a major role in the control of blood pressure 
are divided into two classes, glucocorticoids and mineralocorticoids, on the basis of 
their major physiological properties.
Mineralocorticoids stimulate unidirectional transepithelial sodium transport mainly 
in exchange for potassium (Crabbe, 1961). The principal human physiological 
mineralocorticoid is aldosterone, although other steroids, in particular DOC have 
mineralocorticoid potency. Mineralocorticoids promote the active reabsorption of 
sodium in exchange for potassium in the kidney mediated via the action of Na+K+ 
ATPase. Mineralocorticoids also mediate hydrogen ion secretion in the kidney by 
an apparently independent mechanism involving an ATP-dependent hydrogen ion 
pump.
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The classification of glucocorticoids was based on the principal physiological effect 
of steroids on intermediary carbohydrate metabolism. This definition is perhaps not 
ideal as it really only refers to one of the more easily observed effects of cortisol 
despite the fact that glucocorticoids have potent effects on lipid metabolism, the 
modulation of immune responses and inflammatory processes, tissue 
development, also sodium: hydrogen exchange and glomerular filtration rate.
Another perhaps more appropriate way to classify corticosteroids is to look at their 
binding properties to nuclear receptors. Nuclear steroid receptors form part of a 
larger nuclear receptor family encompassing steroid, thyroid, retinoic acid, vitamin 
D and other orphan receptors. Two receptors of direct importance to this 
discussion are the human glucocorticoid receptor (hGR or GR) and the human 
mineralocorticoid (hMR or MR) receptor.
The cDNA for hGR was first cloned from lymphocytes (Hollenberg et al., 1985). 
Subsequently, the human mineralocorticoid receptor was cloned and sequenced 
from a kidney cDNA (Arriza et al., 1987). The DNA binding regions of the two 
receptors was 94% identical and the C-terminal ligand binding domains are 57% 
identical whilst the N-terminal region of the receptors is < 15% homologous (Figure 
1.5. j).
MR
Identity <15% 94% 57%
DNA binding domain
Ligand binding domain
Figure 1.5 j Schematic representation of human mineralocorticoid (MR) 
and glucocorticoid (GR) receptors
Binding of steroids to steroid hormone receptors leads to the activation of cis- 
acting elements located in or near hormone responsive genes (Beato, 1989). On
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binding steroids the receptor and its associated molecules ('chaperonins' (Bodine 
and Litwack, 1988)) dissociate and the steroid-receptor complex can travel to the 
cell nucleus. Dissociated from the satellite proteins, the steroid-receptor complex 
can then bind as a dimer to a specific region of DNA termed the hormone response 
element (HRE). HRE are present in many genes and fall into three groups, the 
glucocorticoid/progesterone-responsive element (GRE/PRE) which also serves as 
the mineralocorticoid-responsive element, the estrogen responsive element (ERE), 
and the thyroid responsive element (TRE) (Table 1.5 b). Binding to these sites is 
through the highly conserved 'zinc finger' region of the receptor which, if altered, 
leads to depression of DNA binding (Freedman, 1992). Thus bound, the steroid- 
receptor complex leads to transcriptional activation of the bound gene by switching 
on enhancer regions of the gene (Carson-Jurica et al., 1990), a process which may 
be modified by other factors, e.g. insulin and binding of activated glucocorticoid 
receptor to DNA in the liver (Tsawdaroglou et al., 1989). It is through this series of 
events that steroid hormones exert their effects in man. In the case of MR, the 
exact mechanism is not known but it is likely to be similar to that of GR (Carson- 
Jurica et al, 1990).
Hormone-responsive element II Consensus sequences
GRE-MRE-A RE 5'-AGGACANNNTGTACC-3'
ERE | 5,-NGGTCANNNTGACCN-3‘
VDRE || 5'-TT GGTG ACT CACCGGGT G AAC-3’
TRE || 5'-GGGTCATGACAG-3'
RARE || 5'-AGG ACAT G ACCT-3'
GRE - glucocorticoid-responsive element, MRE - mineralocorticoid-responsive element, ARE - 
androgen-responsive element, ERE - estrogen-responsive element, VDRE - vitamin D-responsive 
element, TRE - thyroid-responsive element, RARE - retinoic acid-responsive element. N - any 
nucleotide.
Table 1.5 b Consensus sequences of gene hormone-responsive elements
Studies of the in vitro receptor affinity of GR and MR have revealed that the affinity 
of GR for steroids mirrors their in vivo therapeutic potency whilst MR has equal 
affinity for aldosterone, cortisol and corticosterone in both adrenal tissue and 
recombinant MR studies (Arriza et al, 1987, Krozowski and Funder, 1983) This 
does not mirror the in vivo observations of the effects of aldosterone and cortisol in 
classic mineralocorticoid target tissues (Sheppard and Funder, 1987). In normal 
subjects cortisol concentrations are 100-1000 times that of aldosterone and would 
thus be expected to exert important mineralocorticoid effects well in excess of 
aldosterone at normal plasma concentrations which is clearly not the case in vivo.
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It has been shown that cortisol undergoes dehydrogenation to form cortisone, an 
inactive metabolite in man. The enzyme which performs this reaction, 116- 
hydroxysteroid dehydrogenase (1113-OHSD), also catalyses the opposite 11- 
oxoreductase step in man (Figure 1.5. k) (Edwards et al., 1988).
NADP+ NADPH
Cortisol ^  ^  Cortisone
11BOHSD
^  Reduction
Oxidation ^
Figure 1.5 k 11B-hydroxysteroid dehydrogenase (11BOHSD) activity
A single gene on chromosome 1 encodes an 11G-OHSD enzyme (Tannin et al.,
1991) and which is expressed in mineralocorticoid target tissues such as the 
kidney and salivary glands (Edwards et al, 1988, Tannin et al, 1991).
It was hypothesised that 118-OHSD protects MR from the effects of cortisol in 
target tissues by converting it to cortisone, which does not bind to MR (Oberfield et 
al., 1983) and thus allows only aldosterone to exert a physiological effect at the MR 
(Oberfield et al, 1983, Stewart et al., 1987). Studies of glycyrrhetinic acid, the 
active derivative of liquorice, have shown that liquorice-induced hypertension 
occurs only in the presence of cortisol or ACTH (Hoefnagels and Kloppenborg, 
1983), thus ruling out the possibility of a direct effect of glycyrrhetinic acid on the 
MR in the kidney producing hypertension. Therefore, it would appear that if 
11GOHSD was inactivated, binding of cortisol, or corticosterone in the rat, would 
occur and induce mineralocorticoid effects. The administration of inhibitors of 
11 GOHSD (liquorice and carbenoxolone ) to rats (Edwards et al, 1988, Funder et 
al., 1988) given [3H]-corticosterone was shown to result in binding of both [3H]- 
corticosterone and [3H]-aldosterone to MR target tissues confirming that 11 GOHSD 
confers protection on the MR from cortisol in man or corticosterone in the rat.
Figure 1.5 I outlines the mechanism whereby aldosterone and cortisol interact with 
their respective receptors and the role of 11 G-OHSD in modulating the effect of 
cortisol in aldosterone target tissues.
Mineralocorticoid effects are therefore caused by binding of a corticosteroid to the 
MR and the nature of the steroid itself is may not be of principal importance. The
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CORTISOL ALDOSTERONE CORTISOL-J-....ri--------r
11BOHSD in )
( endopl asmi c reticulum
)
CORTISONE
NUCLEUS NUCLEUS
AE - Accessory element, AP - Accessory Proteins, e.g. cFos, cJun 
HRE - Hormone-response element
GR - Glucocorticoid Receptor, MR - Mineralocorticoid Receptor 
Zn - Zinc finger DNA-binding region of receptor 
1113-OHSD - 11f3-hydroxy steroid dehydrogenase enzyme
Figure1.5 I Mechanism of enzyme-mediated protection of mineralocorticoid receptor
effects of mineralocorticoids on target tissues are discussed in 1.6 whilst the 
effects of abnormalities in 11BOHSD activity are reviewed in 1.8.4.
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1.6 Aldosterone and its Effects in Man
The principal physiological effect of aldosterone is to regulate electrolyte transport 
across epithelial surfaces. The principal physiological target organ for aldosterone 
is the kidney, but the salivary gland and the colon also demonstrate aldosterone- 
sensitive regulation of electrolyte transport (Orth et al, 1992). This occurs through 
binding to high-affinity receptors, MR, as described in 1.5.6. In addition, MR is 
present in liver, hippocampus, pituitary, and peripheral blood leucocytes (Orth et al, 
1992). The specificity of the human MR for cortisol and aldosterone is identical and 
it is the enzyme 1160HSD which confers enzyme-mediated receptor protection for 
the MR in situations where cortisol is present in a large excess over aldosterone.
Although the classical MR is a member of the nuclear receptor superfamily, recent 
work has suggested that membrane receptors for aldosterone exist and may 
mediate rapid non-genomic effects in human mononuclear leucocytes .
1.6.1 Aldosterone and the renal tubule
Receptors in the kidney bind aldosterone and effect a net increase in sodium 
resorption at the expense of potassium and hydrogen ions (Figure 1.6 a). The 
major sites of aldosterone-induced sodium and potassium transport are the cortical 
collecting tubules, and the distal convoluted tubule and it is the luminal cells which 
appear to mediate sodium:potassium transport. The basolateral membrane of 
these cells is lined by a Mg2+-dependent Na+K+-activated ATPase. This ubiquitous 
transmembrane protein maintains the sodium and potassium electrochemical 
gradient across the cell membrane. During chronic aldosterone administration, 
these cells undergo characteristic ultrastructural changes with a marked increase 
in basolateral membrane surface area, and a high degree of expression of the 
genes for the a- and 6- subunits of the Na+K+-ATPase (Komesaroff et al., 1994). 
Aldosterone acts to promote sodium retention at the expense of potassium by this 
and other mechanisms (See 1.6.3). Approximately 95% of all filtered sodium is 
reabsorbed prior to arriving at the site of aldosterone-sensitive sodium reabsorption 
by the loop of Henle. However, the remaining 5% still constitutes some 80 grams of 
sodium daily, 10-20 times the normal amount ingested daily, and regulation of the 
reabsorption is clearly important in regulating blood pressure.
Aldosterone also regulates hydrogen ion excretion by the kidney in the distal 
nephron. The mechanisms are different, however, from those of sodium and 
potassium. Aldosterone-mediated hydrogen ion secretion occurs in the intercalated
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Figure 1.6 a Sodium transport across the renal tubular epithelium
cells of the collecting tubule. These cells along with the principal cells of the tubule 
arise from a common precursor, the (3-intercalated cell (Komesaroff et al, 1994).
Hydrogen ion secretion is through a sodium-insensitive route; given that this 
segment of the nephron exhibits little or no aldosterone-induced sodium transport, 
aldosterone-induced natriuresis and hydrogen ion secretion appear to be 
independent events. This effect appears to be mediated via an effect of 
aldosterone on the activity of the ATP-dependent apical hydrogen ion pump and 
parallel regulation of the basolateral membrane CIVHCO3- exchanger (Hays, 1992).
The net effect of aldosterone on the renal tubule is therefore to promote sodium 
retention at the expense of potassium and also to promote hydrogen ion excretion 
by the kidney. This explains the clinical features observed in cases of primary 
aldosterone excess, i.e. plasma hypokalaemia, alkalosis, a raised exchangeable 
sodium content and low total body potassium (Ferriss et al., 1983, Kremer et al., 
1977).
1.6.2 Aldosterone and the heart
Although the classical effects of aldosterone are those related to the control of 
electrolyte balances across epithelia, a number of non-epithelial actions of 
aldosterone on blood pressure, 6-adrenoceptor density and salt appetite have 
been noted (Funder, 1992). Another important non-epithelial effect of aldosterone 
reported is the promotion of perivascular and interstitial cardiac fibrosis when 
aldosterone levels are inappropriately high in relation to sodium status. That is, in 
sodium-loaded rats with aldosterone excess due to infusion there is a marked 
accumulation of fibrillar type I collagen around the intracoronary arteries and 
extending into the neighbouring interstitial spaces (Weber et al., 1992). In these 
models, hypertension is present and left ventricular hypertrophy develops. 
However, fibrosis can develop in the absence of hypertension or hypertrophy in 
animals with aldosterone excess (Weber et al, 1992), and pre-treatment of animals 
with the aldosterone antagonist spironolactone, inhibits the accumulation of cardiac 
collagen (Brilla et al., 1993b). Comparable studies using infrarenal aortic banding 
to produce aldosterone-independent hypertension and ventricular hypertrophy to a 
similar degree have shown that in these models there is no appreciable increase in 
myocardial collagen (Weber et al, 1992).
Thus it appears that in animal models of aldosterone-dependent hypertension 
myocardial fibrosis may result from non-epithelial actions of aldosterone. Nuclear 
MR are present in all four chambers of the heart but are not protected by the
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presence of 11BOHSD and are thus in effect high-affinity glucocorticoid receptors 
given the disparity in plasma concentrations of aldosterone and cortisol (Funder et 
al, 1988). This raises the possibility that aldosterone may be acting to produce 
myocardial fibrosis via mechanisms other than the classic nuclear receptor despite 
the fact that spironolactone can inhibit the fibrotic reaction,. The description of high- 
affinity aldosterone receptors on leucocyte membranes with low affinity for 
spironolactone or cortisol may provide an alternative mechanism (Wehling et al., 
1992). Cardiac fibroblasts can produce collagen in vitro in response to low doses of 
aldosterone which is not inhibited by spironolactone, an observation which 
supports a role for the membrane bound aldosterone receptor (Funder, 1992).
There are few data about such a role in man but one post-mortem study of 5 
patients with aldosterone-secreting adenomata revealed the presence of 
perivascular fibrosis of the intramural cardiac and systemic arteries in a similar 
distribution to that seen in rats with mineralocorticoid excess (Campbell et al., 
1992). Thus non-classical effects of aldosterone may be important in modulating 
blood pressure by altering vascular compliance or influencing the progression of 
end-organ damage such as left ventricular hypertrophy by interaction with 
membrane bound or classical MR.
1.6.3 Mechanism of action of aldosterone
The mechanism of action of aldosterone is not fully understood at present. 
Obviously its actions may differ depending on which receptor is involved, i.e. 
nuclear or membrane. In tissues such as the mononuclear leucocyte, the effects 
are thought to be non-genomic and mediated through interaction of the membrane 
bound aldosterone-receptor complex with a second messenger system which 
increases intracellular levels of IP3 and results in activation of Na+/H+ antiporters 
(Wehling et al, 1992).
The slower, genomic effects are produced by a series of steps following binding of 
aldosterone to its receptor and take a number hours to days to reach a maximum 
and involves the synthesis of mRNA and proteins . When MR binds aldosterone it 
migrates to the cell nucleus where it binds to an HRE thought to be similar to that 
of the human GR (Beato, 1989). Following this transcriptional activation occurs and 
during this latent period DNA transcription and protein translation occurs. The 
resultant gene product(s), termed 'Aldosterone-induced protein (AIP), is then 
thought to promote sodium reabsorption and excretion of potassium and hydrogen 
ions by one of three mechanisms (Figure 1.6 b) (Komesaroff et al, 1994).
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Sodium enters the tubular cell via amiloride-sensitive sodium channels in the 
apico-luminal membranes of the cell by passive diffusion down a concentration 
gradient; its exit from the cell across the basolateral membrane in exchange for 
potassium is mediated by the energy dependent Na+K+-ATPase. AIP may have 
effects on the apical membrane, cellular energy production, and/or the sodium 
pump. It would appear that the initial response is an increase in apical sodium 
conductance and an increase in Na+K+-ATPase activity subsequent upon the rise 
in intracellular [Na+] with chronic aldosterone administration leading to an increase 
in the synthesis of pump proteins (Komesaroff et al, 1994, Schafer and Hawk,
1992). Similarly the synthesis of citrate synthetase and other Krebs' cycle enzymes 
increases following the acute response (Komesaroff et al, 1994, Schafer and 
Hawk, 1992).
The effect of aldosterone on apical sodium channels appears not to be an increase 
in synthesis of sodium channels. There is evidence however that aldosterone 
increases the number of open channels in the membrane by some post 
translational effect, either by methylation of a channel subunit by enzymes which 
produce a concomitant rise in s-adenosylmethionine levels, or by altering some 
modulatory subunit of the channel (Komesaroff et al, 1994).
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1.7 Molecular Biology of Aldosterone Synthesis
Aldosterone is synthesised exclusively in the zona glomerulosa in man and is the 
principal human mineralocorticoid. Aldosterone is the end-product of a series of 
reactions starting with the conversion of cholesterol to pregnenolone by P-450scc 
in the inner mitochondrial membrane. Pregnenolone is then converted to 
progesterone by 36-hydroxysteroid dehydrogenase/A5 -A4 isomerase and 
progesterone converted to 11 -deoxycorticosterone by P-450C2i in the smooth 
endoplasmic reticulum of the cell. In the zona glomerulosa there is no significant 
expression of P-450C17 (Curnow et al, 1991) and the result is the production of 17- 
deoxycorticosteroids, i.e. 11-deoxycorticosterone (DOC). In the zona fasciculata 
not all progesterone undergoes 17a-hydroxylation by P-450C17 (White et al., 1994) 
and as a result both DOC and 11-deoxycortisol are formed. It is at this point that 
the major difference between zona glomerulosa and zona fasciculata cells 
becomes apparent. In man, both the zona fasciculata and the zona glomerulosa 
can convert DOC to corticosterone. Indeed, in man the major quantitative source of 
corticosterone is the zona fasciculata. However, it is the formation of aldosterone 
from DOC through corticosterone which is unique to the cells of the zona 
glomerulosa.
1.7.1 110-hvdroxvlation in the adrenal cortex
The steps involved in the conversion of DOC to aldosterone and 11 -deoxycortisol 
to cortisol are often termed the 'late reactions' or 'late pathways' in adrenal steroid 
synthesis. The conversion of 11 -deoxycortisol to cortisol and DOC to 
corticosterone requires the addition of an 116-OH group at the C11 position of both 
DOC and 11-deoxycortisol (Figure 1.7 a). The 116-hydroxylase step is catalysed 
by the mitochondrial enzyme P-450-mb in man. This enzyme is able to 11 - 
hydroxylate both substrates in man and is encoded by a single gene on 
chromosome 8, CYP11B1 (Chua et al., 1987, Mornet et al, 1989). Analysis of a 
panel of human somatic cell hybrids coupled with in situ hybridisation to 
metaphase chromosomes has localised this gene to chromosome 8q22 (Wagner et 
al, 1991). In vitro expression of human P-450-mg cDNA in COS-7 cells has shown 
that the conversion of DOC to aldosterone by human P-450-mb is negligible 
although it can form corticosterone and a little 18-hydroxycorticosterone (Table 1.7
a) (Kawamoto et al., 1992). Thus we have good evidence that in man P-450-mb is 
responsible for the formation of cortisol and corticosterone in the zona fasciculata 
but is unable to perform the necessary reactions for the conversion of DOC to 
aldosterone.
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11-DEOXYCORTICOSTERONE
■11 B-hydroxylation-^r|A ldo»1»ron« »yn th« i [ l1 P -h yd ro xy l« « e |
CORTICOSTERONE
CORTISOL
-18-hydroxylation[A ld o x t fo n »  »yn th«»e|
Zona fasciculata
■18-oxidation
ALDOSTERONE
Zona glomerulosa
Conversion of 11-deoxycorticosterone to aldosterone is performed by a 
single enzyme, aldosterone synthase,without the release of intermediates.
Conversion of 11-deoxycorticosterone to corticosterone is carried out in 
both the glomerulosa and the fasciculata zones. However, 1113-hydroxylase 
in the fasciculata cannot catalyse the formation of aldosterone.
Figure 1.7 a 'Late reactions' of adrenal corticosteroidogenesis
Substrate Product Hydroxylase
Activity
P-450-j 1 b P-450a|do
DOC Corticosterone 482 438
18-OH-Corticosterone 2.7 14
Aldosterone <0.02 2.0
11-deoxycortisol Cortisol 411 393
18-OH-cortisol 1.1 7.0
18-oxocortisol <0.02 1.8
Corticosterone 18-OH-Corticosterone 1.5 10.6
Aldosterone <0.02 0.9
Cortisol 18-OH-cortisol 0.7 4.0
18-oxocortisol <0.02 0.4
Table 1.7 a Hydroxylase activity of P450s expressed in COS-7 cells. Results are expressed 
as pmol/mg of protein. Adapted from (Kawamoto et al, 1992).
The bovine adrenal gland may be different from the human gland. Bovine P-450nG 
can convert corticosterone to aldosterone in addition to the 11 3-hydroxylation of 
DOC (Yanagibashi et al., 1986, Yanagibashi et al., 1988). Further characterisation 
of the bovine enzyme suggested that not one but two isozymes existed; both had 
113-hydroxylase and 18-hydroxylase activity and could convert DOC to 
aldosterone (Ogishima et al., 1989b) This suggested that two isozymes of bovine 
P-450-113 existed in the adrenal cortex with differing substrate specificities relative 
to their location within the adrenal cortex. In the rat two distinct forms of P-450hb 
have been identified with differing catalytic activities. One has a molecular mass of 
51 kDa and can convert DOC to corticosterone but has minimal ability to convert 
DOC to aldosterone. The other has a molecular mass of 49 kDa but is highly active 
in converting DOC to aldosterone (Ogishima et al., 1989a).
Therefore, there is evidence from studies of rat adrenal corticosteroidogenesis that 
aldosterone synthesis from DOC can be performed by an enzyme distinct from P- 
450iib. Thus, in the human zona glomerulosa aldosterone synthesis could also be 
performed by an enzyme similar to but distinct from P-450hb .
1.7.2 Aldosterone synthase activity in the adrenal cortex
In addition to describing the presence of a gene for P-450-mb in man, Mornet 
described the presence of a second gene, CYP11B2, with a high degree of 
homology to CYP11B1 in human genomic clones (Mornet et al, 1989). The 
nucleotide sequence of CYP11B1 and CYP11B2 are 95% identical in coding
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regions, and 90% identical in the intronic regions. The predicted amino acid 
sequence of the gene products of CYP11B1 and CYP11B2 are 93% identical. 
However, analysis of mRNA from human adrenal glands showed that there was 
strong hybridisation of a CYP11B1-specific probe to the adrenal mRNA but no 
detectable hybridisation of a CYP11B2-specific probe, suggesting that the gene 
CYP11B2 was a pseudogene with no function or was expressed at very low levels 
in normal adrenals in man. Later, a cDNA clone was isolated from tissue from a 
patient with idiopathic hyperaldosteronism which was shown to be the transcript of 
CYP11B2 and to possess the ability to convert DOC to aldosterone (Kawamoto et 
al., 1990a). This was the first evidence that CYP11B2 may encode a functionally 
important gene product with aldosterone synthase activity, i.e. P-450aido- A similar 
report of P-450aido expression in aldosterone-producing adenoma tissue showed 
that P-450aido did indeed catalyse aldosterone synthesis from DOC and the protein 
product had a molecular mass of 48.5 kDa compared with 50 kDa for P-450n3 
(Ogishima et al., 1991).
The final confirmation that P-450aidO was entirely responsible for aldosterone 
synthesis in the human zona glomerulosa came from Curnow (Curnow et al, 1991). 
She showed that although Northern blot analysis did not reveal the presence of 
CYP11B2 in human adrenal tissue, a more sensitive method using a reverse 
transcriptase-PCR (RT-PCR) assay did reveal CYP11B2 transcripts in normal 
adrenal glands. The level of transcription in normal human adrenal was low, both 
compared to CYP11B1 transcripts in normal adrenals and the level of transcription 
of CYP11B2 seen in aldosterone-secreting tumours. The entire coding sequences 
of CYP11B1 and CYP11B2 were then amplified from aldosterone-secreting tumour 
tissue and expressed in COS-1 cells along with pCD-Adx (a plasmid containing the 
cDNA for adrenodoxin which is inadequately expressed in COS-1 cells (Zuber et 
al., 1988)). These cells were incubated with [14C]DOC or [3H]11-deoxycortisol.
Cells transfected with CYP11B1 converted 11-deoxycortisol almost entirely to 
cortisol although a little cortisone was formed by the action of the intrinsic 1113- 
hydroxysteroid dehydrogenase activity of the COS-1 cells. DOC was converted to 
corticosterone and 11 -dehydrocorticosterone but no aldosterone was detected. 
Cells transfected with CYP11B2 produced substantial amounts of corticosterone 
and 18-hydroxycorticosterone from DOC and in addition, aldosterone was 
detected. With 11-deoxycortisol as the substrate, CYP11B2 transcripts produced 
cortisol, cortisone, and a third steroid 18-hydroxycortisol. Unpublished observations 
from this group (PC White, personal communication) revealed that the conversion 
of DOC to aldosterone by P-450aidO is similar to that for the conversion of 
cholesterol to pregnenolone, i.e. the three stages of the reaction occur without the
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release of intermediate products (Lambeth et al., 1982). White has shown that both 
corticosterone and 18-hydroxycorticosterone are much less good as substrates for 
P-450aido than DOC and that addition of both corticosterone and 18- 
hydroxycorticosterone does not inhibit aldosterone synthesis from DOC.
1.7.3 Molecular genetics of CYP11B1 and CYP11B2
The genes CYP11B1 and CYP11B2 are very similar in many respects. Both lie on 
chromosome 8q21-22 (Chua et al, 1987, Mornet et al, 1989, Wagner et al, 1991). 
The organisation of introns and exons in each gene is similar; each gene consists 
nine exons with the coding regions of each gene spread over approximately 7 
kilobases of DNA (Figure 1.7 b). The nucleotide sequence of the exons is 95% 
identical and that of the introns approximately 90%. The putative proteins encoded 
by CYP11B1 and B2 each contain 503 amino acids including a 24-residue signal 
peptide. These sequences are 93% similar to each other and 75% similar to the 
predicted sequence of bovine P-450hg and 36% identical to that of CYP11A. The 
positions of the introns of CYP11B1 and B2 are identical to those of CYP11A (gene 
for P-450scc) (Morohashi et al., 1987). For these reasons these genes are 
grouped into a single family within the cytochrome P-450 gene superfamily (Nelson 
et al., 1993).
Both CYP11B1 and B2 possess a TATA box variant at position -35 to -29 
(GATAAAA) relative to the transcription initiation site. Both possess a palindromic 
sequence identical to sequences seen in cAMP-responsive genes (TGACGTA), i.e. 
a cAMP response element (CRE), which binds to cAMP-responsive element 
binding protein (CREB), downstream from the TATA box. Factors that bind to 
TATA boxes (Kao et al., 1990) and cAMP response elements (Meyer and Habener,
1993) have been identified. Clinical and biochemical observations of in vitro 
responses to ACTH suggest that cAMP is responsible for the regulation of 
steroidogenic enzyme synthesis (Simpson and Waterman, 1988) through 
increased transcription of steroidogenic enzyme cDNA (John et al, 1986), and 
expression of cDNA constructs in vitro has shown that cAMP regulates the 
transcription of CYP11B1 (Kawamoto et al., 1990b). It is thought that the 
generation of cAMP by adenylate cyclase leads to the activation of cAMP- 
dependent kinase and subsequent phosphorylation of CREB which binds to the 
CRE with resultant increased gene expression.
Cell-specific expression of steroidogenic enzymes may arise due to sharing of a 
specific promoter element in these genes. In support of this was the discovery of a 
AGGTCA motif in the promoter regions of mouse P450scc» P450c2i» P450aido, and
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i. Structure of human CYP11B genes 
CYP11B1
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8.3 1.9
CYP11B2
Probe
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Probe
ii. BamHI restriction sites of CYP11B1 and CYP11B2
Figure 1.7 b Organisation of human CYPB 11 genes
bovine P450hb, which binds a protein alternatively designated steroidogenic 
factor I (SF-I) (Rice et al., 1991), or adrenal-4-binding protein (Morohashi et al., 
1992). Several copies of this sequence appear in the regulatory regions of all 
steroid hydroxylase genes expressed in the adrenal cortex and the gonads and are 
found in the 5' flanking regions of CYP11B1 and B2.
Isolation of the cDNA for SF-I from a bovine adrenal library and study of the 
nucleotide sequence revealed that the nucleotide sequence and organisation of 
the SF-I gene was similar to that of members of the nuclear receptor family, i.e. 
thyroid, steroid, retinoic acid and vitamin D receptors (Morohashi et al, 1992). 
However, the nature of the in vivo ligand of this receptor is not yet known (Honda 
et al., 1993). In addition, SF-I is expressed only in steroidogenic tissues (Lala et al.,
1992) and its cDNA bears considerable homology to two unusual proteins. Firstly, 
SF-I cDNA resembles that of embryonal long-terminal repeat binding protein (ELP), 
which silences retroviral expression in mouse embryonal carcinoma cells 
(Tsukiyama et al., 1992). It has been shown that both ELF and SF-I are encoded 
by the same gene but that transcripts differ due to alternative processing of the 
gene at the time of transcription depending on the developmental stage of the 
animal (Tsukiyama et al, 1992). Secondly, it resembles the cDNA for encoding a 
protein that regulates fushi tarazu (ftz) homeobox gene in Drosophila, termed FTZ- 
F1 (Tsukiyama et al, 1992). Two different forms of FTZ-Z1 exist, early and late, 
expressed at different stages in development, but with similar DNA binding 
properties (Ueda et al., 1990). In summary, there is some evidence to suggest that 
the FTZ-F1 gene in Drosophila and mouse encode developmental^ specific 
proteins that provide alternative functions: ELP/early FTZ-F1, which are essential 
in early embryonic development, and SF-l/late FTZ-F1 which are expressed at a 
later stage and persist in the adult animal. These proteins have important factors in 
gene regulation. In particular SF-I can bind to and increase the transcription of 
steroidogenic enzymes in the adrenal gland. Finally, recent work has shown that by 
using gene targeting to disrupt the SF-1 gene in mice, SF-1 deficient mice do not 
survive the neonatal period and do not develop adrenal glands or gonads (Ikeda et 
al., 1994). Therefore, SF-1 is essential to the post-embryonic development and SF-
I may be an important global regulator of steroid hydroxylase gene expression.
Aldosterone synthase activity is confined to the zona glomerulosa cells and 
therefore expression of CYP11B2 must be regulated in a manner different from 
that of CYP11B1 (1.7.2). In primary cultures of human zona glomerulosa cells, Ang
II markedly increases the level of both CYP11B1 and B2 transcripts (Curnow et al,
1991). ACTH increases CYP11B1 mRNA levels but has no effect on CYP11B2
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transcription (Curnow et al, 1991). In NCI-H295 human adrenocortical carcinoma 
cells, which synthesise both cortisol and aldosterone, Ang II increases CYP11B2 
mRNA levels and aldosterone synthesis (Bird et al., 1993). These cells are 
unresponsive to ACTH, but both CYP11B1 and B2 mRNA levels are increased by 
8-bromo cAMP administration, i.e. the ACTH second messenger (Staels et al.,
1993).
Differences in gene transcription may result from important divergence's in the 
structure of the relative promoter regions of the two genes. In the 5' untranslated 
region of both genes, outwith the immediate vicinity of the transcription initiation 
site, the nucleotide sequence of the two genes diverges quite considerably. These 
regions are only 48% identical, the difference arising principally due to the 
presence of a long palindromic sequence in CYP11B2 from -1734 to -1001 
(Kawamoto et al, 1992). For CYP11B1 the 5' flanking region up to -1093 displays 
8-bromo cAMP-responsive promoter ability. Deletion of the promoter to -760 or 
-505 results in a diminution of promoter activity and deletion to -294 virtually 
abolishes promoter activity. Deletion to -105 or -47 also abolishes promoter 
activity. CYP11B2 is different. Expression of constructs containing up to -2015 of 
the 5' flanking region had no promoter activity in response to 8-bromo cAMP. 
Deletion of the region to -1490, -654, -373 also destroyed promoter activity. A 
weak, presumably basal promoter response, however, was detected when the 
flanking region was deleted to -64, i.e. the region -2015 to -65 in CYP11B2 inhibits 
the promoter activity of CYP11B2 in vitro (Figure 1.7 c) (Kawamoto et al, 1992).
These differences in the promoter regions between genes clearly result in 
important alterations in promoter-dependent regulation of gene expression, 
particularly the differential response to cAMP effects, and may also have a role in 
determining the site-specific expression of the genes.
Finally, in the mouse, CYP11B1 and CYP11B2 lie in tandem with CYP11B2 on the 
left, if the genes are pictured as being transcribed right to left (Domalik et al.,
1991). As yet no genomic clones have been identified which link these genes in 
man but evidence from studies of patients with congenital hypoaldosteronism due 
to aldosterone synthase deficiency (corticosterone methyloxidase II deficiency) 
(Pascoe et al., 1992b) and glucocorticoid-suppressible hyperaldosteronism (1.9) 
suggest that the same arrangement exists in man. Study of large restriction 
fragments generated by rare cutting restriction enzymes and separated by pulsed 
field gel electrophoresis suggests that the two genes are located in close proximity, 
approximately 40 kilobases apart (Lifton et al., 1992, Pascoe et al., 1992a).
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In summary, in man two highly homologous genes encoding steroidogenic 
enzymes lie together on chromosome 8q21-22 approximately 40 kilobases apart. 
One gene, CYP11B1 encodes the enzyme P-450-mb which catalyses the formation 
of cortisol and corticosterone in the zona glomerulosa. Its transcription is regulated 
by ACTH via cAMP and it is unable to catalyse the formation of aldosterone. The 
other, CYP11B2 is expressed only in the zona glomerulosa in normal human 
adrenal tissue and catalyses the synthesis of aldosterone from DOC. CYP11B2 is 
regulated in vitro by Ang II and its promoter region differs considerably from that of 
CYP11B1, a difference which may reduce responsiveness to cAMP. These genes 
are clearly of central importance in the synthesis of aldosterone and cortisol and 
mutations altering the activity of their gene products may have important effects on 
blood pressure in man.
The entire sequence of both genes is listed in Appendix IV.
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1.8 Mineralocorticoid-hvpertension in Man
Mineralocorticoid-dependent hypertension is uncommon in man (1.3.1). However, 
there are a number of important clinical syndromes in which either aldosterone or 
other mineralocorticoids are secreted in excess. Several of these have a genetic 
basis and may give an insight into the nature of the genetic component of essential 
hypertension.
1.8.1 Syndromes of Primary Aldosterone Excess
Excessive aldosterone production occurs in three principal situations - 
Aldosterone-secreting adenoma or carcinoma, idiopathic hyperaldosteronism due 
to bilateral adrenal hyperplasia, and glucocorticoid-suppressible 
hyperaldosteronism. Hyperaldosteronism is an uncommon cause of hypertension 
with a prevalence reported between 2-12% in some series of patients with 
hypertension (Grim et al., 1977, Streeten et al., 1979), although in most series of 
screened populations the prevalence is considerably lower (Lewin et al, 1985, 
Sinclair et al, 1987). However, given the high prevalence of hypertension in 
western populations, in the order of 20% at some time in the lifetime of an 
individual, as many as 1 in 10000 of the population could be expected from these 
estimates to have primary hyperaldosteronism as the cause of their hypertension 
although this is likely to be an over estimate.
Aldosterone-secreting adrenal adenoma was first described in 1955 (Conn, 1955), 
less than 3 years after the discovery of aldosterone (Simpson et al., 1953). The 
case report detailed a patient with hypertension and hypokalaemia with 
aldosterone excess. The patient had a 4cm adenoma arising from the cortex of the 
right adrenal gland which had detectable aldosterone activity some 75-150 times 
that of normal adrenal tissue. Following this report numerous other descriptions of 
aldosterone-secreting adenomas were published along with studies of the 
abnormal physiology in such patients (Brown et al., 1972b).
Aldosterone-secreting adenomas account for approximately 75% of patients with 
primary hyperaldosteronism (Biglieri et al., 1989). The majority of cases occur in 
individuals aged 30-50 years and in more females than males (Ferriss et al, 1983). 
The majority of such patients are asymptomatic although some may manifest 
symptoms of hypokalaemia such as polyuria, muscle weakness and parasthesiae 
(Conn et al., 1964). Hypertension is a virtually invariable outcome of aldosterone- 
secreting adenomas and can result, albeit rarely, in malignant phase hypertension
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(Brown et al., 1965). Excessive aldosterone secretion leads to sodium retention 
and renal potassium excretion which may be reflected by plasma hypernatremia 
and hypokalaemic alkalosis. Exchangeable sodium levels are elevated in 
proportional to the degree of hypertension (Davies et al., 1979), and total body 
potassium levels low. Sodium-induced plasma volume expansion leads to 
suppression of plasma renin activity and plasma Ang II but has no effect on plasma 
aldosterone concentrations as this is produced autonomously by the adrenal 
adenoma.
Plasma aldosterone concentrations in patients with primary hyperaldosteronism 
with adenoma (Conn's syndrome) may vary throughout the day, with an ACTH-like 
diurnal rhythm, and at times may lie within the normal range (Weinberger et al., 
1979) and occasionally other measurements are require to confirm the diagnosis. 
Measurement of plasma concentrations of precursors of aldosterone, in particular 
18-hydroxycorticosterone (raised in virtually all cases (Biglieri and Schambelan, 
1979, Fraser et al., 1981)) and DOC (raised in 50% of cases (Biglieri and 
Schambelan, 1979)), may be helpful in some situation. In patients with marked 
hypokalaemia, conversion of 18-hydroxycorticosterone to aldosterone may be 
impaired and measurement of 18-hydroxycorticosterone levels may be of greater 
value than aldosterone alone (Biglieri and Schambelan, 1979). In normal subjects, 
assuming an upright posture stimulates renin secretion and a rise in Ang II and 
subsequently plasma aldosterone. In subjects with Conn's syndrome plasma renin 
and Ang II are suppressed and on assuming an upright posture there is usually a 
fall or no change in plasma aldosterone concentrations . Similarly, infusion of 
normal saline or administration of oral 9a-fludrocortisone (a synthetic 
mineralocorticoid) in normal subjects results in sodium retention and suppression 
of the renin angiotensin system and a fall in plasma aldosterone concentration. 
Individuals with Conn's syndrome fail to suppress plasma aldosterone in such 
circumstances (Streeten et al, 1979, Weinberger et al, 1979). Another features of 
altered aldosterone regulation in Conn's syndrome is the absence of aldosterone 
secretory response to Ang II infusion (Fraser et al, 1981) and an augmented 
response to ACTH infusion. However, some authors have reported a sub-group of 
aldosterone-secreting adenomas which are Ang II sensitive which highlight the 
importance of not relying entirely on physiological testing to determine the 
pathological diagnosis of hyperaldosteronism (Gordon et al., 1987).
Diagnosis of Conn's syndrome is made by documenting primary 
hyperaldosteronism and identifying an adrenal tumour as a source of the excess 
aldosterone secretion. In addition, clinical observations of the response of blood
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pressure and plasma electrolytes to therapy with spironolactone or amiloride can 
give an indication of both the presence of an adenoma and the likelihood that 
surgical removal will lead to resolution of the hypertension (Brown et al.t 1972, 
Kremer et al, 1977). That is, resolution of hypertension and plasma electrolyte 
abnormalities with spironolactone or amiloride indicates a high chance of complete 
cure following surgery. Tumours can be detected |by computed tomography (CT) 
scanning, ultrasound, magnetic resonance imaging and adrenal vein sampling to 
measure aldosterone concentrations. CT scanning can detect up to 90% of 
adenomas (Davies et al, 1979) whilst the majority of the rest can be localised to 
one adrenal by analysis of adrenal vein blood (McAreavey et al., 1981).
Idiopathic hyperaldosteronism (IHA) is less common than true Conn's syndrome 
and accounts for approximately 25 % of cases of hyperaldosteronism (Ferriss,
1992). Subjects with IHA also display many of the classical features of 
hyperaldosteronism although in general the degree of aldosterone excess is less 
than in patients with Conn's syndrome (Ferriss et al., 1978b). In particular serum 
potassium levels are more likely to be within the normal range, plasma aldosterone 
concentrations only modestly elevated and blood pressure levels lower than in 
Conn's syndrome patients (Ferriss et al, 1978b). In contrast to patients with Conn's 
syndrome, patients with IHA display a normal aldosterone postural response, i.e. 
aldosterone rises on assuming an upright posture (Ganguly et al., 1973, 
Schambelan et al., 1976). A similar response is seen in plasma levels of 18- 
hydroxycorticosterone, the levels of which are generally much lower than in Conn's 
syndrome (Fraser et al, 1981). In contrast to patients with adenomas, IHA 
patients display an increased adrenal sensitivity to Ang II infusion (Fraser et al, 
1981). Another feature often observed, although not constantly present, in patients 
with IHA is the circadian rhythm of plasma aldosterone in parallel with cortisol 
(Ganguly et al, 1973, Schambelan et al, 1976). Features of IHA overlap those of 
low renin essential hypertension and its validity as a separate syndrome has been 
questioned.
In patients with IHA there is no lateralisation of aldosterone secretion and there is 
no discrete adrenal adenoma to account for the aldosterone excess although 
various forms of bilateral, micronodular hyperplasia have been described. This has 
also been described in patients with essential hypertension and normal post 
mortem specimens. Such patients should receive specific anti-mineralocorticoid 
therapy with spironolactone or amiloride to control blood pressure. Surgical 
removal of adrenal tissue is non-curative and can lead to recurrence and
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exacerbation of hypertension possibly via the adrenal regeneration hypertension 
mechanism (Ferriss et al., 1978a, Kenyon, 1994).
Glucocorticoid-suppressible hyperaldosteronism is discussed in 1.9.
1.8.2 Deficiency of 11 3-hydroxylase
Clinical deficiency of 113-hydroxylase was first noted in 1951 (Shepard and 
Clausen, 1951). Although the majority of patients with congenital adrenal 
hyperplasia lose salt, it was noted that a small proportion developed hypertension 
in the face of impaired cortisol synthesis (White et al, 1994). Although there is 
impaired 113-hydroxylase activity, aldosterone synthesis is unimpaired although 
plasma aldosterone may be low due to suppression of renin synthesis (Levine et 
al., 1980). In these patients hypertension is relieved by the administration of 
glucocorticoids. Other features of clinical 113-hydroxylase are those attributable to 
adrenal androgen excess, i.e. masculinization of the female genitalia, premature 
growth spurt, early closure of bony epiphyses with subsequent short stature. Figure 
1.8 a shows the effects of a block in cortisol synthesis at the level of 113- 
hydroxylase. The build up of precursors of cortisol and aldosterone such as DOC 
and 11-deoxycortisol, and perhaps 18-hydroxy-DOC and 19-nor metabolites of 
DOC, results in mineralocorticoid effects, i.e. volume-dependent hypertension, in 
addition to a shunting of the excess precursors into the androgen biosynthetic 
pathways. Deficiency of cortisol results in a lack of feedback inhibition of ACTH 
secretion and this leads to a rise in ACTH secretion and a subsequent rise in the 
production of DOC and adrenal androgens. The build-up of DOC leads to 
suppression of renin activity. Administration of glucocorticoids, dexamethasone, 
prednisolone or ideally cortisol to replace absent physiological cortisol, suppresses 
ACTH secretion which in turn switches of the excessive formation of DOC and 
adrenal androgens and also provides replacement for deficient cortisol production. 
Alleviation of the mineralocorticoid excess leads to renal sodium loss, correction of 
hypokalaemia, resolution of hypertension and a rise in plasma renin activity.
The incidence of classic 113-hydroxylase deficiency is about 1/100000 births in the 
general Caucasian population (Zachmann et al., 1983). In other populations, 
particularly Jews of Moroccan descent living in Israel, the incidence is considerably 
higher, 1/5000 - 1/7000 births with a gene frequency of 1.2-1.4% (Rosier et al.,
1992). The condition demonstrates an autosomal recessive form of inheritance and 
thus it is not surprising that the incidence of the condition is higher in populations 
which are relatively inbred.
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Deficiency of 11 (3-hydroxylase results from mutations in CYP11B1 (Table 1.8 a).
Mutation Exon Activity
(%normal)
Effect Clinical
Severity
Ethnic
Group
P32AC 1 0 Frameshift +++ White
W116X 2 0 Nonsense +++ Japanese
K174X 3 0 Nonsense +++ White
T318M 5 0 ?Alters
Proton
Transfer
+++ Yemenite
Q338X 6 0 Nonsense +++ Sikh
Q356X 6 0 Nonsense +++ Afro-
American
R374Q 6 0 Adrenodoxin
Interaction
+++ Lebanese
R384Q 7 0 ?Substrate
Binding
+++ White
N394 2nt 7 0 Frameshift +++ Turkish
V441G 8 0 ?Alters 2° 
structure
+++ White
R448H 8 0 ?Affects
Haem
Binding
+++ Moroccan
Jews
Table 1.8 a Mutations in CYP11B1 causing clinical 118-hydroxylase deficiency
In Moroccan Jews, almost all affected subjects have the same disease allele, 
R448H (White et al., 1991). R448 is adjacent to C450 which is presumed to be a 
ligand of the haem iron atom in the P-450 complex, and is highly conserved in all 
eukaryotic P-450 enzymes examined thus far. This would suggest that C450 is of 
great importance to the function of P450n3 and mutation of this amino acid 
abolishes enzyme activity (Curnow et al., 1993). So far, 11 additional mutations 
have been identified in patients with classic 11 (3-hydroxylase deficiency (Curnow et 
al, 1993, Helmberg et al., 1992, Skinner et al., 1993, White et al, 1991) (Figure 1.8
b). These mutations are of two types; frameshift mutations in codons P32 (1 
nucleotide) and N394 (2 nucleotides) and nonsense mutations W116X, K174X, 
T318M, Q338X, Q356X, R374Q, R378Q, V441G and R448H. All of these 
mutations abolish enzyme activity and all missense mutations occur in regions of 
functional importance to P4501ib (Curnow et al, 1993). In particular, the T318M 
mutation modifies an absolutely conserved residue that is thought to be critical for 
proton transfer to the bound oxygen molecule on the P-450 enzyme (Ravichandran 
et al., 1993). In addition, R374Q mutates a completely conserved residue which 
may affect adrenodoxin binding, whilst R384Q is in a region which may form part of 
the substrate binding pocket (Ravichandran et al, 1993). Finally, V441G is adjacent
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R348Q
1394
CYP11B1
Exon 1 2 3 4 5  6 7 8 9
Cluster of mutations around 
haem-binding region
Figure 1.8 b Distribution of mutations in CYP11B1 causing 
steroid 118-hydroxylase deficiency in man
Q338X
Q356X
R374Q
V441G
R448HA32*| | W116X| j K174X| |T318M |
to the highly conserved haem binding region, and this mutation may alter the 
secondary structure of P-450-M3 in this region.
The phenotype correlation in patients with 1113-hydroxylase deficiency are often at 
variance with the genetic features of the mutation in the affected individuals. 
Mutations which result in complete absence of enzymatic activity in vitro may lead 
to clinical features which are mild in comparison to other mutations which would be 
expected to result in less disruption of the gene product. For example, R448H 
leads to a wide variety of observed phenotypes, both clinical and biochemical, e.g. 
plasma levels of 11 -deoxycortisol and DOC, in Moroccan Jews. However, 
nonsense mutations encoding a truncated non-functional enzyme (P32n) result in 
only mild virilistion of affected females (Curnow et al, 1993, Rosier et al, 1992, 
White et al, 1991). This disparity between clinical and biochemical phenotype and 
the enzymatic activity of expected the mutated gene product suggests that 
unknown factors outwith the CYP11B1 locus may determine phenotypic 
differences in 116-hydroxylase deficiency.
1.8.3 Deficiency of 17a-hvdroxylase
First described in 1966,17a-hydroxylase deficiency is an uncommon cause of 
mineralocorticoid-dependent hypertension (Biglieri et al., 1966). P450c i7 is active 
in the zona fasciculata where it is a key enzyme involved in the synthesis of cortisol 
and the adrenal androgens. In the gonad, P-450c i7 catalyses the formation of 
testosterone and oestrogens because of its combined 17a-hydroxylase/17, 20 
lyase activity. In man, P-450c i7 is not expressed in the zona glomerulosa. Absence 
of 17a-hydroxylase activity leads to impaired synthesis of 11-deoxycortisol and 
cortisol in the adrenal, with resultant increased ACTH secretion from the pituitary 
(Figure 1.8 c). Synthesis of estradiol and testosterone is similarly impaired with a 
resulting rise in LH and FSH secretion. The combined effects of excess ACTH and 
gonadotrophin secretion are two-fold. First, there is a build up of immediate 
precursors of P-450c i7 such as progesterone and pregnenolone. Secondly, 
increased ACTH secretion results in activation of conversion of DOC to 
corticosterone and 18-hydroxyDOC in the zona glomerulosa. DOC, and to a lesser 
extent, 18-hydroxyDOC have sodium retaining properties which suppress renin 
secretion and as a result plasma aldosterone levels are suppressed (Table 1.8 b). 
Signs of glucocorticoid deficiency are usually absent and the very high levels of 
corticosterone probably compensate for the lack of cortisol (Fraser et al., 1987).
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Before After Normal
Cortisol 4 0.06 6-26 (ug/100ml)
11-deoxycortisol 3 15 40-400 (ng/100ml)^
DOC 154 13 3-16 (nq/100ml)
18-OH-DOC 438 41 10-50 (ng/100ml)
Corticosterone 29 0.7 0.08-0.8 (ug/100ml)
18-OH-
corticosterone
104 6.7 3-25 (ng/100ml)
Aldosterone 2 12 4-18 (ng/100ml)
ACTH 154 <20 18-60 (pg/ml)
Renin 3 18 4-20 (U/l)
Angiotensin II 9 36 5-35 (pg/ml)
Testosterone 1.3 not detectable 2.0±0.4 (nmol/1)
Estradiol 73 not detectable 180±1470 (pmol/l)
Progesterone 12.5 1.3 -
17a-hydroxy-
progesterone
1.0 - -
FSH 79.1 96.9 -(U/l)
Blood Pressure 224/153 134/82
Table 1.8 b Blood pressure and hormone data in a 46XX female with 17a-hydroxylase 
deficiency before and after dexamethasone therapy. Adapted from (Fraser et al, 1987).
The clinical features of 17a-hydroxylase deficiency are as follows: hypertension, 
absence of secondary sex characteristics such as breast development or pubic 
hair; in XY genetically male fetuses there is a variable degree of 
pseudohermaphroditism, secondary sex characteristics do not develop at puberty 
and affected males are often raised as females (Fraser et al, 1987, Goldsmith et 
al., 1967).
P-450C17 is encoded by a single gene on chromosome 10q24-25 (Matteson et al, 
1986) and a number of mutations leading to clinical 17a-hydroxylase deficiency 
have been described. Of these cases three were due to nonsense mutations 
(Ahlgren et al., 1992, Yanase et al., 1988, Yanase et al., 1992), three were 
deletions (Biason et al., 1991, Fardella et al., 1993, Yanase et al., 1989), and three 
were duplications (Imai et al., 1993, Imai et al., 1992, Yanase et al., 1990). Six 
were due to point mutations leading to single amino acid changes in P-450C17 
(Ahlgren et al, 1992, Fardella et al., 1994a, Imai et al, 1993, Lin et al., 1991, Monno 
et al., 1993, Yanase et al, 1992).
It is of interest that in a number of cases of 17a-hydroxylase deficiency, affected 
individuals are not homozygous for a single mutant allele (Ahlgren et al, 1992, 
Yanase et al, 1992). In these cases both alleles of P450ci7 are sufficient to abolish 
17a-hydroxylase activity but this is in contrast to the known cases of 116-
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hydroxylase deficiency where all reported mutations are homozygous for the 
disease allele. This may suggest that mutations in CYP11B1 occur less frequently 
but have occurred in populations where consanguineous relationships are more 
frequent, whereas mutation in CYP17A are more common but have occurred in 
populations which limit consanguineous relationships and thus the possibility {of 
17a-hydroxylase deficiency is less #
1.8.4 Deficiency of 11 Q-hydroxvsteroid dehydrogenase
11G-OHSD plays an important role in modulating the mineralocorticoid effect of 
cortisol in tissues such as the kidney (1.5.6). In man, three situations arise where 
disordered 11B-OHSD action leads to hypertension; firstly ingestion of liquorice, 
secondly ingestion of carbenoxolone for the treatment of peptic ulcer disease, and 
finally in the uncommon condition of apparent mineralocorticoid excess.
Ingestion of liquorice has long been known to cause hypertension (Nicholls and 
Espiner, 1983). Glycyrrhetinic acid has been shown to be the active component of 
liquorice causing hypertension (Stewart et al, 1987). Glycyrrhetinic acid inhibits 
1113-OHSD in man which results in so-called 'deprotection' of renal 
mineralocorticoid receptors (Stewart et al, 1987). Absence of 1113-OHSD activity in 
the renal tubule allows cortisol, normally converted to inactive cortisone, to bind to 
mineralocorticoid receptors to promote sodium retention and subsequent sodium- 
dependent hypertension (Stewart et al, 1987) (Figure 1.8.d). In addition, there is 
some evidence to suggest that glycyrrhetinic acid inhibits 5a- and 513-reductase 
pathways in the metabolism of aldosterone (Latif and Morris, 1989).
Carbenoxolone is a semisynthetic hemisuccinate derivative of glycyrrhetinic acid 
and has its effect through a mechanism analogous to that of liquorice (Funder et al, 
1988).
Apparent mineralocorticoid excess (AME) is a rare syndrome of hypertension and 
hypokalaemia associated with suppression of plasma renin activity and low plasma 
concentrations of aldosterone and other known mineralocorticoids (Ulick et al., 
1979). Studies of a number of these patients revealed that the hypertension in this 
disorder is sodium-dependent but that there is no detectable excess secretion of 
mineralocorticoids (Ulick et al, 1979). However, administration of 11-[H3]-cortisol to 
patients with AME results in impaired excretion of [H3]-water suggesting that the 
problem is impaired conversion of cortisol to cortisone (Stewart et al., 1988, Ulick 
et al, 1979), i.e. defective dehydrogenase activity of 118-OHSD. This suggestion 
has been supported by observations on the urinary excretion of metabolites of 
cortisol (tetrahydrocortisol, THF) and cortisone (tetrahydrocortison, THE) with AME
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ALDOSTERONE
11QOHSD 
CORTISOL — ^  CORTISONE
Normally regulated renal sodium reabsorption
A
Renal Tubule
No binding to MR despite massive 
excess of cortisol in renal tubule
Normal renal tubular cell
Suppression of
mineralocorticoid
production
Excessive renal sodium retention
t
*
*
ALDOSTERONE
CORTISOL-
11 BOHSD
A
Renal Tubule
CORTISONE
A
A
Cortisol is present in amounts >1000x 
that of aldosterone in the region of the 
MR and binds with equal affinity
Abnormally high urine ratio of 
tetrahydrocorti8ol:tetrahydrocortisone
Defective action due to congenital absence of 
(AME), or inhibition (liquorice or carbenoxolone).
Inhibition of 1 BOHSD in renal tubule
Figure 1.8 d Development of hypertension following inhibition 
of 118- hydroxy steroid dehydrogenase in man
patients noted to have abnormally low urinary THE:THF ratios (<1) (Stewart et al, 
1988). Administration of dexamethasone causes reversal of the clinical features 
(by suppression of ACTH-dependent cortisol secretion), which are reproduced by 
administration of physiological doses of cortisol (Stewart et al, 1988). A variant of 
the syndrome has been described where the urinary excretion of THF and THE is 
normal (Ulick et al., 1990), suggesting that in some cases both oxidation and 
reduction defects may be present.
Following cloning of the human cDNA for 11GOHSD it was hoped that study of this 
gene in patients with AME would reveal the molecular defect underlying AME in 
these patients. However, detailed molecular studies of the 11BOHSD gene in 
patients with AME have not detected any mutations to explain the clinical 
syndrome (Nikkila et al., 1993). Recently, however, a cDNA for a second 118- 
OHSD transcript has been described in the human kidney (Albiston et al., 1994.)
s* . . This transcript is not detected in the liver, lung or heart, is 
exclusively NAD-dependent and is inhibited by carbenoxolone. Thus it appears that 
this transcript encodes a kidney-specific isoform of 1180HSD and analysis of this 
gene in patients with AME may shed light on the pathogenesis of AME.
1.8.5 Miscellaneous forms of mineralocorticoid excess
Adrenal carcinoma may arise from the adrenal cortex and give rise to either 
excessive aldosterone or DOC secretion (Ferriss, 1992, Gordon et al., 1994). They 
account for approximately 1% of mineralocorticoid-secreting tumours and are often 
associated with a greater degree of aldosterone excess than benign tumours. They 
are generally larger than adenomas and display similar alterations in aldosterone 
secretion in relation to orthostasis or circadian variations (Ferriss, 1992, Gordon et 
al, 1994).
Liddle's syndrome is a congenital syndrome of hypertension, hypokalaemia and 
suppressed plasma renin and aldosterone levels (Gordon et al., 1992, Liddle et al., 
1963). The pathogenesis of this condition is unclear but may be caused in part by 
increased renal tubular sodium permeability which leads to increased renal sodium 
retention and suppression of the RAS. Renal potassium loss is also a feature of the 
syndrome suggesting that the distal renal tubule reabsorbs sodium in excess and 
at the expense of potassium and hydrogen ions (Gordon et al, 1992). Treatment 
with triamterene (a drug to inhibit renal sodium resorbtion independent of 
aldosterone) is only partially effective and requires the addition of dietary sodium 
restriction to control blood pressure (Gordon et al, 1992, Liddle et al, 1963).
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Similarly spironolactone is ineffective in this condition because aldosterone levels 
are often undetectable (Liddle et al, 1963).
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1.9 Glucocorticoid-Suppressible Hyperaldosteronism
Glucocorticoid-suppressible hyperaldosteronism (GSH), also known as 
dexamethasone-suppressible hyperaldosteronism and glucocorticoid-remediable 
aldosteronism, is an uncommon cause of secondary hypertension in man. It was 
first described in the medical literature by a Canadian group (Sutherland et al.,
1966), who investigated a father and son with hypertension. Both patients had 
elevated blood pressure, hypokalaemia, increased aldosterone secretion rate and 
suppressed plasma renin activity. In neither case was there an adrenal adenoma 
as a source of aldosterone hypersecretion, and removal of one adrenal gland from 
the father had no effect on blood pressure although his aldosterone secretion rate 
halved. However, following the administration of dexamethasone, a synthetic 
glucocorticoid with no in vitro mineralocorticoid activity, to both patients blood 
pressure, aldosterone secretion rate and serum [Na+] fell, and plasma renin 
activity and serum [K+] rose. An associated fall in urinary potassium excretion and 
a rise in urinary sodium excretion was observed. Throughout the period of 
investigation no abnormality in cortisol metabolism was found.
The features observed in the initial report outline the key clinical and biochemical 
features observed in affected individuals with GSH:
Hyperaldosteronism with suppression of plasma renin activity
_________________A dominant mode of inheritance_________________
_________________________Hypertension_________________________
________________________ Hypokalaemia________________________
Following the initial description of the condition, a number of other kindreds with 
the disorder were identified and reported in the medical literature (Connell et al., 
1986, Davis et al., 1988, Ganguly et al., 1981, Giebink et al., 1973, Grim and 
Weinberger, 1980, Jamieson et al., 1994, Lifton et al, 1992, Miura et al., 1968, New 
and Peterson, 1967, Salti et al., 1969, Stockigt and Scoggins, 1987, Woodland et 
al., 1985). Study of the GSH patients described in these reports has resulted in the 
identification of a number of important biochemical and physiological abnormalities 
in adrenal steroid metabolism in GSH.
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1.9.1 Clinical Features of GSH
The most obvious clinical abnormality noted in patients with GSH is the presence 
of hypertension. The initial case report noted that the son of the index cases was 
hypertensive, BP 180/120 nrimHg, at age 16 years (Sutherland et al, 1966). The 
discovery of hypertension in young patients has been a key feature in cases of 
GSH, with hypertension detected in children as young as 2.5 years (New and 
Peterson, 1967). In the study of one large North American kindred, hypertension 
was present in all affected individuals with GSH. In addition, adult patients were all 
diagnosed as hypertensive before the age of 21 years (mean 16.1+/-3.4) (Rich et 
al., 1992). In general, the majority of patients will develop hypertension at some 
time during their life although the age of onset may be quite variable (Chapter 4) 
(Jamieson et al, 1994).
A second feature of GSH which was initially described by Sutherland (Sutherland 
et al, 1966) was hypokalaemia. In both the index case and his son plasma [K+] 
varied between 2.5-3.5 mmol/l (normal 3.6-5.2 mmol/l). Subsequent reports varied 
as to the level of plasma [K+] in affected individuals, although in a significant 
number it may be normal (Fallo et al., 1985, Grim and Weinberger, 1980, New and 
Peterson, 1967, O'Mahony et al., 1989, Stockigt and Scoggins, 1987). The serum 
[K+] in the study by Rich (Rich et al, 1992) was found to be normal in all subjects 
screened and serum [K+] was no different in affected and unaffected relatives. 
However, they did note that development of severe hypokalaemia in affected 
individuals given thiazide diuretics was characteristic of GSH patients. Indeed, 
cardiac arrest secondary to hypokalaemia in a patient with GSH given a thiazide 
has been reported (Gill and Bartter, 1981).
As noted previously, hypertension is an important risk factor for stroke. A study of 
the pedigrees of most kindreds with GSH reveals a considerable excess mortality 
from stroke, in particular stroke before the age of 50 years (Connell et al, 1986, 
Rich et al, 1992, Sutherland et al, 1966). The reason for this is unclear as the 
majority of individuals with GSH have only moderate degrees of aldosterone- 
excess and moderate hypertension. However, this elevation of blood pressure is 
present from an early age and this may be an important factor in the genesis of 
'premature' stroke in these patients.
In addition to stroke, GSH has been associated with the development of a 
syndrome indistinguishable from acute glomerulonephritis with evidence of 
nephrosclerosis on renal biopsy (Lee et al., 1982).
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Finally, the presence of an autosomal dominant mode of inheritance of the 
condition is universal. This is often most revealing when the cause of death of 
patients not known to have hypertension is established. If a relative of a patient 
suspected as having GSH died under the age of 50 from a stroke or renal failure 
then it is highly likely that they also had GSH.
Treatment of GSH with dexamethasone is clearly effective. In addition, amiloride 
and spironolactone, an aldosterone antagonist, have been used effectively to 
control blood pressure in these patients (Connell et al., 1986, Jamieson et al, 
1994).
1.9.2 Zona Glomerulosa Function in GSH
In normal man, the diurnal rhythm of cortisol is mirrored by that of the ACTH- 
dependent precursors of aldosterone, DOC and corticosterone. Diurnal variation in 
aldosterone secretion is less marked, presumably due to the important 
superimposed effects of the renin-angiotensin system and plasma [K+]. However, 
in patients with GSH the diurnal variation in plasma cortisol correlates strongly with 
plasma aldosterone concentrations (Connell et al, 1986). Similarly, the plasma 
levels of DOC also correlate strongly with plasma aldosterone concentration 
(Connell et al, 1986). In GSH patients, long-term dexamethasone administration 
abolishes the diurnal rhythm of both cortisol and aldosterone, although plasma 
aldosterone concentrations, after initially being undetectable rise to within the 
normal range (Connell et al, 1986). This maintenance of aldosterone secretion 
after suppression of ACTH reflects a secondary rise in renin levels, permitting a 
return to normal regulation of aldosterone by the RAS.
In patients untreated with GSH, administration of ACTH, either as an intravenous 
infusion, an intramuscular injection or topically as a gel, results in an exaggerated 
rise in plasma aldosterone and plasma 18-hydroxycorticosterone concentrations 
(Connell et al, 1986, Ganguly et al., 1984). In addition, there is an associated rise 
in blood pressure and exaggeration of the aldosterone-dependent effects, i.e. 
hypokalaemia, suppression of plasma renin activity and associated urinary 
electrolyte excretion patterns (Connell et al, 1986, Ganguly et al, 1984). When 
aminoglutethimide, an inhibitor of the conversion of cholesterol to pregnenolone, is 
given to GSH patients receiving ACTH there is a reduction in blood pressure and 
aldosterone secretion and a rise in plasma [K+] and renin activity which reversed 
on cessation of aminoglutethimide (Gill and Bartter, 1981). Conversely, when 
patients receive metyrapone, an inhibitor of P-450hg , plasma levels of cortisol and 
aldosterone fall dramatically. This is associated with a marked rise in blood
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pressure, probably due to ACTH-driven DOC production (New and Peterson,
1967). Plasma 11-deoxycortisol concentrations are aldo raised. After 7-10 days of 
metyrapone therapy there is an 'escape' in cortisol and aldosterone secretion, i.e. 
plasma cortisol and aldosterone levels rise despite continued metyrapone 
administration. The reason for this is unknown but may relate to ACTH-induced 
hyperexpression of the gene causing GSH, which can synthesise cortisol in vitro, 
with resultant recovery of cortisol secretion (Pascoe et al, 1992a).
In contrast to the exaggerated aldosterone-responsiveness of GSH patients to 
ACTH, Ang II has relatively little effect on aldosterone secretion. If untreated 
patients with GSH are subjected to dietary sodium restriction (Oberfield et al.,
1981), frusemide administration (Ganguly et al, 1981), or head-up tilt (Ganguly et 
al, 1981), in an attempt to enhance endogenous Ang II production via the RAS, 
there is a much diminished plasma aldosterone response. Similarly, intravenous 
infusion of Ang II to such patients, up to doses of 4 ng/kg/min results in little 
change in plasma aldosterone concentration (Connell et al, 1986, Fallo et al,
1985). Normal individuals subjected to such interventions would expect to 
experience a 2 to 3-fold increase in plasma aldosterone concentrations (Zoccali et 
al, 1983).
The effect of dexamethasone on the control of aldosterone secretion in GSH is 
dramatic. Sodium depletion in dexamethasone-treated patients with GSH induces 
a normal rise in plasma aldosterone and 18-hydroxycorticosterone concentrations 
and a rise in plasma renin activity (Oberfield et al, 1981). Similarly, head-up tilt and 
frusemide administration also increase plasma renin and aldosterone 
concentrations in dexamethasone treated patients (Ganguly et al, 1981). The 
normal plasma aldosterone response to intravenous Ang II infusion in 
dexamethasone-treated patients is also restored (Connell et al, 1986, Fallo et al, 
1985).
Similarly, ACTH infusion in GSH patients taking dexamethasone show that the 
previously exaggerated rises in blood pressure and plasma aldosterone 
concentration is diminished (Connell et al, 1986). However, it has been noted that 
prolonged high dose ACTH administration (Oberfield et al, 1981) and psychological 
stress and trauma (N Benjamin, personal communication) can result in excessive 
rises in blood pressure and plasma aldosterone concentration in patients with GSH 
taking dexamethasone.
These findings suggest that ACTH has characteristic effects on aldosterone 
secretion in GSH:
88
1) a direct effect on aldosterone secretion, principally by increasing aldosterone 
synthase activity and increasing the conversion of corticosterone to aldosterone
2) the normal regulation of aldosterone secretion by Ang II is disturbed and 
aldosterone secretion is controlled by ACTH
3) the removal of the influence of ACTH, by suppression of ACTH with exogenous 
glucocorticoids, restores the regulation of aldosterone secretion to normal.
In summary, individuals with GSH clearly exhibit aberrant responses to 
physiological stimuli such as ACTH, and Ang II. In addition, the control of 
aldosterone secretion in patients with GSH is upset. Observations in patients with 
GSH have shown that the abnormality in GSH centres around increased 
aldosterone secretion which appears to ACTH-dependent.
1.9.3 Unusual Biochemical Features of GSH
Although hypertension in GSH could easily be ascribed to the presence of elevated 
plasma aldosterone concentrations, early work suggested that it might not be the 
sole cause of the hypertension in this condition. A series of elegant investigations 
in a subject with GSH suggested the possibility that an ACTH-induced steroid, not 
aldosterone, 18-hydroxy-DOC or DOC, was responsible for some of the pressor 
effects of ACTH (New et al., 1976). In particular, these workers showed that 
infusion of aldosterone, 18-hydroxy-DOC or DOC to a dexamethasone-treated 
GSH patient did not produce the same effect on blood pressure as stopping 
dexamethasone. In addition, metyrapone caused hypertension and sodium 
retention but the addition of aminoglutethimide resulted in a considerable fall in 
blood pressure, natriuresis and reduction in aldosterone secretion. Administration 
of metyrapone to normal subjects results in impairment of cortisol and 
corticosterone synthesis by inhibiting P-450hg . A compensatory rise in ACTH 
secretion occurs with an overproduction of precursors, predominantly DOC and 11- 
deoxycortisol, sufficient to maintain blood pressure within the normal range or even 
elevate it slightly (Orth et al, 1992). Aminoglutethimide has similar effects in normal 
individuals as those observed in patients with GSH (Orth et al, 1992). Finally the 
patient received intravenous ACTH and oral dexamethasone. The results showed 
that dexamethasone reduces blood pressure and aldosterone secretion by 
suppressing ACTH secretion rather than by any direct effect of dexamethasone. 
One caveat in the interpretation of these studies is the absence of cortisol following 
many of the pharmacological manipulations, i.e. dexamethasone, metyrapone and 
aminoglutethimide administration. This may remove any effect cortisol might have
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on maintaining blood pressure in patients with GSH if aldosterone secretion were 
to be lowered independently.
This series of studies did however suggest the possibility that other ACTH- 
regulated steroids with blood pressure raising effects were being produced by the 
adrenal cortex in GSH.
Workers looking at the secretory products of aldosterone-secreting adenomas had 
postulated that although the adenoma was the source of the hypertension, the 
degree of hypertension was often disproportionately high in comparison to the 
degree of hyperaldosteronism. When the urine of patients with aldosterone- 
secreting adenomas was studied using gas chromatography/ mass spectrometry, it 
was found that in the unconjugated fraction of the samples a single steroid 
molecule accounted for more than half of the mass of the extract. The compound 
was identified as the 20,18,-hemiketal form of 116, 17a, 18, 21-tetrahydroxy-4- 
pregnen-3, 20-dione and the trivial name 18-hydroxycortisol was proposed (Chu 
and Ulick, 1982). Further study using aldosterone-secreting adenoma tissue and 
bovine adrenal slices and tritiated cortisol showed that cortisol was the immediate 
precursor of 18-hydroxycortisol, and that corticosterone could not be converted to 
18-hydroxycortisol (Chu and Ulick, 1982). Study of patients with aldosterone- 
secreting adenomas demonstrated that they excreted between 0.3-2.0 mg/ 24 
hours of 18-hydroxycortisol in contrast to normal individuals who secrete < 0.1 mg/ 
24 hours (Ulick and Chu, 1982).The only other patient group shown to excrete 
appreciable amounts of 18-hydroxycortisol were GSH patients (Ulick and Chu,
1982).
Further studies of aldosterone-producing adrenal tissue showed that cortisol is also 
readily converted into a second substance 18-oxocortisol (Ulick et al., 1983a), 
resulting from further 18-hydroxylation and dehydration of 18-hydroxycortisol. An 
alternative trivial name for this steroid is 17a-hydroxyaldosterone.
Study of the biological properties of both 18-hydroxycortisol and 18-oxocortisol 
show that both have relatively low affinity for steroid hormone receptors (Table 1.9 
a).
In particular, 18-hydroxycortisol has an extremely low affinity for both glucocorticoid 
and mineralocorticoid receptors (Gomez-Sanchez et al., 1984, Ulick et al, 1983b), 
whilst 18-oxocortisol has greater affinity than 18-hydroxycortisol for both receptors. 
Even so, the affinity of 18-oxocortisol for the mineralocorticoid receptor was only
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1% of that of aldosterone and 3% of that of dexamethasone for the glucocorticoid 
receptor (Gomez-Sanchez et al., 1985, Ulick et al, 1983b).
Relative binding %
Steroid Receptor
GRa MRb CBGc
Dexamethasone 100 8 <0.01
Cortisol 32 17 100
Aldosterone - 100 <1
18-hydroxycortisol <0.3 <0.01 <1
18-oxocortisol 2.4 1.7 8
CBG - cortisol binding globulin, GR - glucocorticoid receptor, MR - mineralocorticoid receptor 
a - relative to dexamethasone, b - relative to aldosterone, c - relative to cortisol
Table 1.9 a Relative binding of C18-oxygenated and related steroid hormones for 
corticosteroid hormone receptors and binding globulin (Ulick et al., 1983b)
Studies of normal subjects have revealed that 18-hydroxycortisol is secreted in 
small amounts and that its secretion is enhanced by ACTH and salt restriction, but 
not by Ang II infusion (Corrie et al., 1985). In normal subjects, ACTH raises urinary 
18-hydroxycortisol excretion in parallel with that of cortisol and 18-oxocortisol 
(Gomez-Sanchez et al., 1988, Gomez-Sanchez et al., 1987). As expected 
dexamethasone leads to a suppression of urinary 18-hydroxycortisol excretion 
(Gomez-Sanchez et al, 1987). Sodium depletion (10mEq/day restriction) also has 
an effect on 18-hydroxycortisol secretion, causing a 2-3 fold increase in urinary 18- 
hydroxycortisol excretion (Gomez-Sanchez et al, 1987).
In patients with GSH, urinary excretion rates of both 18-hydroxy- and 18- 
oxocortisol are raised (Connell et al, 1986, Gomez-Sanchez et al., 1984, Ulick and 
Chu, 1982). Studies of untreated patients with GSH have shown that 18-oxocortisol 
is excreted in the urine in large amounts (25-55 p,g/24hrs) compared to normal 
man (0.8-7.0 |ig/24hrs) (Gomez-Sanchez et al, 1984). Treatment with 
dexamethasone suppresses urinary 18-hydroxycortisol and 18-oxocortisol 
excretion rates to normal (Connell et al, 1986, Rich et al, 1992, Ulick et al., 1990). 
Plasma 18-hydroxycortisol concentration in GSH patients follows the circadian 
rhythm of cortisol and ACTH administration leads to an exaggerated rise in plasma 
concentration (Connell et al, 1986).
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Comparison of the ratio of urinary 18-hydroxycortisol or 18-oxotetrahydrocortisol 
(18-oxoTHF), the principal urinary metabolite of 18-oxocortisol, and 
tetrahydroaldosterone (THAIdo), the principal urinary metabolite of aldosterone, 
has been used to aid diagnosis of the condition (Rich et al, 1992, Ulick et al, 1990). 
In addition to grossly elevated basal urinary excretion of C18-oxygenated cortisol 
derivatives, urine ratios of 18-oxoTHF:THAIdo >3 and 18-hydroxycortisol:THAIdo 
>5 are considered diagnostic of GSH (Rich et al, 1992, Ulick et al, 1990).
Both 18-hydroxycortisol and 18-oxocortisol bear striking structural similarities to 18- 
hydroxycorticosterone and aldosterone, their 17deoxy- equivalents (Figure 1.9 a). 
These steroids are derived from cortisol, the obligate precursors of both, following 
18-hydroxylation and subsequent dehydration. These steps are identical to those 
performed by aldosterone synthase in the conversion of corticosterone to 
aldosterone. Cortisol, however, is synthesised by the zona fasciculata in man, a 
tissue where aldosterone synthase is not expressed (Curnow et al, 1991). 
Therefore for synthesis of 18-hydroxycortisol and 18-oxocortisol to occur, cortisol 
must be formed in cells which also express aldosterone synthase, i.e. ectopic 
aldosterone synthase gene expression in the human zona fasciculata.
In summary, patients with GSH show excessive secretion of secretion of 18- 
hydroxycortisol and 18-oxocortisol which is ACTH-responsive. This situation is 
similar to that of aldosterone secretion in GSH, suggesting that there is ACTH- 
responsive aldosterone synthase activity in the zona glomerulosa and also in the 
zona fasciculata.
1.9.4 Molecular genetics of GSH
The biochemical and physiological studies of aldosterone secretion in GSH 
suggest that aldosterone secretion and by inference, aldosterone synthase activity 
and gene expression, are regulated by ACTH in a manner different to that seen in 
normal individuals. In addition, the finding of 18-hydroxylated derivatives of cortisol, 
a zona fasciculata-derived steroid, suggests that ectopic aldosterone synthase 
activity in the zona fasciculata may be responsible for their formation. Molecular 
genetic studies have shown that the genes CYP11B1 and CYP11B2 lie in tandem 
together on the long arm of chromosome 8 (8q22) and that both genes are highly 
homologous, particularly in their exons. CYP11B1 is regulated in vitro by ACTH, 
has the ability to convert DOC to corticosterone and 11-deoxycortisol to cortisol 
and is expressed in the zona fasciculata. CYP11B2 is expressed solely in the zona 
glomerulosa, is regulated by Ang II in vitro and performs the conversion of DOC to 
aldosterone. Thus a mutation involving the control of CYP11B1 and CYP11B2
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Figure 1.9 a Comparison of 17-desoxy-18-hydroxy- and 17-oxy-18-hydroxy-corticosteroids
expression could give rise to the biochemical and physiological abnormalities in 
steroid metabolism noted in GSH.
Litton (Litton et al, 1992) showed that a mutation involving these genes was indeed 
the basis tor the steroid abnormalities tound in GSH. Subjects trom a single North 
American kindred with GSH had hypertension and biochemical abnormalities 
appropriate to GSH. DNA trom these individuals was digested with the restriction 
enzyme Bam HI, and transterred to a nylon membrane by the Southern technique. 
The membrane was probed with a probe containing exons 3-4 ot CYP11B1 and 
individuals with GSH were shown to possess a novel 6.3kb hybridising species in 
addition to the two expected normal species (8.5kb - CYP11B1, 4.5kb - CYP11B2). 
A linkage study in the kindred yielded a maximum lod score ot 5.23 tor complete 
linkage ot the 6.3kb band and GSH. A densitometry study ot the 6.3kb band 
showed that it had an intensity approximately 50% ot that ot the bands tor 
CYP11B1 and CYP11B2 suggesting that individuals with GSH have one copy ot an 
additional CYP11B1/B2-like gene in addition to their normal complement ot 
CYP11B1/B2 genes. These tindings were explained by postulating that an unequal 
crossover event between homologous regions ot CYP11B1 and CYP11B2, 
resulting in a chimeric gene with the 5' sequence, including the ACTH-responsive 
element, ot CYP11B1 tused to a coding region trom CYP11B2 conterring 
aldosterone synthase activity on the resultant gene product (Figure 1.9 b, c). Such 
a gene would be regulated in vivo by ACTH and have aldosterone synthase 
activity. It expressed in the zona glomerulosa, the result would be aldosterone 
secretion which tollows the diurnal rhythm ot cortisol and which is sensitive to 
dexamethasone. The output ot aldosterone would be high as ACTH secretion is 
not suppressed by aldosterone. Thus mineralocorticoid excess would supervene 
and result in hypertension and the other teatures of the syndrome. If expressed in 
the zona fasciculata, cortisol could be converted to 18-hydroxycortisol and 18- 
oxocortisol in an ACTH-dependent process.
The findings of Litton were confirmed by Pascoe (Pascoe et al, 1992a) in subjects 
from 4 unrelated kindreds. Furthermore, Pascoe selectively amplified the chimeric 
genes of the 4 subjects by a polymerase chain reaction (PCR) method using 
oligonucleotide primers specific to CYP11B1 and CYP11B2. The region of the 
suspected crossover was sequenced in the 4 subjects and localised to a region 
encompassing intron 2 to intron 4 of the chimeric gene. Kindreds had discrete 
crossover regions although the exact site of the crossovers were not reported. 
Subsequent findings from other groups have confirmed that all chimeric genes 
causing GSH so far described have crossover regions lying within the intron 2 to
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intron 4 region of the chimeric gene and have given details of the site of the 
crossovers based on direct sequencing (Lifton et al, 1992, Miyahara et al., 1992).
Thus, in all kindred so far identified with GSH, the cause of the condition is the 
inheritance of a copy of a chimeric 11 B-hydroxylase/aldosterone synthase gene 
from either parent. No de novo mutations have been detected so far and all of the 
chimeric genes are of similar structure, i.e. they consist of a 5' region of CYP11B1 
comprising the ACTH-responsive promoter region an up to and including the first 4 
exons coupled to a variable length of CYP11B2 but always including exon 5. This 
observation has been complemented by in vitro studies of the steroidogenic 
capacity of cDNA constructs in COS cells. These constructs comprised variable 
proportions of the CYP11B1 and CYP11B2 exonic DNA formed in a manner similar 
to those found in GSH (Pascoe et al, 1992a). Constructs comprising exons 1-3 of 
CYP11B1 coupled to the remainder from CYP11B2 possessed aldosterone 
synthase activity (Figure 1.9 d). Constructs possessing exons 1-5 or more of 
CYP11B1 had no detectable aldosterone synthase activity, again suggesting that 
exon 5 of CYP11B1 has residues important for conferring aldosterone synthase 
activity on the resultant gene product. Steroidogenic ability of cDNA's of CYP11B1 
in COS cells can be altered by site-directed mutagenesis. Alteration of a few 
nucleotides in the CYP11B1 cDNA to change the sequence of exon 5 of CYP11B1 
to that of CYP11B2 confers aldosterone synthase activity on the resultant cDNA 
(Pascoe and Curnow, 1994).
It is not surprising therefore, that GSH is caused by chimeric genes resulting from 
crossovers limited to the first 4 exons of CYP11B1, given the results of these in 
vitro observations. Why this region of the gene should be so important in 
controlling the nature of the gene products catalytic powers is not clear. Mutations 
involving CYP11B1 may result in clinical 11 B-hydroxylase deficiency (see 1.8.2) 
and only one mutation involving exon 5 of CYP11B1, T318M, has been described 
(Curnow et al, 1993). However, this mutation modifies an absolutely conserved 
residue that is thought to be critical for proton transfer to the bound oxygen 
molecule on the P-450 enzyme (Ravichandran et al, 1993) and results in profound 
loss of 113-hydroxylase activity with no evidence of aberrant aldosterone synthase 
activity (Curnow et al, 1993).
Another striking observation is the unusual preponderance of GSH kindreds with a 
Celtic origin. Lifton has reported that of 12 kindreds identified with GSH, 8 had 
definite or likely Irish ancestry (Lifton et al, 1992). Of the kindreds known 
throughout the United Kingdom, 6 out of 7 are of Scottish origin and a seventh is
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from Northern Ireland. Thus, of 21 kindreds with definite GSH, 15 have a Celtic 
background, i.e. 71%. One attempt to explain this unexpected susceptibility of 
Celts was to ascribe it to a founder gene effect. However, detailed sequence 
analysis has shown that there are at least 7 different chimeric genes n these 
kindreds, suggesting that a founder effect is unlikely (Lifton et al, 1992) (and 
Chapter 5). Alternatively, there may be an allele in these populations which favours 
the formation of chimeric genes (Lifton et al, 1992). A Single-Strand 
Conformational Polymorphism (SSCP) identified by Lifton, AldoX9, in exon 9 of 
CYP11B2 was used to test such a hypothesis (Lifton et al, 1992). In 9 pedigrees of 
Irish/English origin, all possessed allele 1 of the SSCP in the aldosterone synthase 
gene of the chromosome carrying the chimeric gene, a significant deviation from 
that expected by chance; 8 out of 9 had allele 1 present in the chimeric gene. 
Among these 9 kindreds, 4 different crossover sites have been identified and three 
different haplotypes have been seen, indicating that within this subgroup 
independent duplications had occurred (Lifton et al, 1992). Although the 
importance of this finding is unclear in the genesis of the chimeric genes causing 
GSH it does underscore the importance that the discovery of allelic variation may 
have on determining the mechanisms responsible for the inheritance of GSH.
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1.10 Aims of Investigation
Genetic factors are important in the development of hypertension in man. What 
these factor may be is not yet clear but abnormalities of steroid hormone 
metabolism may be important. The underlying molecular pathology of GSH has 
been defined in a number of affected individuals and suggestions regarding the 
possible pathogenesis of the disorder have been made. In addition, abnormalities 
of steroid secretion in essential hypertension have been detected which may be 
important in the aetiology of hypertension and could have a genetic basis.
1.10.1 Glucocorticoid-Suppressible Hyperaldosteronism
In Glasgow a number of kindreds with GSH have been identified over the last 15 
years. This has been achieved by a combination of clinical observation and 
biochemical testing.
The purpose of the work described in this thesis was:
1) To assess the viability of using a genetic test to screen kindreds with
GSH to detect milder and perhaps asymptomatic cases
2) To determine the precise molecular structure of the chimeric 1113-
hydroxylase/aldosterone synthase gene in these kindreds
3) To assess the role, if any, of a polymorphism in the promoter region of
CYP11B2 on the inheritance of GSH
4) To define the biochemical and clinical features, i.e. phenotype, of GSH
in these kindreds and relate this to genotypic differences
4) To assess the effect of prolonged hyperaldosteronism on left ventricular
mass index in patients with GSH
1.10.2 Adrenal Steroid Abnormalities in Hypertension
The aims of this part of the thesis were:
To measure the effect of ACTH-stimulation on steroid secretory 
responses in normal subjects and patients with essential hypertension, GSH and 
Conn's syndrome
The findings of the studies are presented in Chapters 3-7 and the conclusions 
drawn in Chapter 8.
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Chapter 2
MATERIALS AND METHODS
2.1 Materials
All reagents employed were of the highest quality available and were obtained from 
the following suppliers:
2.1.1 General reagents
The following reagents were obtained from Sigma Chemical Company Ltd., Poole, 
Dorset, U.K.: type V high gelling temperature agarose, urea, ethidium bromide, 
mineral oil, dried milk powder, N.N'-methylene-bis-acrylamide, N,N,N,N'- 
tetramethylethylenediamine (TEMED), Sephadex-G50, mineral oil.
The following reagents were obtained from BDH Chemicals Ltd., Poole, Dorset, 
U.K.: sodium tetradecyl sulphate (SDS), ammonium persulphate, acetic acid 
(glacial), glycerol, bromophenol blue, Triton X-100.
The following reagents were obtained from FSA Laboratory Supplies, 
Loughborough, United Kingdom: sucrose, diaminoethanetetra-acetic acid disodium 
salt (EDTA), Tris hydrochloride, sodium hydroxide, sodium citrate, ammonium 
acetate, sodium chloride, potassium chloride, magnesium chloride.
The following reagents were obtained from University of Glasgow Chemistry Store: 
absolute ethanol, absolute methanol, chloroform, hydrochloric acid.
Rathburn Chemicals, Westburn, United Kingdom supplied phenol.
Ciba Laboratories (Horsham, United Kingdom) supplied tetracosactin, 250pg/ml 
(Synacthen).
Baxter Healthcare Ltd. (Norfolk, United Kingdom) supplied 0.9% sodium chloride.
2.1.2 Molecular Genetic Reagents
97
The following reagents were obtained from Gibco BRL-Life Technologies, Paisley, 
United Kingdom: the restriction enzymes BamHI and Haelll, Reactl and React2 
buffers, random primer labelling kit (18187-013).
The following reagents were obtained from Promega, Madison, Wl, U.S.A.: 
proteinase K, Taq DNA polymerase, deoxyribonucleotides, T4 polynucleotide 
kinase, 10x reaction buffers.
Epicentre Technologies, Madison, Wl, U.S.A. supplied GELase enzyme 
preparation.
Sequenase DNA sequencing Kit was supplied by United States Biochemicals, 
Ohio, U.S.A.
Bethesda Research Laboratories-Life Technologies, Inc, Paisley, United Kingdom 
supplied: double stranded DNA molecular size standard.
NuSieve GTG Metaphor agarose was obtained from Flowgen, Instruments Ltd, 
Sittingbourne, UK.
Oswel DNA Service, University of Edinburgh, United Kingdom, supplied 
oligonucleotides for polymerase chain reactions and DNA sequencing.
Amersham Ltd, U.K. supplied Hybond N+ nylon membrane.
2.1.3 Radiochemicals
The following radioisotopes and products were purchased from Amersham 
International pic, Buckinghamshire, United Kingdom: [t32P] adenosine 5'- 
triphosphate, 32P deoxycytidine 5' triphosphate, hypercassette (18x24 cm), and 
hyperscreen intensifying screens (18x24 cm).
New England Nuclear, U.S.A. supplied 35S - adenosine 5'-triphosphate.
2.1.4 Photographic Equipment
Photographs of agarose gels were obtained using polaroid type 667 film (Sigma 
Chemical Company Ltd., Poole, Dorset, U.K.) in a Polaroid DS34 Instant Print
98
camera fitted with a Kodak 22A Wratten filter. Autoradiographs were exposed on 
Hyperfilm NP (Amersham, U.K.)
2.2 Blood Samples
Blood samples were taken using Vacutainer needles and bottles supplied by 
Becton Dickson, Vacutainer Systems Europe, Meylan, Cedex-France.
2.3 Apparatus
The following apparutus were obtained as listed:
Laminar flow hood (MDH, Andover, Hampshire, United Kingdom), 11x64mm 
polystyrene tubes, sterile polyethylene eppendorfs, universals and plastic Pasteur 
pipettes (standard and fine tipped) (Alpha Laboratories Ltd., Hants., United 
Kingdom), GNA-100 electrophoresis tanks, teflon combs, glass plates, 
electrophoresis constant power supply ECPS 3000/150 (Pharmacia Biosystems 
Ltd., Milton Keynes, United Kingdom), Model S2 sequencing gel apparatus, 
spacers (Life Technologies Ltd., Paisley, United Kingdom), Beckman DU-70 
spectrophotometer (Beckman, Buckinghamshire, United Kingdom), UV Stratalinker 
1800 (Statagene Industries Inc., U.S.A.), 316nm UV transilluminator (UVP, United 
Kingdom), IMED 940A volumetric infusion pump (Imed Corp., California, U.S.A.), 
Hybaid OmniGene Thermal Cycler (Hybaid Ltd., Teddington, United Kingdom), 
Maxidry Gel Dryer (Watman Ltd., United Kingdom), Hybridisation oven (Technie 
S.A., France), mercury sphygmomanometer (Accuson Ltd., United Kingdom).
2.4 General Procedures
2.4.1 Glassware
All items of glassware were washed in solutions of the detergent decon 75 (Decon 
Laboratories Ltd., Hove, United Kingdom), rinsed thoroughly with tap water, then 
distilled water (dH20) and dried in an oven at 37°C.
2.4.2 Micropioetting
Solution volumes in the range 0.1-25.00|il were transferred accurately using Rainin 
EDP-plus electronic pipettes (Rainin Instrument Co., Inc., Woburn, USA). Volumes
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in the range 25-1000|il were transferred reproducibly using Finnpipettes 
(Labsystems, Helsinki, Finland).
2.4.3 pH measurement
Measurements of pH were performed using a digital pH/temperature meter 
obtained from Electronic Instruments Ltd. (United Kingdom). The apparatus was 
regularly standardised with a solution of pH 7 prepared from buffer tablets.
2.4.4 Centrifugation
Forces of up to 3500 r.p.m. (1500 g) were attained using a Damon/IEC division 
DPR-6000 centrifuge purchased from International Equipment Company 
(Bedfordshire, United Kingdom). Microcentrifugation at 13000 r.p.m. (100 g) was 
performed using a Microcentaur centrifuge (MSE Ltd., United Kingdom).
2.5 Clinical Methods
2.5.1 Blood Pressure Measurement
Blood pressure was measured in supine, rested individuals. Three measurements 
were taken over 30 minutes and the mean taken. Blood pressure was measured 
using a standard mercury sphygmomanometer and inflatable bladder and cuff, 
sized appropriately for each patient. Korotkoff phase V was taken as the diastolic 
pressure.
2.5.2 Blood sampling
Blood samples were obtained via direct puncture of a forearm vein in the absence 
of an occlusive tourniquet using the Vacutainer system. Blood for renin estimation 
and DNA extraction was taken into chilled 4.5ml bottles containing potassium 
EDTA (0.054ml of 0.34M EDTA K3) as anticoagulant. Blood for aldosterone, 
potassium and steroid assays was taken into chilled 7ml bottles containing lithium 
heparin (143 USP units) as anticoagulant. Plasma was separated and stored at 
-20°C until assayed.
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2.5.3 Basal State Sampling
Basal blood samples were obtained via an indwelling intravenous cannula (23G 
intavenous cannula, Becton Dickson, Meylan, Cedex-France) using the Vacutainer 
system. Subjects forearm veins were cannulated 14 hours before sampling and the 
subjects lay supine overnight prior to sampling at 9.00am.
2.5.4 Sampling During Continuous Intravenous Infusion
During a continuous intravenous infusion, blood was sampled from the arm 
contralateral to the infusion at 15 minute intervals from 30 minutes prior to 
commencing the infusion until the completion of the infusion.
2.5.5 Intravenous ACTH Infusion
A graded dose intravenous infusion of ACTH was administered to individuals in a 
quiet environment at 9.00am following an overnight fast and recumbency. An 
intravenous cannula was placed into a vein in both forearms and basal blood 
samples taken at -30, -15 and 0 minutes. Blood pressure and heart rate were 
measured at the time of blood sampling. At time 0 minutes, determined by a settled 
heart rate < 75 beats/minute, an intravenous infusion of ACTH was commenced. 
The infusion solution was prepared in the following way:
2ml of ACTH (250pg/ml) added to 498ml 0.9% NaCI Solution A
50ml of Solution A added to 450 ml of 0.9% NaCI Solution B\
Solution B (0.1pg/ml ACTH) was administered by continuous intravenous infusion 
using an IMED 800 pump in incremental doses: 0.1pg/kg/min, 1.0pg/kg/min, 
10.0pg/kg/min, for 30 minutes at each dose. Blood was taken and blood pressure 
and heart rate measured at 15 minute intervals until the end of the 90 minute 
infusion.
2.5.6 Echocardiograohic Measurements
Echocardiograms were performed by a single operator using an Accuson 128 PX 
ultrasound machine with a 3.75MHz transducer (Accuson Ltd, USA). Patients were 
placed in the partial (45°) left lateral decubitus position with 30° of upright tilt.
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Echocardiographic measurements for the calculation of left ventricular mass were 
taken from standard M-mode echocardiograms obtained from the left parasternal 
short-axis view.
Left ventricular mass was calculated using the Penn convention formula and 
corrected for body surface area to deduce the left ventricular mass index (LVMI) for 
each individual (Devereuxand Reichek, 1977).
Body surface area was calculated from the formula of Du Bois and Du Bois (Du 
Bois and Du Bois, 1916).
2.6 Biochemical Assays
2.6.1 Aldosterone
Plasma aldosterone concentrations were measured using a solid phase (coated 
tube) radioimmunoassay (Diagnostic Products (UK) Ltd), the coefficient of variation 
is <8.3% and the limit of detection 1 ng/dl.
2.6.2 Renin
Plasma active renin concentration was determined using an antibody trapping 
technique developed in the MRC Blood Pressure Unit, Western Infirmary, Glasgow 
(Millar et al., 1980). The coefficient of variation is 3.4% and the limit of detection < 
0.5jiU/ml.
2.6.3 Potassium
Plasma potassium samples were assayed in the routine clinical biochemistry 
laboratory, Gartnavel General Hospital, Glasgow, using an indirect ion selective 
electrode on an Olympus AU5200 Analyser (Olympus Optical Co. (UK) Ltd., 
Eastleigh, United Kingdom).
2.6.4 Steroid assays
Plasma cortisol was measured in the routine clinical biochemistry laboratory, 
Gartnavel General Hospital, Glasgow, using a coated tube radioimmunoassay 
(Diagnostic Products (UK) Ltd).
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Plasma concentrations of 11-deoxycorticosterone (DOC), corticosterone, 11- 
deoxycortisol and 18-hydroxycorticosterone were measured in the Steroid 
Laboratory of the MRC Blood Pressure Unit, Western Infirmary, Glasgow by 
radioimmunoassay after extraction and partial purification by paper 
chromatography (Belkien et al., 1980, Fraser et al., 1975). Samples (2ml) to which 
had been added 3H-steroid standards had been added were extracted with freshly 
distilled dichloromethane and the extract evaporated to dryness under nitrogen at 
30°C. The residues were chromatographed on paper (Whatman 2) using a volatile 
system and the steroid regions located by isotope scanning and eluted in 
methanol. Aliquots were assayed using 3H-steroids and antisera raised in rabbits 
to corticosterone-3-carboxymethyloxine conjugated to bovine serum albumin. 
Bound and free steroid were separated using the dextran-coated charcoal method 
(Fraser et al, 1975).
2.7 Genomic DNA extraction
2.7.1 DNA extraction from blood
Genomic DNA was extracted from peripheral blood samples (fresh and frozen) 
using a variation of the method of Sambrook (Sambrook et al., 1989).
Ten millilitres of EDTA-preserved whole blood was placed in a Universal tube and 
40 ml of cell lysis mix (Appendix I) added. Tubes were left on ice for 10 minutes 
before centrifuging at 2800 r.p.m. for 10 minutes at 4°C. The resulting pellet was 
resuspended in 3 ml of nuclei lysis mix (Appendix I), and 200pl 10% SDS and 
10Opil proteinase K (10mg/ml) were added. Tubes were incubated overnight at 
37°C. After incubation, 1 ml of 6M NaCI was added with vigorous shaking, then 5 
ml of phenol:chloroform:isoamyl alcohol (25:24:1), pH aqueous phase >7.6, was 
added and the tubes spun at 2800 r.p.m. for 20 minutes at 4°C. The upper 
aqueous phase of the supernatant was then transferred to a fresh universal 
container and two volumes of absolute ethanol added. DNA was then spooled out 
with a glass rod, washed in 70% ethanol, allowed to air dry and then suspended in 
100|il TE buffer and stored at 4°C.
2.7.2 Determination of DNA concentration
The concentration of each DNA sample was determined by measuring the optical 
density of samples at 260nm. One microlitre of the DNA solution was added to 1ml 
dH20 in a quartz cuvette and the OD260 measured in a dual beam
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spectrophotometer with a deuterium lamp. An optical density of 1 corresponds to 
50mg/ml of DNA.
2.8 Southern Blot Methods
2.8.1 Preparation of Agarose Gels
Agarose (0.8-5% w/v) was added to 100 ml EB buffer, shaken and heated in a 
650W microwave oven for 120 seconds. Whilst cooling, 1pl of ethidium bromide 
was added to the agarose, the agarose shaken and poured into gel moulds with 
teflon combs. The gel was allowed to set for 1 hour at 4°C before the combs were 
removed.
Gels were placed in standard electrophoresis tanks containing 100ml EB buffer 
and connected to a constant power source.
2.8.2 Restriction enzyme digestion of genomic DNA
Ten micrograms of DNA was placed in a 1.5ml Eppendorf tube with 1pJ of high 
concentration Bam HI restriction enzyme (50U/ml) and 1pl of 20X buffer (Appendix 
II). dH20 was added to make the final reaction volume 20pJ. Digests were 
incubated at 37°C for 2 hours and a further 2|il of high concentration enzyme were 
added and the mixture incubated overnight. The completeness of each digestion 
was determined by electrophoresis of 10pl of each reaction mix in a 1.0% agarose 
gel.
2.8.3 Restriction enzyme digestion of PCR products
Eighteen microlitres of each PCR product were placed in a sterile 1.5ml Eppendorf 
tube together with 1pl of 10x buffer (React 2) and 1pl of Haelll enzyme (10U/|il) 
and the reaction mixture incubated for 4 hours at 37°C. The completeness of each 
digestion was determined by electrophoresis of 10pl of each reaction mix in a 3.0% 
Metaphor agarose gel.
2.8.4 Agarose gel electrophoresis for Southern Blotting
DNA was resolved on agarose gels containing 0.05% ethidium bromide (10mg/ml). 
Ten microlitres of digest was added to 5|il of loading mix (Appendix II) in a sterile 
Eppendorf tube and then placed into wells by pipetting and electrophoresed at
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200mA (200V) for 5 hours until the digest was fully resolved. One well of the gel 
contained 10pl of DNA size marker with 5pl of loading mix. Gels were visualised on 
an UV transilluminator (316nm) and photographed.
2.8.5 Southern Blotting
Southern blotting was carried out using a modification of the method of Southern 
(Southern, 1975). Gels were placed in a bath containing 0.25M HCI for 45 minutes 
to allow depurination to occur. Completion of this step was gauged by the colour 
change of the marker dye from blue to yellow. Next the gel was rinsed with dH20  
and placed in 0.4M NaOH for 45 minutes to denature the digested DNA. 
Denaturation was deemed complete when the gel dye marker changed from yellow 
to blue. The gel was then transferred to the blotting apparatus.
A wick made from 0.4M NaOH-soaked 3mm Whatman paper was placed on top of 
a sheet of glass with its ends reaching the surface of an underlying tank containing
0.4M NaOH. The gel was then placed on top of the Whatman paper base up, 
rinsed with 0.4M NaOH, and a precut piece of Hybond N+ hybridisation membrane 
placed on the surface of the gel. Care was taken to remove all air bubbles from the 
gel-membrane interface. Two pieces of 3mm Whatman paper cut to the same size 
as the membrane and soaked in 0.4M NaOH solution were placed on the surface 
of the membrane. Paper towels to height of 15cm were placed on top of the 
Whatman paper, and a glass plate with a 1 kg weight placed on top of the towels. 
The gel was left for 16-24 hours to allow full transfer of DNA to the membrane. 
When DNA transfer was complete, the membrane was removed, rinsed in 2X SSC 
and exposed to short wave ultraviolet light (340 nm) in a UV Stratalinker for 30 
seconds to allow fixation of the DNA to the filter.
2.8.6 Blotting of low molecular weight DNA
The technique was the same as that for the transfer of high molecular weight DNA 
except that transfer took place using 6XSSC/1%SDS as the transfer buffer 
(Curnow et al, 1993).
2.8.7 Prehvbridisation of membranes
Membranes were placed in a glass hybridisation cylinder with 10 ml of pre­
hybridisation solution: 6XSSC/1 %SDS/Dried milk powder 40mg/100mg heat 
denatured salmon sperm DNA, and placed in a rotatory oven at 65°C for one hour
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to prevent non-specific hybridisation of the probe to the membrane. At the end of 
the pre-hybridisation period the pre-hybridisation solution was removed from the 
glass cylinder and replaced with 15 ml hybridisation solution and the radiolabelled 
probe.
For transfer of low molecular weight DNA molecules to membranes no pre­
hybridisation step was performed as the subsequent washing stages were so 
stringent that non-specific hybridisation was eliminated (Curnow et al, 1993).
2.8.8 Radioactive labelling of DNA probes
Labelling of DNA probes for hybridisation to membranes was performed using the 
random primer method for large probes, i.e. greater than 500 basepairs, or end 
labelling of synthetic oligonucleotides using polyadenylate kinase.
Random primer labelling of probes was carried out using a standard kit (Random 
Primer Labelling System, Gibco BRL) in a regulation radioactivity hood. The 
method relies on the ability of the hexanucleotide random primers supplied with the 
kit to hybridise with a complimentary sequence in the probe DNA. Following 
hybridisation the Klenow fragment of DNA polymerase uses the available dNTP's, 
including, 32P-dCTP to extend the oligonucleotide and create a new molecule of 
the template DNA with 32P labelled dCTP incorporated into it.
Probe was prepared by PCR amplification of genomic DNA using oligonucleotide 
primers 3 and 5 as described in 2.9.2.
The PCR product was run on a 0.8% agarose gel to confirm the presence of the 
desired fragment, and then cut out of the gel using a sterile scalpel blade. The gel 
fragment was weighed and placed in a 1.5ml Eppendorf tube with 2 volumes of 
dH20  and boiled for 20 minutes to ensure both the adequate solubilisation of the 
agarose and that the probe DNA was in the single stranded state. The optical 
density of the probe DNA was determined and then 25 ng of probe DNA (volume 
approximately 20pil) was added to an Eppendorf tube containing:
2pl each of dATP, dGTP, dTTP (0.5 mM)
5pl 32P labelled dCTP (0.5 mM strength, 1.85 MBq)
1 pi Klenow fragment of DNA polymerase (3 U/pl)
15pl of random primer buffer mix
3pl dH20 to make the total reaction volume 50 pi.
The mixture was incubated at 37°C for one hour. The solution containing the 
labelled probe was then passed through a Sephadex G50 column primed with
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1XSSC/0.1%SDS and the eluate collected in eppendorfs. When the count of the 
column eluate rose above 1000 cpm, the eluate was collected until the count fell 
back below 1000 cpm. This eluate contained probe with the highest specific activity 
and was used for hybridisation.
2.8.9 Preparation of end-labelled oligonucleotides
Oligonucleotide probes were prepared by end-labelling them with [t32P] ATP. The 
reaction utilises the enzyme T4 polyadenylate kinase to covalently bond the t32- 
phosphate from ATP to the 5'-terminus of polynucleotides bearing a 3'-phosphate 
group.
The labelling reaction was carried out as follows:
4fjJ of oligonucleotide (10pmol/ml) was added to 25pl of dH20 and heated to 80°C 
for 2 minutes. Five microlitres of reaction buffer and 15(il of y^PATP are added 
with 1.5pJ of T4 polyadenylate kinase and the reaction mix heated to 37°C for 30 
minutes and then to 65°C for 10 minutes. The end-labelled oligonucleotide is 
stored at -20°C for up to one week prior to use.
2.8.10 Probe hybridisation
Labelled probe was added to the glass hybridisation cylinder containing the 
membrane, 20ml of hybridisation solution (6XSSC/1%SDS/0.25% fat-free skimmed 
dried milk) and 20jil of labelled probe and placed in a rotary oven at 65°C.
Genomic DNA blot hybridisation took 18 hours, whilst blots of PCR products 
required only 4 hours at 420c.
2.8.11 Filter washing and autoradiography
After hybridisation, genomic DNA filters were washed for 10 minutes in 
2XSSC/0.1%SDS at room temperature, 10 minutes in 1XSSC/0.1%SDS at room 
temperature, 10 minutes in 0.5XSSC/0.1%SDS at 65°C, and in
0.1XSSC/0.1%SDS at 65°C for 10 minutes or until the background radioactivity of 
the membrane was 10 cpm.
Membranes blotted with PCR products were washed in 6XSSC/1%SDS for 40 
minutes at 58°C, ASO - 2360, or 56°C, ASO - 2361. The substitution of C/G 
(2360) for a T/A (2361) leads to a 2°C reduction in the melting temperature of the 
ASO. This meant that at 58°C 2361 is stripped from the filter whilst 2360 will still
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remain hybridised and thus allow alleles to be differentiated on this basis (5.2.1) 
(Curnow et al, 1993, Kogan et al., 1987, White et al, 1991).
Membranes were then wrapped in clingfilm, placed in a X-ray cassette with 
Hyperfilm MP and left at -70°C for 48 hours. Autoradiographs were developed in a 
Kodak X-Omat automated developer.
2.9 Polymerase Chain Reaction amplification of DNA
2.9.1 Preparation of synthetic oligonucleotides
Synthetic oligonucleotides were designed from the published sequences of 
CYP11B1 and CYP11B2 and obtained from a commercial source (2.1.2).
2.9.2 Polymerase chain reaction amplification of genomic DNA
Amplification of genomic DNA to provide probes for Southern Blot procedures or 
amplification of specific chimeric sequences to allow determination of DNA 
sequences was performed using the polymerase chain reaction (PCR) method. 
Genomic DNA extracted from the blood of affected individuals or DNA extracted 
from the placenta of one affected individual was used as the reaction template. 
Reactions were carried out in sterile polypropylene Eppendorf tubes. A standard 
reaction protocol was used for amplification reactions although the template and 
oligonucleotide primers were altered according to the requirements of the 
amplification.
A standard reaction mix was prepared as follows:
A 1pl (approximately 50ng/pl) aliquot of the DNA to be amplified was placed in a 
sterile Eppendorf tube and then placed on ice.
A reaction "pre-mix" was prepared for addition to the DNA prior to incubation:
dH20
dNTP's:
34.5pl
1|il each of dATP, dCTP, dGTP, dTTP 
(10mM strength)
2.5pJ (1 OpM/ptl)
2.5|il (10pM/pl)
5jil
0.5}il (5U/pl)
Primer No. 1: 
Primer No. 2: 
10X Buffer:
Taq Polymerase:
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Taq Polymerase, a thermostable DNA polymerase, was used to perform the 
amplification reactions and was added last to the pre-mix directly from storage at 
-20°C, immediately prior to adding an aliquot of the pre-mix to the DNA. Reaction 
mixtures were overlain by 50pl of mineral o il, and placed in a thermal cycler. The 
heating block temperature was raised to 94°C for 60 seconds, to allow complete 
denaturation of the DNA template to occur prior to carrying out the PCR protocol. 
The amplification protocol used was as follows:
Step 1: 94°C for 60 seconds
Step 2: 65°C for 60 seconds - primer annealing
Step 3: 72°C for 120 seconds,
increasing by 5 seconds for each 
subsequent cycle -primer extension
Steps 1 to 3 were repeated for 35 cycles, and followed by a final extension step of 
72°C for 15 minutes.
The total reaction time was approximately 4 hours 30 minutes.
Following completion of the PCR protocol, samples were placed on ice until run on 
1% agarose gels stained with ethidium bromide to determine the presence of the 
desired reaction products.
2.9.3 Purification of PCR products from agarose gels
To use the PCR product for DNA sequencing, it must be obtained in a pure state 
free from any other DNA or oligonucleotides. PCR products were purified using the 
GELase system.
PCR products were loaded onto an ethidium bromide stained 1% low melting point 
agarose gel (SeaPlaque GTG agarose, FMC Bioproducts, U.S.A.) and 
electrophoresed for 3 hours at a low current (60mA) to allow for adequate 
separation of the PCR product from all other reaction constituents. Bands were 
visualised using a long wave ultraviolet light source and removed from the gel 
using a sterile scalpel and forceps. Gel slabs were then placed in sterile Eppendorf 
tubes, weighed and 3 volumes of GELase buffer added to the tube. The mixture 
was left at room temperature for 1 hour and the buffer then removed by pipetting. 
The tube containing the gel was then placed in a water bath at 70°C for 20 minutes 
until molten, spun briefly in the microcentrifuge and then placed in a second water 
bath at 45°C and the GELase enzyme added.
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600mg of agarose was added to 1U of enzyme (on average each gel slice weighed 
150mg) and the reaction incubated at 45°C for 1 hour. Following incubation, the 
volume of the mixture was determined by pipetting, 1 volumes of 5M ammonium 
acetate and 2 volumes of absolute ethanol added to precipitate the DNA and the 
total mixture was centrifuged for 35 minutes at 3500 r.p.m. and 4°C. The 
supernatant was removed by pipette, 500pl of 70% ethanol was added and the 
tube centrifuged for a further 4 minutes. The 70% ethanol was carefully removed 
and the sample air dried. The DNA pellet was re-suspended in 20pl of 1X TE buffer 
ready for use in sequencing reactions.
2.10 Direct DNA sequencing from PCR products
2.10.1 DNA sequencing using the Sequenase System
Determination of nucleotide sequences was performed on PCR-amplified DNA by 
a modification of the chain termination method using the commercially available 
Sequenase Kit (United States Biochemicals, Ohio, U.S.A.). Dimethyl sulphoxide 
(DMSO) was included to enhance the sequencing reaction by improving 
hybridisation of the primer to the template DNA (Winship, 1989). Details of buffers 
are in Appendix II.
The chain termination method of DNA sequencing involves the synthesis of a DNA 
strand by a DNA polymerase in vitro using a single-stranded DNA template. 
Synthesis is initiated at the site of hybridisation of an oligonucleotide of known 
sequence, the so-called "sequencing primer". The sequencing primer anneals to 
the DNA of interest and a DNA strand is elongated until the reaction is terminated 
by the incorporation of a nucleotide analogue that does not support further 
elongation. Such analogues include the 2,,3'-dideoxynucleoside 5'-triphosphates 
(ddNTP's) which lack the 3'-OH group required for DNA chain elongation. Four 
such reactions are carried out in parallel using different ddNTP's mixed with the 
complementary dNTP's to provide complete sequence information. A radioactively 
labelled nucleotide is included in the synthesis so the labelled chains of varying 
length can be visualised by autoradiography after high resolution electrophoresis.
2.10.2 Sequencing Protocol: A) Annealing
Each of the reactions listed below was carried out in a sterile Eppendorf tube:
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a) 4 tubes containing 2.5pl of each of the four ddNTP's in a termination mix
were placed in a bath at 37°C (for 2.10.3, b),
b) 4 tubes were prepared containing the following:
DNA 5pl (approximately 1pg)
H20  2pl
DM SO 25% 1pl
Sequencing Primer 1pl 
Total Volume 10pil
All four were placed in a water bath at 98°C for 120 seconds, and then spun briefly. 
Tubes were then allowed to cool to room temperature over 10 minutes, 2pl of 
Reaction Buffer was added and the tubes spun and left at room temperature.
2.10.3 Sequencing Protocol: B) Labelling and Termination Reactions
The labelling reaction was perfomed as follows:
a) To 1Opl of annealed DNA mixture was added:
DTT, 0.1M 1pl
Diluted labelling mix 2pl
[35S] dATP 1pl
Diluted Sequenase 2pl
The reaction mixture was spun briefly and left at room temperature for 5 minutes,
b) After incubation at room temperature, 3.5pl of labelling reaction mixture
was added to each tube containing the termination mix and incubated at 37°C for 5 
minutes. 4pl of Stop Solution were then added to each tube and the mixture kept at 
-20°C until run on a polyacrylamide sequencing gel.
2.10.4 Polyacrylamide gel preparation
Polyacrylamide gels were prepared using a modification of a standard protocol. 
Two glass plates were siliconised and left to dry in air with the teflon spacers in 
place. A mixture for a Polyacrylamdide : Urea 6% gel was prepared as follows: 
Acrylamide:bisacrylamide (19:1) 6g
Urea 62.8g
10xTE buffer 13.7ml
were mixed together and the volume adjusted to 100ml with dH20 and filtered 
through 3mm Whatman paper. To form a seal at the base of the gel, 3ml of the 
acrylamide:urea mix were removed and 30pl of 10% ammonium persulphate and 
1 pi of TEMED added. This mixture was then poured into the gel plates and allowed
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to set. The remainder of the acrylamide:urea mix was polymerised by adding 1ml 
of 10% ammonium persulphate and 25pl of TEMED, and poured into the plates. Air 
bubbles were removed, the well combs inserted into the top of the gel and the gel 
allowed to set for approximately 3 hours at a 10° angle to the horizontal.
2.10.5 Polyacrylamide oel electrophoresis
Once the sequencing gel was ready for use, it was placed on the electrophoresis 
apparatus and secured by side clamps. The lane combs and spacers were 
removed and the gel heated to 45°C. The lanes were cleared of bubbles by a fine- 
tipped Pasteur pipette and the loading combs replaced.
For each lane of the gel, 3.5pl of the terminated sequencing mix were placed in a 
well. Four reactions were run in parallel on the gel for each sequencing primer in 
the order: GATC allowing the complete sequence of the DNA to be determined. 
Gels were run for approximately 60 minutes at 55-70 Watts, ensuring that the 
surface temperature of the gel did not rise above 50°C. For reading of sequences 
over 300 bases from the sequencing primer, gels were run for approximately 90 
minutes.
2.10.6 Preparation and autoradiography of sequencing gels
After completion of the electrophoresis, gels were soaked in 5% glacial acetic acid/ 
5% absolute methanol (approximately 2 litres) in a flat tank for 30 minutes and then 
washed in wated for 10 minutes. Washed gels were then absorbed onto 3mm 
Whatman paper, covered in clingfilm and then dried for 60 minutes. The clingfilm 
was removed and the dried gels were placed in a photographic cassette in direct 
contact with the emulsion side of the photographic film and left at -70°C for 16 
hours. Following overnight exposure, autoradiographs were developed in a Kodak 
X-Omat.
2.10.7 Determination of DNA sequence from polyacrylamide aels
Sequences were determined by direct reading of the autoradiograph and 
comparison of the deduced sequence with the consensus sequence of the 
CYP11B1 and CYP11B2 genes.
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2.11 Data and DNA sequence analysis
Calculations of statistical significance were performed using Minitab Statistical 
Software, Release 8.21 for the Macintosh (Minitab, Philadelphia, U.S.A.)
Analysis of DNA sequences was performed using the GCG (Genetics Computer 
Group) sequence analysis software package (8.1) (University of Wisconsin, U.S.A.) 
on the University of Glasgow mainframe computer.
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Chapter 3
GENOTYPIC IDENTIFICATION OF SUBJECTS WITH 
GLUCOCORTICOID-SUPPRESSIBLE HYPERALDOSTERONISM
3.1 Introduction
As stated previously, individuals with GSH are at increased risk of developing 
premature cerebrovasular disease. In addition, given the possible difficulties in 
diagnosing GSH, in particular lack of clinical suspicion and variable phenotype of 
GSH, the use of a screening test to detect affected individuals is of considerable 
importance. Such an investigation would require the test to have 100% specificity 
and sensitivity, i.e. all individuals with GSH should be detected and only individuals 
with GSH should be detected, i.e. no false negatives or positives. Two possible 
means of performing such a screen are 1) the use of plasma measurements or 24 
hour urine collections to assess urinary excretion of 18-hydroxycortisol, 18- 
oxocortisol or determination of the 18-oxotetrahydrocortisol: tetrahydroaldosterone 
ratio (Connell et al, 1986, Gomez-Sanchez et al, 1987, Ulick et al, 1990); 2) the 
use of a simple genetic test on a single blood sample to identify affected individuals 
on the basis of the inheritance of a chimeric CYP11B1/B2 gene. The former 
method has been used in a single North American kindred to screen relatives of 
affected probands for the presence of GSH (Rich et al, 1992). It has been shown to 
be effective but has several limitations; 1) the need for accurate 24 hour urine 
collections, 2) assay of urinary steroids which are not widely available, 3) 
interpretation of results at the extremes of the age range where reference ranges 
are not well established. Thus, the use of genetic method with 100% specificity for 
the diagnosis of GSH (Lifton et al, 1992) which can be performed on a single blood 
or tissue sample would be a considerable advance.
In order to assess the utility of the genetic method in detecting cases of GSH, a 
study of genotyping of the extended kindreds of five probands with GSH was 
performed.
3.2 Methods
3.2.1 Subjects
Subjects from five apparently unrelated kindreds were studied.
Probands from four kindreds, kindreds 1,2,3 and 5, were patients under the care of 
Professor JMC Connell, MRC Blood Pressure Unit, Glasgow.
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The largest kindred, kindred 1, were natives of the Isle of Lewis, Outer Hebrides, 
Scotland and have been geographically immobile for at least six generations. The 
members of kindred 2 are inhabitants of South Ayrshire, Scotland, but can trace 
their ancestry through a maternal grandmother who originally came from the Isle of 
Lewis. However, no connexion between kindreds 1 and 2 could be detected on 
close questioning of the kindred members. The members of kindred 3 originate 
from the Glasgow area in central Scotland and can trace no relatives who have 
lived outwith this region of Scotland. The members of kindred 5 originate from the 
Thurso region of Northern Scotland, also have no known antecedents from the 
Hebridean Islands or from central Scotland, and have been geographically 
immobile for 7 generations.
The proband of the fifth kindred, kindred 4, was under the care of Dr PM Stewart, 
Queen Elizabeth Hospital, Birmingham. This kindred originated in Belfast, Northern 
Ireland and subsequently migrated to the West Midlands area of England in the 
1950's.
The five probands had been diagnosed as having GSH on clinical and biochemical 
grounds (Chapter 6). The kindreds of the 5 probands were extended as far as 
possible and subjects tested for the presence of GSH by genotyping of DNA 
extracted from stored whole blood.
3.2.2 DNA Preparation and Southern Blotting
Genomic DNA was prepared from EDTA-preserved blood and stored as described 
in 2.7.1. An aliquot of DNA was then digested with the enzyme BamHI, subjected 
to agarose gel electrophoresis and blotted onto a nylon membrane as described in 
2.8.2, 2.8.4 and 2.8.5.
Placental DNA obtained at birth was used for the diagnosis of GSH in one 
individual (1-3-8). Chorionic villi were cut into manageable pieces, homogenised 
manually and subjected to the same extraction process as whole blood (2.7.1.)
3.2.3 Probe Preparation and Membrane Hybridisation
A 32P-labelled probe was prepared as described in 2.8.8 by PCR amplification of 
genomic DNA from a normal control using oligonucleotides 1 and 2 (Appendix III) 
as described in 2.9.2. This primer pair amplify a 800 bp region spanning exons 2-5 
of CYP11B1.
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Membranes were pre-hybridised as described in 2.8.7 and the probe hybridised to 
the membrane as described in 2.8.10.
3.2.4 Autoradiography
Hybridised membranes were washed, wrapped in clingfilm, placed in an X-ray 
cassette with Hyperfilm MP and left at -70^0 for 48 hours. Autoradiographs were 
developed in a Kodak X-Omat automated developer as described in 2.8.11.
3.3 Results
Studies of the families of the five probands resulted in the identification of 60 
subjects related to the 5 probands who were regarded as suitable for genotyping. 
There was no apparent connexion between any of the kindreds following detailed 
pedigree analysis.
Figures 3.3 a-e show the pedigrees of the five kindreds with the subjects 
genotyped highlighted.
Figures 3.3 f and 3.3 g show a typical result of Southern blots of subjects from the 
5 kindreds.
Affected individuals possess three hybridising species on the Southern Blot: a 8.4 
kb species corresponding to CYP11B1, a 4.2 kb species corresponding to 
CYP11B2 and a third 6.3 kb band corresponding to the chimeric 
CYP11B1/CYP11B2 gene. Unaffected subjects exhibit only two species 
corresponding to the normal CYP11B1 and CYP11B2 genes.
In total, genotyping of kindred members by this method identified 19 individuals 
with GSH in the five kindreds studied. Nine subjects were identified as having GSH 
with no clinical or routine biochemical evidence suggestive of hyperaldosteronism,
i.e. hypertension or hypokalaemia.
Included in this group was a newborn infant from kindred 1. GSH was diagnosed 
on the basis of a positive result from a Southern Blot of chorionic villous DNA 
obtained from the placenta directly after delivery, stored in TE buffer and 
transferred by air to our unit. This is the first time such an observation has been 
made and would appear, at present, to be unique (Jamieson et al, 1994).
The relevance of the relationship between the clinical and biochemical indices of 
the 19 patients with GSH is discussed in full in Chapter 6.
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Kindred 2
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■  Affected Proband
□  Unaffected
OS Unscreened Presumed affected 
zz UnscreenedPresumed unaffected
Figure 3.3 b Kindred 2.
Affected individuals are identified by a three part identifier, 
i.e. Kindred Number-Generation-Member.
For example the proband of this kindred is 2-III-2.
Kindred 3
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1
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■  Affected ^  Proband
□  Unaffected
m  Unscreened Presumed affected 
UnscreenedPresumed unaffected
Figure 3.3 c Kindred 3.
Affected individuals are identified by a three part identifier, 
i.e. Kindred Number-Generation-Member.
For example the proband of this kindred is 3-111-1.
Kindred 4
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f f l  Unscreened Presumed affected 
0  UnscreenedPresumed unaffected
Figure 3.3 d Kindred 4.
Affected individuals are identified by a three part identifier, 
i.e. Kindred Number-Generation-Member.
For example the proband of this kindred is 4-11-1.
Kindred 5
■  Affected ^  Proband
□  Unaffected
m  Unscreened Presumed affected 
B  UnscreenedPresumed unaffected
Figure 3.3 e Kindred 5.
Affected individuals are identified by a three part identifier, 
i.e. Kindred Number-Generation-Member.
For example the proband of this kindred is 5-11-1.
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i.e. 8.4 kb, 6.3 kb, 4.4 kb and therefore have GSH
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i.e. 8.4 kb, 4.4 kb and therfore do not have GSH
Figure 3.3 f Southern blot of 6 individuals from kindred 4
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A, B, G, H and P possess three hybridising species, 
Le. 8.4 kb, 6.3 kb, 4.4 kb, and therefore have GSH
C, D, E, F, I, J, K, L, M, N, O and Q possess two  
hybridising species,
Le. 8.4 kb, 4.4 kb, and therfore do not have GSH
Figure 3.3 g Southern bbt of 16 individuals from kindreds 1,2,3 and 5
3.4 Discussion
The method used in this study to detect the presence of a chimeric CYP11B1/B2 
gene has been shown to have a 100% sensitivity and specificity for the diagnosis 
of GSH in all kindreds studied to date (Connell et al, 1986, Lifton et al, 1992, Lifton 
et al, 1992, Miyahara et al, 1992, Pascoe et al, 1992a). Lifton (Lifton et al, 1992) 
showed that the diagnosis of GSH was in strong linkage with the 6.3 kilobase band 
on the Southern blot in a single large kindred, lod score 5.23 for complete linkage,
i.e. the odds of there being no linkage were greater than 100000 to 1. In addition, 
the method allows for the rapid diagnosis of individuals suspected of having GSH. 
The time taken from blood sampling to a result from autoradiography can be as 
little as 60 hours in our laboratory and gives results with 100% accuracy. I have 
also shown that a diagnosis of GSH in the perinatal period is possible (Jamieson et 
al, 1994), with the potential for appropriate counselling of the parents to be 
organised and delivered long before the affected child is at any risk from the effects 
of aldosterone excess. The potential for prenatal diagnosis of GSH from chorionic 
villus sampling material or amniocentesis-derived tissue should not be overlooked. 
However, the condition has a low early mortality and an effective, specific therapy 
and no in utero gene therapy for the condition is available. Therefore the need for 
such a diagnostic method is questionable as termination of pregnancy would be 
inappropriate given the high biological fitness of affected individuals.
The method is of particular benefit in assessing the relatives of an affected 
individual who do not have any obvious features of aldosterone-excess (e.g. 
hypertension or hypokalaemia) and can readily exclude or confirm the diagnosis in 
hypertensive relatives of affected patients. It also has the potential for identifying 
affected individuals prior to the onset of hypertension, allowing the clinician to 
monitor subsequently the blood pressure to detect any rise in blood pressure and 
consequently to institute appropriate therapy at an early stage with the hope of 
minimising the risks of stroke in these patients.
Finally, the identification of untreated, clinically silent patients with GSH allows for 
the detailed study of the effects of growth, sexual maturation, environmental and 
genetic factors on the severity of GSH phenotype. As will be shown in Chapter 6, 
there is a wide spectrum of clinical phenotypes in affected individuals with GSH. 
Environmental and epistatic genetic factors may be important in modulating the 
effect on blood pressure of the chimeric CYP11B1/B2 gene in a given individual.
Another intriguing observation regarding kindreds with GSH is the considerable 
excess of kindreds with a Celtic bias, i.e. originating from Ireland, Scotland or
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possibly North-west France. Of those kindreds studied so far, an Irish origin is 
either established or strongly suspected in 9, Scottish ancestry in 6 and English in 
2, approximately 75% of all kindreds described in the literature (Lifton et al, 1992, 
Woodland et al, 1985). Thus, it would appear that there is something peculiar to 
the inhabitants western aspects of northern Europe which predisposes to the 
formation of these chimeric genes. This predisposition may simply reflect the 
geographical distribution of the descendants of the index cases in relation to 
centres able to diagnose the condition, i.e. ascertainment bias, and the condition 
may be uniformly prevalent throughout all ethnic groups but simply underdianosed.
The majority of cases of GSH described in the literature are not the result of a 
single founder gene. Multiple chimeric genes have been found in the affected 
kindreds (Lifton et al, 1992, Miyahara et al, 1992, Pascoe et al, 1992a). However, a 
number of kindreds have chimeric genes indistinguishable by sequencing and 
analysis of linked markers has shown that in such kindreds there are haplotypic 
differences in the linked markers which confirm that they arise as the resuit of 
independent mutations (Lifton et al, 1992).
Similar work on a limited number of kindreds has shown that one SSCP marker, 
AldoX9, in exon 9 of CYP11B2 may be important in the development of a chimeric 
gene. In 9 pedigrees of Irish or English origin studied, all possessed allele 1 of the 
AldoX9 SSCP in the aldosterone synthase gene of the chromosome carrying the 
chimaeric gene, a significant deviation from that expected by chance (p<0.04); 8 
out of 9 had allele 1 present in the chimeric gene. Among these 9 kindreds, 4 
different crossover sites have been identified and three different haplotypes have 
been seen, indicating that within this subgroup independent duplications had 
occurred (Lifton et al, 1992). Thus, it would appear that the possession of certain 
marker haplotypes favours the formation of chimeric genes by, as yet, unknown 
mechanisms.
In the most common inherited disorder of adrenal steroid biosynthesis, steroid 21- 
hydroxylase deficiency, gene conversion events between the normal gene for 
steroid 21-hydroxylase (CYP21B) and a highly homologous pseudogene (CYP21A) 
lying in tandem, are a common cause of enzymatic deficiency (White et al, 1984, 
White et al, 1984). Gene conversion refers to a non-reciprocal recombination event 
in which a segment of one gene replaces the corresponding segment of a related 
genes, initially described in fungi. Such gene conversions have been described in 
cultured cells at a rate of 5x10-6 (Liskay and Stachelek, 1983), and suggested to 
occur in human B-globin genes, human fetal y-globin genes, and immunoglobulin
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genes (Kourilsky, 1986). In 21-hydroxylase deficiency, recombination occurs 
between CYP21B and CYP21A to produce mutant alleles which introduce 
nucleotides into CYP21B which result in the production of truncated non-functional 
enzymes or alteration of key amino acids in the enzyme (White and New, 1992).
The mechanism whereby such transfer of genetic material occurs is not entirely 
clear, but two principal mechanisms have been suggested depending on whether 
the transfer of genetic material from the donor to the acceptor gene is via a single 
or a double stand and has been reviewed in detail previously (Kourilsky, 1986) 
(Figure 3.4 a, b).
First, a break in both strands of the acceptor gene double helix allows both strands 
to be repaired by the donor gene with the incorporation of donor genetic material 
into both strands of the acceptor helix. This is in effect a double recombination 
event and may result in the transfer of large pieces of DNA between genes. Such a 
break in the DNA helix is enlarged by nucleases; the 4 free ends of the DNA 
molecule are then free to invade the double stranded partner molecule and initiate 
the recombination event. This process favours the formation of extrachromosomal 
recombination in yeast and mouse models (Kourilsky, 1986).
Second, a break in a single strand of the donor gene may allow the advancing limb 
of the donor gene to invade the acceptor gene to form a heteroduplex. Subsequent 
repair of the donor strand leaves it intact and unaltered whilst the acceptor strand 
contains new material. Such a mechanism is thought to involve only short 
distances along the DNA strand and thus only a few nucleotides will be 
incorporated into the acceptor gene. However, many such conversion events may 
occur in areas of high homology leading to a 'patchwork' appearence of the 
acceptor gene such as that seen in certain forms of B-thalassaemia (Kourilsky, 
1986).
The chimeric gene in patients with GSH could have arisen from a non-homologous 
exchange of DNA between CYP11B1 and CYP11B2 on the same chromosome, or 
from recombination occuring between sister chromatids at meiosis. The 
mechanism is likely to be that of a double stranded break mechanism given the 
size of the conversion event although the precise mechanism remains to be 
determined.
In summary, the use of a molecular genetic technique to identify individuals with 
GSH is straightforward and easily applicable to large numbers of 'at risk' 
individuals. It allows the identification of clinically 'silent' affected individuals which
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A - gene conversion between genes on different chromosomes 
B - gene conversion event between genes on the same chromosome
Figure 3.4 a Schematic airangements favouring gene conversion events
Doubto-strand break
N  i
Single-strand break
-------- .------------ »
A
A.
■ft
• A.
1 i -  — .... ; i .....
\ — A
» ...._A.
----- \
▲
A, B - non-homologous genes on different chromosomes 
involved in gene duplication event
Figure 3.4 b Mechanisms of gene conversion events
allows for the early institution of appropriate therapy when necessary and the 
identification of a cohort of patients who can be studied to allow assessment of the 
factors which may alter the observed phenotype of GSH.
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Chapter 4
DETERMINATION OF CROSSOVER REGIONS IN CHIMERIC CYP11B1/B2 
GENES IN KINDREDS WITH GLUCOCORTICOID-SUPPRESSIBLE 
HYPERALDOSTERONISM
4.1 Introduction
Identification of affected individuals with GSH by genotyping is of considerable 
benefit to the clinician dealing with the affected individuals and members of their 
kindred. However, while this method shows the presence of a chimeric gene it 
gives no information as to the exact nature of the crossover event giving rise to the 
gene. Without this information kindreds cannot be distinguished on the basis of the 
nature of their chimeric gene, i.e. the possibility of a founder effect giving rise to 
these 5 kindreds cannot be ruled out. Similarly the effect of a variable genotype 
(i.e. a variable site of crossover) on phenotype cannot be determined unless the 
exact composition of the chimeric gene is known.
To address these problems the nucleotide sequence of the chimeric CYP11B1/B2 
gene in each affected kindred was determined by PCR amplification of the 
segment of the chimeric gene containing the crossover and sequenced using the 
dideoxy- chain termination method.
4.2 Materials and Methods
4.2.1 Subjects
Subjects from each of the 5 kindreds were studied. In each case the proband of the 
kindred and one or more of the affected relatives identified by genotyping were 
studied.
4.2.2 Methods
DNA was prepared from peripheral leukocytes as described in 2.7.1. Polymerase
chain reactions were carried out in sterile Eppendorf tubes as described in 2.9.2.
A series of three reactions per chimeric gene were performed (Figure 4.2 a). Three 
sets of overlapping oligonucleotide primers were used to span the region of the 
chimeric gene (Appendix III). Each primer pair consisted a 5' sense primer specific 
to CYP11B1 and a 3' antisense primer specific to CYP11B2. A high (65°C) 
annealing temperature was used to maximise the chance of annealing of each 
primer to the template DNA in regions of high homology between CYP11B1 and B2
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and thus limit the possibility of non-specific amplification. Identical reactions were 
carried out on plasmid DNA containing pure clones of CYP11B1 and B2, DNA from 
unaffected relatives and reactions containing water only. Table 4.2 a summarises 
the findings of these reactions when carried out on an individual with GSH.
1/2X 3A/5N 6/CC
Patient negative 1.4 kb product negative
Unaffected Sib negative negative negative
CYP11B1 clone negative negative negative
CYP11B2 clone negative negative negative
Water negative negative negative
Table 4.2 a. Results of standard PCR reactions on DNA from a patient with GSH.
Following each PCR reaction, 5 i^l of each reaction mix was loaded onto a 1% 
agarose gel and subjected to electrophoresis to check for the presence of a PCR 
product. In those reactions which showed the presence of a PCR product, the 
remainder of the PCR reaction product was loaded in to a 1% LMP gel and 
subjected to electrophoresis as described in 2.9.3. The PCR DNA was then 
purified from the agarose as described in 2.9.3 and reconstituted in 20jil of 1X TE 
buffer ready for sequencing. In general three PCR reactions, total volume 135pl 
(approimately 250 ng of amplified DNA), were used to ensure enough purified DNA 
was available for the sequencing protocol.
4.2.3 Sequencing of Chimeric Genes
Purified PCR product from affected patients was sequenced as described in 
2.10.1-3. Three sequencing primers were used to sequence the amplified region 
(Figure 4.2 b). In all cases, the PCR amplification only occurred using primers 
spanning the intron 2 - intron 5 region and therefore sequencing primers that 
spanned this region were used.
Each primer hybridised to a non-unique exonic region of the chimeric gene, i.e. a 
region found in either CYP11B1 or B2. Primers 1178 and 4, both 5' sense primers, 
hybridised to the 5' end of exons 3 and 4 respectively, whilst primer 5N, a 3' anti­
sense primer, hybridised to the 3' end of exon 5. These primers allowed the 
chimaeric PCR product to be sequenced in both the sense and anti-sense
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directions to allow accurate determination of the region of change from CYP11 B i­
specific to CYP11B2-specific nucleotides.
Following completion of the sequencing reactions, the sequence of the PCR 
products was determined by polyacrylamide gel electrophoresis and 
autoradiography of dried blotted filters (2.10.4-6). The resulting sequence of the 
PCR product was compared with the consensus sequence of CYP11B1/B2 to 
determine the site of each crossover (2.10.7).
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M 1
1  a h+i
2X 5N
CYP11B1 exon
CYP11B2 exon
Primer
Figure 4.2 a PCR strategy to amplify crossover region
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I
CYP11B1 exon
CYP11B2 exon
Primer
Figure 4.2 b Sequencing strategy to determine crossover site
4.3 Results
Sequencing reactions were carried out on PCR-amplified DNA from each of the 5 
kindreds studied. Test reactions on unaffected individuals and test plasmids 
showed no evidence of non-specific amplification. Figure 4.3 a shows the result of 
a typical PCR amplification on 4 affected individuals from different kindreds.
In each affected individual a 1.4 kb PCR product was obtained using the primer 
pair 3A/5N, spanning the region containing intron 2 - intron 5 of the chimeric gene. 
No PCR products were detected when either 1/2X (spanning the 5' flanking region 
to intron 2) or 6A/CC (spanning intron 5 to the 3' flanking region) were used.
Direct sequencing of the PCR products using 1178, 4 and 5N allowed accurate 
delineation of the crossover region of the chimeric gene in all cases.
The crossover region in kindreds 1, 2 and 3 was localised to a region 
encompassing the exon 3 - intron 3 boundary of the chimeric gene (Figure 4.3 
b,c,d). The region of the crossover in these kindreds spans some 89 nucleotides 
from an A residue in exon 3 of CYP11B1 at position 1335 (G in CYP11B2) to a T 
residue in intron 3 of CYP11B2 at position 1797 (C in CYP11B1).
The crossover region in kindred 4 was localised to a region encompassing exon 4 
of the chimeric gene (Figure 4.3 e). The region of the crossover in this kindreds 
spans some 138 nucleotides from a G residue in exon 4 of CYP11B1 at position 
1558 (A in CYP11B2) to a T residue in exon 4 of CYP11B2 at position 2071 (C in 
CYP11B1).
The crossover region in kindred 5 was localised to a region encompassing the 
exon 4 - intron 4 boundary of the chimeric gene (Figure 4.3 e). The region of the 
crossover in this kindred spans some 94 nucleotides from a C residue in exon 4 of 
CYP11B1 at position 1646 (T in CYP11B2) to a G residue in intron 4 of CYP11B2 
at position 2164 (C in CYP11B1).
The results of sequencing of the chimeric genes of the 5 kindreds are summarised 
in Figure 4.3 f. In all cases, the crossover points lie within the exon 3 - intron 4 
region of the chimaeric gene. In no case is there evidence of a gene duplication or 
insertion of a DNA segment at the site of the crossover.
The degree of comparison of the predicted amino acid sequences of the translated 
chimeric genes is given in Table 4.3 a. This shows that the differences in predicted 
amino acid sequences between the chimeric proteins is minimal.
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Amplification of the chimaeric 11 (3-hydroxylase/aldosterone synthase gene 
using the Polymerase Chain Reaction
3A
_Jpn n_i3 Ui\ I I 1 i
1 2 3 4
5N
5 6 7 8 9
CYP11B1 Exon 5N Oligonucleotide Primer
CYP11B2 Exon
KILOBASES
Size
Marker
Figure 4.3 a Specific amplification of CYP11B1/B2 crossover region by PCR.
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Figure 4.3 b Sequence analysis delimiting the crossover region
in the chimeric CYP11B1/B2 gene in Kindred 1
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Figure 4.3 c Sequence analysis delimiting the crossover region
in the chimeric CYP11B1/B2 gene in Kindred 2
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Figure 4.3 d Sequence analysis delimiting the crossover region
in the chimeric CYP11B1/B2 gene in Kindred 3
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Figure 4.3 e Crossover rgions in the chimericCYP11B1/B2 gene of Kindreds 4 and 5
Kindreds 1, 2,3
Exon ExonExon 3 Exon 4Exon 1
AAGAAGAAGGTGCTG-(62 basesl-GGTGTGGGCCA TGC
Kindred 4
Exon ExonExon 4Exon 3Exon 1
TTGGCTCTTTTTGGA-( 111 bases )-CTGTCTCGCTGGA TC
Kindred 5
Exon ExonExon 4Exon 3Exon 1
ACCAGCCCCAAGGTG-( 65 bases 1-TGCTATGGGGAAGG G
Bases in plain typeface are common to both CYP11B1 and CYP11B2.
Underlined bases (ATG) indicate intronic sequence.
Bases in larger bold typerface (ATC) are specific to CYP11B1, whilst bases in larger italic and bold 
typeface (TGC) are specific to CYP11B2.
The intervening region is the largest domain within which a crossover event could occur.
Figure 4.3 f Schematic representation of sequence data for the crossover regions 
of kindreds 1 to 5.
CYP11B1 CYP11B2 Kindreds -3 Kindred 4 Kindred 5
Kindreds1-3 96.2 96.4 100 100 99.9
Kindred 4 96.2 96.4 100 100 99.9
Kindred 5 96.4 96.2 99.9 99.9 100
Table 4.3 a. Comparison of predicted amino acid sequence homology (percent) between 
CYP11B1, CYP11B2 and the predicted amino acid sequence of the 5 chimeric genes 
detected in kindreds 1 -5 .
4.4 Discussion
The results of these experiments yield two pieces of important information. Firstly, 
the distribution of the crossover regions in the chimeric genes is similar to that 
observed in previous studies (Figure 4.4 a) (Lifton et al, 1992, Miyahara et al,
1992, Pascoe et al, 1992a). The site of crossovers in all patients with GSH so far 
studied have been localised to the intron 2 - intron 5 region of the chimeric 
CYP11B1/B2 gene. This is not surprising if the evidence regarding the location of 
the active site of aldosterone synthase is taken into consideration. Observations of 
the in vitro steroidogenic capacity in COS cells of chimeric CYP11B1/B2 cDNA 
constructs comprising variable proportions of the CYP11B1 and CYP11B2 exonic 
DNA formed in a manner similar to those found in GSH (Pascoe et al, 1992a) have 
revealed that constructs comprising exons 1-3 of CYP11B1 coupled to the 
remainder from CYP11B2 possess aldosterone synthase activity (Figure 4.4 b). 
Constructs possessing exons 1-5 or more of CYP11B1 coupled to the remainder 
from CYP11B2 had no detectable aldosterone synthase activity, suggesting that 
exon 5 of CYP11B2 has residues important for conferring aldosterone synthase 
activity on the resultant gene product. Similar results have been obtained when 
chimeric rat CYP11B1/B2 cDNA hybrids were expressed in COS7 cells containing 
exons 1-5 ofCYP11B1 (Zhou et al., 1994).
The steroidogenic ability of cDNA's of CYP11B1 in COS cells can also be altered 
by PCR-mediated site-directed mutagenesis of CYP11B1-specific residues to the 
corresponding CYP11B2-specific nucleotides. Alteration of a few nucleotides in the 
CYP11B1 cDNA to change the nucleotide sequence of exon 5 of CYP11B1 to that 
of CYP11B2 confers aldosterone synthase activity on the resultant cDNA when 
expressed in vitro (Pascoe and Curnow, 1994).
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In a single case of corticosterone methyloxidase type II deficiency, the condition 
has been shown to arise from a gene duplication altering exons 3 and 4 of the 
patients CYP11B2 gene (Fardella et al., 1994b). The resulting gene has exons 3 
and 4 derived from CYP11B1 with resultant lack of aldosterone synthase activity. 
Three amino acids in the predicted protein product differ from that of the predicted 
aldosterone synthase and two of these, K152N and I248T, alter the nature of the 
amino acid side chains present and may also therefore have an important role in 
conferring aldosterone synthase activity on the protein.
Thus, as an alternative mechanism to unequal sister chromatid exchange and 
formation of a chimeric gene, it is possible that a GSH-like syndrome could result 
from the presence of a gene duplication event resulting in the incorporation of 
CYP11B2 sequences into exon 5 of CYP11B1 in a similar fashion to those seen in 
classical steroid 21-hydroxylase deficiency (White et al, 1984) although large 
duplications could give rise to deficient enzyme action rather than over activity. No 
such cases have been reported as yet but it may be that some cases of idiopathic 
hyperaldosteronism or low-renin essential hypertension could arise as a result of 
such mutations.
Similarly, classical GSH would appear not to result from the formation of chimeric 
genes containing exon 5 of CYP11B1. The possibility of 'formes fruste' of GSH 
resulting from crossovers which involve the first 5 or more exons of CYP11B1 
should be considered. Such genes may be expressed in the adrenal glands and 
result in altered steroid 11 B-hydroxylation ability such as that previously 
demonstrated in patients with essential hypertension (De Simone et al, 1985) and 
in animal models of hypertension (Fraser et al., 1994), or low-renin forms of 
hypertension where subtle alterations in steroid secretion secondary to the 
expression of a CYP11 B1-like gene throughout the adrenal cortex may lead to an 
alteration in the normal renin-aldosterone relationship. However, no evidence of 
such crossover events has so far been obtained.
Apparently unrelated kindreds may derive the condition from a common ancestor, 
i.e. a founder effect may exist even if not expected. Kindreds 1, 2, and 3 have 
indistinguishable crossover regions when sequenced. The chimeric gene in these 
kindreds may have a common ancestral origin, i.e. a single founder mutation has 
given rise to three kindreds. Kindreds 1 and 2, for example, share a common 
geographical ancestral origin in the Isle of Lewis and the possibility that these two 
kindreds arose from a common ancestor must be high. However, the possibility of
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discrete independent mutational events, giving rise to similar chimeric genes 
cannot be ruled out by these sequencing studies.
To establish or refute the possibility of a single founder gene would require the 
study of linked markers in the region of the gene such as that carried out by Lifton 
previously (Lifton et al, 1992). This group used a series of linked markers detected 
by SSCP, present within exon 5 of CYP11B1 or in the 5' and 3' flanking regions of 
CYP11B2. Using this set of markers a haplotype for each kindred was established 
and the haplotype data for each kindred used to determine whether or not kindreds 
with indistinguishable crossover sequences were related.
By this method they were able to distinguish kindreds with identical chimeric gene 
nucleotide sequences on the basis of their linked markers and concluded that they 
must have arisen as the result of independent mutational events. A similar analysis 
of these kindreds will be undertaken in the future.
In summary, 5 kindreds with GSH have been studied. In all cases the nature of the 
chimeric gene has been determined. Three kindreds are indistinguishable on the 
basis of the nucleotide sequence of their chimeric gene whilst the other kindreds 
possess discrete mutations. The crossover regions of the 5 kindreds lie within the 
exon 3 to intron 4 region of the chimeric gene, in keeping with previous 
observations in this condition.
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Chapter 5
DISCOVERY OF AN HAEIII POLYMORPHISM IN THE CYP11B2 PROMOTER 
REGION. RELEVANCE TO PATIENTS WITH AND WITHOUT 
GLUCOCORTICOID-SUPPRESSIBLE HYPERALDOSTERONISM.
5.1 Introduction
In patients with GSH, there is ectopic expression of a chimeric CYP11B1/B2 gene 
throughout the adrenal cortex (Lifton et al, 1992). In addition, patients with GSH 
show a wide variation in phenotype despite possessing similar or identical chimeric 
genes (Jamieson et al, 1994) (Chapter 6). This may arise through differences in 
environmental factors such as diet, including salt intake and alcohol ingestion, or 
through phenotypic expression of small genetic differences.
One possible mechanism altering the phenotype of individuals with GSH is through 
differential expression of the chimeric CYP11B1/B2 gene or the normal CYP11B1 
and B2 genes in the adrenal cortex. Such differential expression might arise 
through differences in the 5' flanking regions of the chimeric gene which could alter 
the degree of response to transcriptional regulation factors such as cAMP or SF-1 
(Lala et al, 1992). In addition, it has been suggested that allelic differences in the 
flanking regions of CYP11B1 and B2 may predispose to the formation of the 
chimeric gene, perhaps by altering the secondary structure of the DNA at this point 
and favouring unequal crossing over at meiosis (Lifton et al, 1992).
A putative SF-1 binding region in the 5' flanking region of CYP11B2 has been 
identified (Figure 5.1 a) (Kawamoto et al, 1992, Mornet et al, 1989, Parker and 
Schimmer, 1993). The role of SF-1 has been discussed earlier (1.7.3). It is an 
important transcriptional regulation factor regulating steroid hydroxylase gene 
expression. Studies using gene targeting to disrupt the SF-1 gene in mice have 
shown that SF-1 deficient mice do not survive the neonatal period and do not 
develop adrenal glands or gonads (Ikeda et al, 1994). The absence of SF-1 is also 
clearly detrimental to the post-embryonic development of mice and the adrenal in 
particular (Lala et al, 1992, Parker and Schimmer, 1993). Any alteration of the 
affinity of SF-1 for its binding site in CYP11B2, e.g. by a polymorphism in the 
binding region, should therefore alter the regulatory potency of SF-1 for this gene 
and thus alter the degree of expression of aldosterone synthase in the zona 
glomerulosa.
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5' flanking region of CYP11B1
Transcription start
site = 0
a
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-355 -310 -75 -40
5' flanking region of CYP11B2
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cAMP-responsive element 
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SF-1 binding region
Palindromic insert in CYP11B2 promoter
Figure 5.1 a Structure of promoter region of CYP11B1 and CYP11B2
Within the putative SF-1 binding region in the 5' flanking region of CYP11B2, a C/T 
single base pair change polymorphism has been detected at the -340 position by 
direct sequencing (-340C/T) (Figure 5.1 b) (PC White, personal communication). 
Gel mobility shift assays have shown that oligonucleotides carrying the -340C 
allele bind SF-1 approximately 4 times as strongly as the -340T allele (White et al., 
1994). Thus it is possible that the C/T polymorphism may result in different rates of 
expression of CYP11B2 in the adrenal and alter the risk for the development of 
hypertension in an individual. It has been reported previously that patients with 
essential hypertension show enhanced aldosterone secretory responses to 
infusion of Ang II compared with normal subjects suggesting that aldosterone 
secretion is upregulated in essential hypertension (Kisch et al, 1976, Zoccali et al, 
1983).
-340C
Haelll site 
<  >
TCCAAGGGGCCCTCTCATCTCACGATAAGATAAAGTCCCC
 +----------------+----------------+--------------- +
A
-340T
C/T polymorphism
A
TCCAAGGGGTCCTCTCATCTCACGATAAGATAAAGTCCCC
 +----------------+--------------- +--------------- +
<  >
Haelll site abolished
Figure 5.1 b -340 C/T polymorphism in CYP11B2 promoter region
Analysis of the nucleotide sequence in the region of this polymorphism shows that 
the C/T polymorphism confers or abolishes the presence of an Haelll recognition 
site, i.e. the sequence found will either be -GGCC- (-340C, Haelll +ve) or -GGTC- 
(-340T, Haelll -ve). Therefore, if a means of identifying the two haplotypes could be 
found which avoids the need for direct sequencing, this might provide a convenient 
means of screening large populations to quantify the role, if any, of this 
polymorphism in the pathogenesis of hypertension.
Two methods were chosen to simplify the process:
1) Allele-specific oligonucleotide (ASO) hybridisation. This techniques is a 
variation on the basic method of Southern blotting (Curnow et al, 1993, Kogan et
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al, 1987, Southern, 1975, White et al, 1991). A region of the desired gene 
containing the region of the polymorphism is amplified by PCR and blotted to a 
nylon membrane. It is then hybridised with oligonucleotides which are identical to 
the predicted nucleotide sequence flanking the polymorphism but differ by a single 
nucleotide at the polymorphism, i.e. either C or T. Two oligonucleotides are used to 
detect either allele of the polymorphism. This method has already been used 
successfully to identify disease alleles in congenital disorders of steroid 
hydroxylase function (Curnow et al, 1993, Pascoe et al, 1992b, White et al, 1991).
2) Restriction enzyme digest of a PCR-amplified portion of the CYP11B2 
promoter encompassing the polymorphism. The digested PCR product is resolved 
on a high percentage agarose gel and alleles assigned on the basis of observed 
fragment length.
The results of both of these methods in identifying the C/T polymorphism are 
reported with the results of haplotype analysis of the five kindreds with GSH.
5.2 Materials and Methods
Subjects from all 5 GSH kindreds were typed for the presence of a dialleleic 
polymorphism in the promoter region of CYP11B2. DNA was prepared from 
peripheral leucocytes as described in 2.7.1. A portion of the CYP11B2 promoter 
region including nucleotides -576 to +6 was specifically amplified using 
oligonucleotide primers 2523 and 2524 by PCR as described in 2.9.2 (Figure 5.2
a).
A 5pl aliquot of the reaction was run on a 1% agarose gel to confirm the presence 
of the desired PCR product. In all cases a single band of desired length, 578 bp 
was observed after completion of the PCR.
5.2.1 Allele-specific oligonucleotide hybridisation
PCR products were subjected to electrophoresis on a 1% agarose gel and then 
blotted to a nylon membrane as described in 2.8.6. Filters were then hybridised 
with allele-specific oligonucleotides (ASO) recognising either the C (2360) or the T 
(2361) allele of the polymorphism (2.8.9). Following hybridisation, filters were 
washed and autoradiographs exposed as described in 2.8.10-11. Filters were 
stripped, checked to ensure the absence of residual hybridisation and re-hybridised 
with the alternative oligonucleotide.
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Figure 5.2 a -340C/T polymorphism in CYP11B2 promoter region
The ASO used to detect the -340C allele (2360) hybridised exclusively to the 
antisense strand of the PCR product containing the -340C allele, whilst the ASO 
used to detect the -340T allele (2361) hybridised exclusively to the sense strand of 
the PCR product containing the -340T allele. This strategy was chosen to eliminate 
the possibility of false positives occurring. That is, if an ASO intended to hybridise 
specifically to the antisense strand of the -340T promoter (-GGCT-) were used, it 
could also hybridise to the antisense strand of the -340C allele(-CCGG-) because 
G-T bonding forces are relatively stronger than those of G-A or C-A bonds. The 
possibility of a false positive is avoided if this strategy is followed.
5.2.2 Detection of Haelll polymorphism
An aliquot of the completed PCR reaction was placed in a sterile Eppendorf tube 
with 10Units of Haelll in the presence of an appropriate buffer and incubated at 
37°C for 4 hours (2.8.3). On completion of the digest, 10|il of the reaction mix was 
run on an ethidium bromide-stained, 3% Metaphor agarose gel to determine the 
haplotype of the individual. A 3% agarose gel was chosen to ensure adequate 
resolution of the relatively low molecular weight digestion products so that naked 
eye assignment of haplotype was possible.
5.3 Results
All available members of the 5 kindreds were typed using both methods to 
determine the CYP11B2 promoter haplotypes.
The PCR protocol used yielded large quantities of a single product of the desired 
length, i.e. 578 base pairs (Figure 5.3 a).
5.3.1 ASO Hybridisation
The C and T allele of the polymorphism were demonstrated by ASO hybridisation 
as shown in Figure 5.3 b. The lower band corresponds to hybridisation of the probe 
to the C allele (2360) in the PCR product, the upper band the T allele (2361).
This technique allowed homozygotes and heterozygotes for the -340C/T 
polymorphism to be identified easily.
5.3.2 Haelll digestion of CYP11B2 promoter region
The C allele of the polymorphism corresponds to the presence of an Haelll 
recognition site at position -340 to -337 in the 5' flanking region of CYP11B2.
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Figure 5.3 a PCR amplification of CYP11B2 promoter region
31 2
Hybridise with 2360
Hybridise with 2361
CC CT CYP11B2 promoter haplotype
2360,2361 - ASO's used to determine haplotype 
C ,T - Haptotypes assigned on presence of a C orT nucleotide 
at position -340
Figure 5.3 b ASO hybridisation to CYP11B2 promoter region
Digestion of the 578 bp PCR product in subjects with the C allele yields a 245 bp 
fragment in addition to lower molecular weight products, termed 'a'.
Possession of the T allele of the polymorphism abolishes the presence of an Haelll 
recognition site at position -340 to -337 in the 5' flanking region of CYP11B2. Haelll 
digestion of the PCR product in this case yields a 324 bp product along with low 
molecular weight products, termed 'A'.
The result of a typical digestion of PCR products from individuals homozygous for 
'A', 'a', and a heterozygote are shown in Figure 5.3 c. It illustrates that the 
CYP11B2 promoter haplotype of individuals is readily established by Haelll 
digestion of the PCR product without recourse to ASO hybridisation.
5.3.3 Haplotvoe analysis of GSH kindreds
Individuals in all 5 kindreds were typed for the presence of this polymorphism and 
the results shown in Figures 5.3 d-h. A total of 45 subjects were studied.
The frequencies of each allele and haplotype are given in Table 5.3 a.
II Affected II Unaffected
Allele II I
c I 25 I 22
T | 9 I 34*
Haplotype | I
CC || 8 I 8
CT | 9 I 6
TT || 0 I 14+
* x2 = 9.94 df=1, p=0.0016, + X2 = 912.67 df=2, p=0.0018
Table 5.3 a Frequency distribution of CYP11B2 promoter alleles and haplotypes in patients 
and unaffected relatives.
The most striking feature of the distribution of the Haelll haplotypes is the uniform 
inheritance of the 'a/-340C allele in association with the chimeric CYP11B1/B2 
gene causing GSH. There is a significant excess of -340C alleles in the patients 
with GSH compared with unaffected relatives (or excess of -340T alleles in 
unaffected relatives) and a significant excess of CC homozygotes in the patients 
compared with the unaffected relatives (or an excess of non-CC homozygotes in 
the unaffected relatives) (Table 5.3 a).
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Figure 53 c Haelll digest of CYP11B2 promoter region
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Kindred 2. CYP11B2 promoter polymorphism haplotypes.
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Kindred 3. CYP11B2 promoter polymorphism haplotypes.
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Kindred 4. CYP11B2 promoter polymorphism haplotypes.
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Kindred 5. CYP11B2 promoter polymorphism haplotypes.
The uniformity of the co-inheritance of the 'a' allele with GSH suggests that the 
-340C and GSH are in linkage disequilibrium.
5.4 Discussion
Both of the techniques employed to distinguish the two alleles in the CYP11B2 
promoter were equally effective. The method based on restriction enzyme 
digestion of the promoter PCR product was quicker and avoided the need for end- 
labelling of ASO's eliminating the requirement for radioactivity. Both methods were 
used to haplotype the members of the 5 kindreds for the polymorphism and 100% 
concordance was seen. Thus I recommend that the Haelll digestion of the 
promoter region PCR product be used as the initial screening tool and that the 
ASO hybridisation method be used in cases where this fails. Similar methods have 
been used previously to determine the presence or absence of disease causing 
mutant alleles in steroid 113-hydroxylase deficiency (Curnow et at, 1993, White et 
al, 1991), corticosterone methyloxidase type II deficiency (Pascoe et al, 1992b) 
and sickle cell anaemia (HbS) (Connor and Ferguson-Smith, 1987). In some of 
these cases, the method can also be used on material obtained at chorionic villus 
sampling or amniocentesis making prenatal diagnosis possible (Curnow et al, 
1993).
The discovery of linkage disequilibrium between the 'a' / -340C allele of the 
polymorphism and inheritance of the chimeric CYP11B1/B2 gene is intriguing. A 
similar finding has been made by Lifton (Lifton et al, 1992) who described linkage 
disequilibrium between allele 1 of AldoX9, a SSCP marker in CYP11B2, and GSH. 
On chromosomes carrying the chimeric gene both the normal CYP11B2 gene and 
the portion of CYP11B2 contributing to the chimeric gene possessed allele 1 of 
AldoX9. This allele was present in the normal CYP11B2 on these chromosomes in 
9 out of 9 kindreds and in the CYP11B2 portion of the chimeric gene in 8 out of 9 
kindreds. In addition, 4 discrete crossover events and three different haplotypes for 
different CYP11B1/B2 SSCP markers were detected in these nine kindreds, 
suggesting that multiple independent crossovers had occurred within this group of 
kindreds. It would appear therefore that allele 1 of AldoX9 is a highly conserved 
feature in the chimeric genes of these kindreds.
However, a gene conversion event transferring most of intron 2 of CYP11B1 to 
intron 2 of CYP11B2 has been described (PC White, personal communication), i.e. 
in one allele CYP11B2 contains an intron virtually identical to that of CYP11B1.
The existence of such an allele gives one possible explanation of how the chimeric 
gene might arise (Figure 5.4 a). In the normal situation where intron 2 of CYP11B2
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Figure 5.4 a. Potential mechanism underlying formation of chimeric CYP11B1/B2 gene
Figure 5.4 b. Formation of chimeric CYP11B1/B2 gene and mechanism of 
linkage disequilibrium between -340C and GSH.
□ CYP11B2
CYP11B1
H  Intron 2 of CYP11B1 
|  5'flanking region of CYP11B2
Intron 2 gene conversion
in CYP11B2 (B2I2+)
does not contain the gene conversion (B2I2-), alignment of CYP11B1 and 
CYP11B2 is reduced because intron 2 of these genes is an area of sequence 
divergence between CYP11B1 and CYP11B2. However, in individuals with the 
CYP11B2 gene with the intron 2 conversion (B2I2+), CYP11B1 and CYP11B2 a 
region spanning approximately 2 kilobases from intron 2 - intron 4 can align with 
almost 100% identity and thus promote the likelihood of non-homologous 
recombination.
In all of the cases of GSH in this series, patients inherit the -340C allele of the 
CYP11B2 promoter polymorphism. This may be explained if the chromosome 
without the gene conversion in CYP11B2 also carries the -340C allele (Figure 5.4
b). Non-homologous recombination between a B2I2+ CYP11B2 gene and 
aCYP11B1 gene on a -340C chromosome results in a -340C-GSH haplotype. 
Observations in a limited number of patients suggests that -340T and B2I2+ are in 
linkage disequilibrium and that -340C and B2I2+ do not occur together on the 
same chromosome (White et al, 1994), thus strengthening the arguement in favour 
of the above mechanism.
Further work to investigate the prevalence of these alleles in other populations is 
planned.
Abnormalities in steroid secretory rates in response to intravenous ACTH infusion 
and Ang II infusion have been described in patients with essential hypertension 
(De Simone et al, 1985, Honda et al, 1977, Kisch et al, 1976, Zoccali et al, 1983). 
Such abnormalities could arise from differences in the rate of expression of genes 
encoding steroidogenic enzymes in the adrenal cortex of hypertensive patients, 
possibly determined by polymorphisms in the promoter regions of these genes.
The -340 C/T polymorphism is in the region of the SF-1 binding site and alters 
binding of SF-1 to DNA (White et al, 1994). Such alteration in binding affinity might 
result in physiologically important differences in the expression of CYP11B2 in the 
zona glomerulosa and lead to detectable differences in aldosterone secretory 
responses to Ang II. At the present time no such polymorphisms have been 
detected in the promoter region of CYP11B1.
Abnormalities of 116-hydroxylase activity have been detected in rat models of 
hypertension (Fraser et al, 1994). In the Milan normotensive and hypertensive 
strains, the hypertensive strain showed evidence of enhanced 116-hydroxylase 
activity when adrenal steroid secretory rates were compared with those in the 
normotensive strain. Polymorphisms in the rat genes encoding enzymes with 116- 
hydroxylase activity have been described (Cicila et al., 1993, Matsukawa et al.,
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1993, Mukai et al., 1991). In addition, in rats a third CYP11B like gene, CYP11B3, 
has been described which is highly homologous to CYP11B1 in both its coding and 
its 5' flanking region (Nomura et al., 1993). CYP11B2 and CYP11B3 in the rat lie in 
tandem approximately 24 kilobases apart. However, there was no detectable 
transcription of CYP11B3 in the adrenal glands of rats fed a normal or potassium- 
enriched diet (Nomura et al, 1993). This suggests that this gene may be a non­
functional pseudogene. In bovine adrenal 5 different CYP11B genes have been 
described and three are pseudogenes (Hashimoto et al., 1993). The tandem 
arrangement of CYP11B genes has been demonstrated in the mouse (Domalik et 
al, 1991), and in man (Lifton et al, 1992, Pascoe et al, 1992a, Pascoe et al, 1992b) 
but as yet no human CYP11B pseudogenes have been identified.
In summary, in man and rat models of essential hypertension there are 
abnormalities of steroid secretion related to the enzymes P450hb and P450aido- 
Polymorphisms in the flanking regions of CYP11B2 and CYP11B1 have been 
described and may be important in the genesis of chimeric CYP11B1/B2 genes 
causing GSH and in influencing the secretory responses to infused ACTH and Ang 
II.
The mechanisms whereby these single base pair changes might influence the 
formation of a chimeric gene are not clear. However, the possibility of linkage 
disequilibrium with a gene conversion favouring non-homologous recombination 
may be an important feature favouring crossover formation.
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Chapter 6
PHENOTYPIC OBSERVATIONS IN PATIENTS WITH 
GLUCOCORTICOID-SUPPRESSIBLE HYPERALDOSTERONISM
6.1 Introduction
The clinical and biochemical features of GSH are attributable to a primary 
aldosterone excess. However, detailed descriptions of affected individuals show 
that the clinical features of the condition, i.e. its phenotype, are variable even within 
the same kindred. The reasons for these differences are not entirely clear but could 
be genotype-environment interactions which alter the clinical expression of the 
genotype. Such influences include dietary sodium intake, alcohol ingestion and 
body weight, all of which may influence blood pressure in patients with essential 
hypertension and in mineralocorticoid-dependent hypertension (Brown et al,
1972b, Ferriss et al, 1983, Kremer et al, 1977, Oelkers et al, 1974, Whelton et al, 
1994).
6.1.1 Phenotypic differences in GSH patients
The clinical phenotype of affected individuals may vary as a result of differences in 
the nature of the chimeric gene, i.e. different chimeric genes may confer variable 
degrees of aldosterone synthase activity and consequent variations in aldosterone 
concentration may determine the subsequent blood pressure and potassium status 
of individuals. Study of the in vitro expression of chimeric CYP11B1/B2 cDNA's in 
COS cells has shown that aldosterone synthase activity of the chimeric gene 
product is limited to those chimeric constructs containing exons 1 - 4 only of 
CYP11B1. Inclusion of exon 5 of CYP11B1 abolishes the aldosterone synthase 
activity of the constructs (Pascoe et al, 1992a). However, it is not clear if there is a 
dose-response relationship between aldosterone synthase activity and the number 
of exons donated from CYP11B2 is increased from 5 (exons 5 - 9) to 8 (exons 2 - 
9).
6.1.2 The role of parental programming in the origin of hypertension
The role of parental inheritance of the chimeric gene may also be important in 
determining the phenotype of the disorder. Studies of pregnant rats given 
dexamethasone during pregnancy have shown that the birth weight of the 
glucocorticoid-treated rats is reduced by 14% and that the adult systolic blood 
pressure of the rats is elevated for many months after exposure to exogenous 
glucocorticoids (Benedicktsson et al, 1993). A similar effect on birth weight has
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been observed in the offspring of dexamethasone treated mothers of fetuses with 
congenital adrenal hyperplasia (Seckl, 1994). In addition, epidemiological data 
suggests that hypertension develops most readily in those children born with a low 
birth weight and a large placenta, but not undernourished in utero (Law and Barker, 
1994, Parker et al., 1990). Children likely to develop hypertension as adults can be 
detected at an early age by the phenomenon of 'tracking' of blood pressure (i.e. the 
blood pressure of a child likely to develop hypertension as an adult tends to be 
higher than average for their age and sex throughout childhood (Lever and Harrap,
1992)) and there is evidence that a child's blood pressure is more closely related to 
that of its mother than its father (Bengtsson et al., 1979, Gerson and Fodor, 1975, 
Law et al, 1991).
6.1.3 Impaired 116-hvdroxvlase activity in hypertension
There is evidence in patients with essential hypertension that conversion of DOC to 
corticosterone and 11-deoxycortisol to cortisol is impaired compared with 
normotensive controls, particularly following ACTH stimulation. This would appear 
to be secondary to impaired 116-hydroxylase activity in hypertensive patients (De 
Simone et al, 1985, Honda et al, 1977) and chapter 1.3.4. Similarly, in patients with 
GSH there is evidence of high basal plasma DOC concentrations in untreated 
patients (Connell et al, 1986, Connell et al, 1986, Oberfield et al, 1981, Ulick et al, 
1990). ACTH infusion in patients with GSH leads to marked increases in plasma 
aldosterone and 18-hydroxycortisol concentrations (Connell et al, 1986) and might 
be expected to exaggerate defective 116-hydroxylase activity if it is present in 
patients with GSH.
Therefore, there are several potential mechanisms whereby the clinical phenotype 
of individuals with GSH may vary both between and within kindreds. In addition, 
increased DOC levels may indicate an additional defect in 116-hydroxylase activity 
in GSH which might influence the clinical phenotype of individual patients with GSH 
and may also contribute to its pathogenesis.
From these introductory sections, it is clear that the rare diseases, GSH and 
Conn's syndrome, and the much more common essential hypertension have in 
common a degree of disturbance of corticosteroid synthesis and control of 
secretion but that, within each group, the phenotypic result may be strongly 
influenced by a series of complex interactions with a large number of 
environmental factors. The following section compares the basal levels and 
responses to ACTH infusion of corticosteroids and other variables of groups of 
subjects with GSH, essential hypertension, Conn's syndrome and a matched group
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of normotensive subjects. An examination of the effects of crossover site and 
parental inheritance on GSH phenotype is also presented.
6.2 Subjects and Methods
6.2.1 Methods
Blood pressure, serum electrolytes and plasma measurements of renin, 
aldosterone and other steroid hormones were obtained and assayed as described 
in 2.5.1-3 and 2.6.1-4.
Intravenous ACTH infusion studies were performed as described in 2.5.5 and 
blood taken for steroid measurements and assayed as described in 2.5.4, 2.6.1-4.
6.2.2 Subjects
A) GSH
All patients with genotypically proven GSH were studied in the basal state.
Twelve patients received oral dexamethasone 0.5mg q.d.s. for 4 weeks. Blood 
pressure measurement and determination of serum potassium and plasma 
concentrations of renin and aldosterone performed.
Nine patients received an intravenous ACTH infusion with blood sampling and 
blood pressure measurements as described in 2.5.5.
Ten first degree relatives of the patients in kindred 1 underwent basal state blood 
sampling for measurement of plasma steroids as described in 2.5.3.
B) Essential Hypertension
Eight patients with essential hypertension received an intravenous ACTH infusion 
with blood sampling and blood pressure measurements as described in 2.5.5. 
These patients had hypertension requiring hypotensive drug therapy, discontinued 
1 month prior to study. Secondary causes of hypertension were excluded by 
relevant investigations.
C) Normotensive control subjects
Five normotensive volunteers, matched for age and sex range of the hypertensive 
subjects, with no family history of hypertension received an intravenous ACTH
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infusion with blood sampling and blood pressure measurements as described in 
2.5.5.
D) Conn's syndrome
Four patients with aldosterone-secreting adrenal adenoma demonstrated by CT 
scanning of the adrenal glands received an ACTH infusion with blood sampling and 
blood pressure measurements as described in 2.5.5.
6.2.3 Statistical Methods
Data are presented as median with the associated range. In cases where the data 
were normally distributed, tests of statistical significance were performed by means 
of a two-way paired t-test. If data were not normally distributed then a non- 
parametric test, either Mann-Whitney U-test or Wilcoxon rank test, was applied.
In section 6.3.1 C, the data for blood pressure and aldosterone were corrected for 
age by analysis of covariance with age as the covariate. Groups were then 
compared by a one-way t-test and p<0.05 regarded as significant.
6.3 Results
The data obtained from the studies are presented in Appendix Vc Results are 
presented as median (range) unless otherwise stated.
6.3.1 Patients with GSH
In total 19 patients from 5 kindreds were identified by means of genotyping of DNA 
obtained from peripheral blood.
A) - Basal Data: patients untreated (Table 6.3 a)
Mean arterial blood pressure was considerably elevated as was plasma 
aldosterone concentration.
Plasma renin concentration was suppressed compared to normal.
The range of serum potassium concentrations included 5 below the lower end of
the normal range (3.5 mmol/l) but the median serum potassium was 3.8 mmol/l
(2.8-4.6) and the majority of the untreated values (14/19) were > 3.5 mmol/l.
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In five patient under the age of 20 years, the mean blood pressure was not 
significantly elevated in spite of significantly elevated plasma aldosterone 
concentrations.
Mean Arterial 
Blood Pressure 
(mmHg)
Serum
Potassium
(mmol/l)
Plasma
Aldosterone
(pmol/l)
Plasma Active 
Renin 
(uU/ml)
Normal Range 3.5-5.1 140-500 5-50
All patients 120 3.8 999 1
with GSH (70-170) (2.8-4.6) (452-2466) (0-4)
Patients with 76* 4.2H 763H 1
GSH and 
normal BP
(70-92) (3.6-4.6) (452-971) (1-4)
* p<0.0001, H p<0.05
Table 6.3 a Baseline data for patients with GSH, n=19, and normotensive patients with GSH, 
n=5.
B) - After treatment with oral dexamethasone (Table 6.3 b)
Treatment with oral dexamethasone led to a significant reduction in mean arterial 
blood pressure (Figure 6.3 a) and lowering of plasma aldosterone concentration 
into the normal range (Figure 6.3 b). This change following treatment was 
statistically significant, p<0.001.
Mean Arterial 
Blood Pressure 
(mmHq)
Serum
Potassium
(mmol/l)
Plasma
Aldosterone
(pmol/l)
Plasma Active 
Renin 
(uq/ml)
Normal Range 3.5-5.1 140-500 5-50
Pre-treatment 130 3.8 999 2
(113.5-170) (2.8-4.4) (452-2466) (1-3)
Post-treatment 89 * 4.2H 203 f 23*
(74-112) (3.7-5.0) (28-252) (16-60)
* p<0.0001, t, p<0.001, H p<0.005
Table 6.3 b Effect of dexamethasone 0.5 mg q.d.s. for 4 week in patients with GSH. n=12.
Plasma renin concentrations rose into the normal range (Figure 6.3 c). This change 
following treatment was statistically significant, P<0.0001.
Serum potassium concentration rose on treatment from 3.8 mmol/l (2.8-4.4) to 4.2 
mmol/l (3.7-5.0). This change following treatment was statistically significant, 
p<0.005.
C) - Effect of parental origin of GSH on blood pressure (Table 6.3 c)
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Mean Arterial 
Blood Pressure 
(mm Hg)
140
130 -
120 -
110 -
100 -
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T
Mean Arterial 
Blood Pressure 
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— I-------------------------------------1—
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p<0.00001
Figure 6.3 a Effect of treatment with dexamethasone 0.5mg q.d.s
on mean arterial blood pressure. (n=12)
Plasma Aldosterone
Concentration
(pmol/l)
Mean Plasma Aldosterone 
Concentration
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Figure 6.3 b Effect of treatment with dexamethasone 0.5mg q.d.s
on plasma aldosterone concentration. (n=12)
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Figure 6.3 c Effect of treatment with dexamethasone 0.5mg q.d.s
on plasma active renin concentration. (n=12)
Mean Plasma Active 
Renin Concentration 
(+/-1 s.e.m.)
The effect of parental origin of the chimeric CYP11B1/B2 on the mean blood 
pressure of affected individuals was determined by comparing age and weight 
corrected blood pressures of individuals who inherited the condition from their 
mother with those who inherited it from their father.
Those individuals who inherited GSH from their mother had significantly higher 
blood pressures than those inheriting the condition from their father, Maternal 
inheritance -137 mmHg (115-170), Paternal inheritance -103.5 mmHg (72-155), 
p<0.05.
Mean Arterial Blood 
Pressure 
(mmHg)
Plasma Aldosterone 
(pmol/l)
Normal Range 140-500
Maternal Inheritance 137 1185
n=9 (115-170) (583-2466)
Paternal Inheritance 103.5 * 688*
n=9 (72-155) (452-971)
* p<0.05
Table 6.3 c Effect of parental origin of chimeric CYP11B1/B2 gene on blood pressure and 
plasma aldosterone concentration in patients with GSH
Plasma aldosterone concentrations were significantly higher in those patients 
inheriting GSH from their mother rather than their father, Maternal inheritance - 
1185 pmol/l (583-2466), Paternal inheritance - 688 pmol/l (452-971), p<0.05.
D) Effect of crossover site on phenotype
Blood pressure and plasma aldosterone were analysed with respect to the 
crossover site in the chimeric gene as described in Chapter 4 (Table 6.3 d).
Mean Arterial Pressure 
(mmHg)
Plasma Aldosterone 
(pmol/l)^
A 122 796
(70-155) (452-1503)
B 113 971
(113-153) (956-2466)
C 138 1040
(115-170) (583-1806)
A - kindreds 1,2,3, B - kindred 4, C - kindred 5
Table 6.3 d Relationship of blood pressure and plasma aldosterone levels to 
crossover site
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There was no significant difference in blood pressure or plasma aldosterone 
concentration between any of the three groups of patients when assessed on the 
basis of crossover site.
E) Basal plasma steroid measurements in GSH patients and unaffected relatives
Patients with GSH in kindred 1 had significantly higher mean blood pressures and 
plasma aldosterone concentrations and lower plasma renin concentrations than 
their unaffected relatives (Table 6.3 e).
Mean Arterial Blood 
Pressure 
(mmHg)
Plasma
Aldosterone
(pmol/l)
Plasma Active 
Renin 
(ng/mi)
Patients with GSH 109 666 1
(n=5) (76-136) (452-971) (0-4)
Relatives 89t 166f 27*
(66-118) (56-249) (19-51)
* p<0.0001, f , p<0.001, H p<0.005
Table 6.3 e Blood pressure and biochemical data for patients and relatives in kindred 1
The data for all patients were pooled and compared with those of the relatives in 
kindred 1. A similar difference observed (Table 6.3 f).
Mean Arterial Blood 
Pressure 
(mmHg)
Plasma
Aldosterone
(pmol/l)
Plasma Active 
Renin 
(ug/ml)
All Patients with 120 999 1
GSH (70-170) (452-2466) (0-4)
Relatives 89f 166f 27*
(66-118) (56-249) (19-51)
* p<0.0001, t, p<0.001, U p<0.005
Table 6.3 f Blood pressure and biochemical data for all patients with GSH and relatives in 
kindred 1
Since previous observations have suggested that 116-hydroxylation is impaired in 
patients with GSH, calculation of the basal molar ratios of plasma 11- 
deoxycorticosterone:corticosterone (DOC:B) and 11-deoxycortisol:cortisol (S:F) 
was performed.
Patients with GSH had significantly higher basal molar plasma DOC:B and S:F 
ratios than their unaffected relatives and unrelated normotensive controls (Table
6.3 g).
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Patients with GSH Relatives Normotensive
DOC:B 0.22 (0.06) 0.04(0.01)* 0.05 (0.02)*t
S:F 0.004 0.00154 0.0016 4 f
(0.0007) (0.0008) (0.0007)
Results are mean (sem)
* p<0.02 for comparison with GSH patients, $ p<0.05 for comparison with GSH patients, 
t  p= not significant for comparison between relatives and normotensive controls
Table 6.3 g Comparison of molar ratios of DOC:B and S:F in patients with GSH, unaffected 
relatives and unaffected noromtensive controls
There was no significant difference in blood pressure or plasma aldosterone when 
the data was analysed with respect to crossover site, i.e. interkindred differences in 
blood pressure were not found.
6.3.2 ACTH infusion studies
ACTH infusion resulted in significant increases in plasma concentrations of steroid 
hormones at 90 minutes in all groups studied (Table 6.3 h), (Figures 6.3 d-h).
DOC
ng/dl
B
ng/dl
Aldo
ng/dl
S
ng/dl
F
n mo I/I
TIME
mins
0 90 0 90 0 90 0 90 0 90
GSH 11 84.9 97.4 1315 17.8 57.1 37.6 229.9 285 747
n=9 (2.9) (16.8) (51) (148) (4.4) (9.1) (7.9) (13.8) (25.9) (34.7)
NT 6.8 21.6 266.4 1344 9.0 28.2 22.8 74.8 368 793
n=5 (2.1) (5.8) (159) (254) (2.2) (4.4) (11.1) (14.7) (28.2) (33.0)
HT 7.6 23.9 227.3 1111 11.4 33.25 37.8 168.5 402 837
n=8 (2.1) (6.7) (80) (179) (1.9) (4.8) (11.1) (31.6) (30.7) (41.5)
CONN 16.7 63.3 292.7 1286 35.7 82 47.3 265 414 803
n=3 (0.3) (20.8) (130) (259) (4.9) (18.5) (47.3) (66.7) (5.2) (49.9)
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension, 
Conn - patients with aldosterone-secreting adenomata
DOC -1 1 -deoxycorticosterone, B - corticosterone, Aldo - aldosterone, S - 1 1-deoxycortisol,
F - Cortisol
Table 6.3 h Effect of ACTH infusion on plasma steroid concentrations at +90 minutes
6.3.3 11 B-hydroxylation activity
Basal molar plasma DOC:B plasma ratios in patients with GSH were significantly 
higher than normotensive controls, patients with essential hypertension and 
patients with Conn's syndrome, p<0.02 (Table 6.3 g). In patients with GSH, 
essential hypertension and normotensive controls there was a significant fall in
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molar DOC:B ratio following ACTH infusion, whilst in patients with Conn's 
syndrome a significant rise in DOC:B ratio was observed (Figure 6.3 i). Following 
ACTH infusion, molar plasma DOC:B ratios were significantly higher in patients 
with GSH than in either normotensive or hypertensive subjects. The post-ACTH 
DOC:B ratio of patients with Conn's syndrome was higher than the other groups, 
but this did not reach statistical significance (Table 6.3 i).
Basal molar plasma S:F ratios were significantly higher in patients with GSH than 
normotensive controls. There was no significant difference in basal molar plasma 
S:F ratio between GSH patients and patients with essential hypertension or Conn's 
syndrome.
Following ACTH there was a rise in plasma S:F ratio in all 4 groups (Figure 6.3 j). 
Post-ACTH plasma S:F ratio was significantly higher in patients with GSH than 
normotensive and hypertensive subjects, and plasma S:F ratio was significantly 
greater in hypertensives than normotensive subjects. Patients with Conn's 
syndrome had higher plasma S:F ratios than both normotensive and hypertensive 
subjects post-ACTH, but this did not reach statistical significance (Table 6.3 i).
I DOC:B | I S:F r ~ ■ ........................
0 min 90 min 0 min Q  90 min
GSH || 0.22 0.07* I 0.004 0.009f
II (0.06) | (0.01) (0.0007) I (0.0009)
NT | 0.05 0.02* I 0.0016H I 0.003**
II (0.02) (0.01) I (0.0007) I (0.0005)
HT || 0.06 0.02* I 0.0023 I 0.006+
I (0.02) (0.003) I (0.0007) (0.001)
CONN || 0.08 0.22* | 0.003 0.009*
I (0.02) (0.09) | (0.0006) (0.005)
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension, 
Conn - patients with aldosterone-secreting adenomata
DOC -1 1 -deoxycorticosterone, B - corticosterone, S -11 -deoxycortisol, F - Cortisol
* p<0.02, t  p<0.01 for comparison between basal and 90 mins 
H p<0.05, *  p<0.02 for comparison with GSH
Table 6.3 i Molar ratios of 11-deoxycorticosterone:corticosterone and 
11 -deoxycortisol:cortisol pre-and post-ACTH stimulation
6.3.4 Aldosterone synthase activity
The conversion of DOC to B and S to F is performed in both the zona fasciculata 
and the zona glomerulosa. However, aldosterone synthesis in normal subjects only 
occurs in the glomerulosa catalysed by aldosterone synthase. Therefore, the molar 
plasma corticosterone:aldosterone ratio (B:ALDO), an index of aldosterone
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synthase activity was calculated before and after ACTH in all 4 groups to assess 
the efficiency of aldosterone synthase (Table 6.3 j) (Figure 6.3 k).
Patients with GSH had the lowest basal B:ALDO ratios which rose significantly 
following ACTH administration. Normotensive individuals had the highest molar 
plasma B:ALDO ratios which fell following ACTH. Patients with essential 
hypertension and Conn's syndrome had intermediate B:ALDO ratios which rose 
following ACTH (Figure 6.3 k).
Basal B:ALDO ratios were significantly lower in GSH patients than normotensive 
subjects, whilst post-ACTH, B:ALDO ratios in patients with GSH were significantly 
lower than in normotensive subjects, but higher than patients with Conn's 
syndrome.
I B:ALDO
L_ 0 min 90 min
GSH I 5.1 30.7*
I (1-2) (4.2)
NT L 55.511 44.8H
1 (9.5) (10.7)
HT 1 17.9 30.1
I (6.2) (4.5)
CONN 13.3 18.0
I (7.2) (5.1)
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension, 
Conn - patients with aldosterone-secreting adnenomata 
B - corticosterone, ALDO - aldosterone
* p<0.001 for comparison between basal and 90 mins 
H p<0.05 for comparison with GSH
Table 6.3 j Molar ratio of plasma corticosterone to aldosterone before and after ACTH
Blood pressure, electrolyte and steroid data for are contained in appendix V.
6.4 Discussion
Clinical descriptions of patients with GSH have previously highlighted the potential 
for affected individuals to develop severe hypertension, with the possibility of end- 
organ damage (Lee et al, 1982), and hypokalaemia (Connell et al, 1986, Fallo et al, 
1985, Ganguly et al, 1981, Lee et al, 1982, New and Peterson, 1967, New et al, 
1976, New et al., 1973, O'Mahony et al, 1989, Sutherland et al, 1966, Ulick et al, 
1990, Ulick and Chu, 1982). However, in a number of cases the degree of
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elevation of blood pressure and hypokalaemia may not be as profound as would be 
expected from the degree of plasma hyperaldosteronism (Rich et al, 1992).
6.4.1 Biochemical features of untreated patients with GSH
The current study examined the members of 5 kindreds with GSH. In 14 of the 19 
affected individuals, plasma potassium concentrations were in the normal range. 
Five patients had blood pressure measurements which were normal for their age 
and sex in spite of plasma aldosterone concentrations elevated outwith the normal 
range. This supports data from the only previous study of a large number of 
patients with GSH in a single North American kindred, which suggested that 
hypokalaemia was an uncommon feature of GSH (Rich et al, 1992). However, the 
patients in that study were all found to be hypertensive in their teens whereas a 
number of the patients studied here were of similar age but normotensive. It is 
relevant that there is evidence to suggest that hypokalaemia may be less common 
than originally thought in patients with aldosterone-secreting adrenal adenomata 
(Gordon et al, 1994) and that plasma potassium measurements may be of little 
benefit in the identification of mineralocorticoid excess.
Treatment of GSH patients with dexamethasone resulted in a prompt and complete 
resolution of the clinical and biochemical features of the condition. Of interest is the 
small, statistically significant rise in plasma potassium level in dexamethasone 
treated patients, even where the untreated level was normal. This would suggest 
that plasma potassium levels in GSH are affected by the prevailing 
mineralocorticoid excess, although the effect is smaller than that seen in patients 
with similar plasma aldosterone concentrations due to Conn's syndrome (Kremer 
et al, 1977). This may reflect the absence of a significant diurnal variation of 
aldosterone secretion seen in Conn's syndrome; patients with GSH exhibit a 
nycthemeral rhythm of aldosterone secretion, similar to that of cortisol, and for 
many hours of the day aldosterone concentrations may be relatively normal 
(Connell et al, 1986, Connell et al, 1986). This and the tendency towards lower 24 
hour plasma aldosterone levels may result in lower blood pressure levels and 
higher plasma potassium concentrations than those seen in Conn's syndrome 
(Brown et al, 1972b, Connell et al, 1987, Ferriss et al, 1983, Kremer et al, 1977, 
Oelkers et al, 1974).
6.4.2 Role of parental origin of chimeric gene on GSH phenotype
Perhaps the most intriguing phenotypic observation in patients with GSH in this 
series is the clear effect of parental inheritance of the condition on plasma
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aldosterone concentration and blood pressure. The observation that a child's blood 
pressure more closely resembles its mother than its father has been reported 
previously in studies of hypertensive families (Bengtsson et al, 1979, Gerson and 
Fodor, 1975, Law et al, 1991). Although the reasons which underly this 
phenomenon are not fully understood, there is now good evidence to suggest that 
adult blood pressure may be partly determined in utero. Thus, epidemiological 
studies examining the relationship among birthweight, placental weight and adult 
blood pressure all suggest that hypertension most commonly develops in those 
adults that were undernourished in utero (Barker et al., 1990, Bengtsson et al, 
1979, Law and Barker, 1994, Law et al, 1991). Indeed, it has been suggested that 
intrauterine retardation of growth may result in the syndrome of insulin resistance, 
a feature of essential hypertension and a risk factor for the development of 
coronary heart disease (Reaven, 1991): a reduction in total pancreatic 3-cell 
numbers resulting from impaired pancreatic growth, may predispose to the 
development of hyperinsulinaemia and insulin resistance occurs (Barker et al., 
1993). In addition, fetal undernutrition leads to a reduction in trunk growth to 
sustain brain growth in utero and it has been suggested that a degree of growth 
hormone deficiency and/or resistance results and persists throughout adult life to 
amplify the hypertensive tendency (Barker et al, 1993).
Of greater possible relevance to the current studies is the apparent link between 
intrauterine exposure to glucocorticoids and later cardiovascular function. Offspring 
of rats given dexamethasone during pregnancy develop higher adult blood 
pressures than those of untreated rats (Benedicktsson et al, 1993, Edwards et al.,
1993), and it was suggested that placental activity of 11BOHSD may be important 
in regulating fetal growth. Placental 11 BOHSD inactivates circulating maternal 
cortisol to cortisone, but the glucocorticoid dexamethasone is unaffected by 
11BOHSD and can cross the placenta to induce changes in birth weight an adult 
blood pressure in the offspring. Furthermore, treatment of pregnant rats with 
carbenoxolone, an inhibitor of 11BOHSD, leads to a reduction in birthweight in rats. 
This was most marked in those rats with the lowest levels of placental 11 BOHSD 
activity (Lindsay et al., 1995).
These studies emphasise the crucial effect of altered intrauterine environment on 
adult cardiovascular function, and provide a possible explanation for the more 
severe hypertension in offspring inheriting the condition maternally: such subjects 
will be exposed to excessive aldosterone (and 18-hydroxylated cortisol derivatives) 
concentrations during the whole of their gestation. However, the mechanism 
whereby excess intrauterine mineralocorticoid exposure results in higher plasma
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aldosterone concentrations and blood pressure levels in patients inheriting the 
chimeric gene from their mothers remains unclear. Vascular endothelial and 
smooth muscle cells have recently been shown to possess CYP11B2 mRNA and 
mineralocorticoid receptor mRNA implying local transcription of aldosterone 
synthase and MR protein (Hatakeyama et al, 1994). In addition, aldosterone 
administration to cultured cells resulted in an increase in protein synthesis which 
was blocked by a specific MR antagonist. Therefore, local vascular aldosterone 
synthesis and increased aldosterone-induced vascular smooth muscle cell 
proliferation in utero may underly the tendency to higher blood pressure levels in 
the offspring of females affected with GSH. Other key organs such as the 
hippocampus of the brain will also be exposed to increased aldosterone 
concentrations, and this may be important in the the long term "setting" of blood 
pressure. Why plasma aldosterone levels are higher in the offspring of affected 
females is not known. Such an effect may arise from an altered level of expression 
of the chimeric CYP11B1/B2 gene product determined by unknown intrauterine 
factors.
Another possible explanation for the observed effect is the principal of genomic 
imprinting, i.e. the phenotype of a genetic mutation differs depending on the 
parental origin of the mutated gene or chromosome. The best known example of 
imprinting is the Angelman's - Prader-Willi syndrome. These syndromes arise from 
the inheritance of a deleted portion of chromosome 15 from the mother or father 
respectively (Nicholls, 1993). Such a hypothesis is difficult to test but cannot be 
excluded.
Thus, from the study of these five kindreds with GSH there is novel evidence to 
support a role for intrauterine corticosteroid exposure in the development of 
hypertension. However, further studies including animal studies of 
mineralocorticoid exposure similar to that seen in GSH are necessary in order to 
explore this phenomenon further.
6.4.3 Effect of crossover location on phenotype
The lack of a significant relationship between blood pressure and plasma 
aldosterone concentrations and chimeric gene crossover site is not unexpected. 
The degree of alteration in nucleotide sequence and subsequent amino acid 
sequence of the chimeric enzyme is minimal (See Chapter 4.4). Similarly the 
studies of in vitro expression of chimeric CYP11B1/B2 cDNA constructs revealed 
an 'all or nothing' response in aldosterone synthase activity of the constructs rather 
than a graduated response relative to the composition of the construct (Pascoe et
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al, 1992a). Thus, it its unlikely that clinically significant variations in plasma 
aldosterone concentrations or blood pressure would arise from the relatively minor 
changes in chimeric gene sequence detected. The absence of in vitro aldosterone 
synthase activity of chimeric cDNA plasmids containing exons 1-5 or more of 
CYP11B1 suggests that classical GSH cannot arise from a chimeric gene with 
more than exons 1-3 of CYP11B1. However, the possibility of the existence of 
chimeric genes comprising more than the first 4 exons of CYP11B1 cannot be 
excluded, and such genes may have minor effects on aldosterone secretion which 
contribute to hypertension, particularly of the 'low-renin' form.
6.4.4 ACTH infusion studies
The ACTH infusion studies confirm the previous observations that 116-hydroxylase 
activity as determined by molar plasma S:F and DOC:B ratios is impaired in GSH 
and essential hypertension. In the basal state, both S:F and DOC:B ratios are 
elevated in patients with GSH compared to normotensive controls. Stimulation by 
ACTH results in further significant elevation in S:F ratios in patients with GSH and 
essential hypertension compared with normotensive controls, confirming the earlier 
observations in essential hypertension (De Simone et a l,, Honda et al, 1977), and 
GSH (Connell et al, 1986). However, following ACTH stimulation the high basal 
DOC:B ratios in patients with GSH fall to levels similar to that seen in normotensive 
controls and patients with essential hypertension .
In normal subjects the formation of cortisol and corticosterone is performed by 
CytP450n3 in the zona fasciculata (the major source of corticosterone), whilst 
synthesis of corticosterone in the zona glomerulosa is performed by CytP450aido 
only. In GSH, three enzymes with 116-hydroxylation capacity are present in the 
adrenal cortex: CytP450n3 in the zona fasciculata, CytP450aido in the zona 
glomerulosa and the chimeric ACTH-responsive CYP11B1/B2 gene product in the 
zona fasciculata. Cortisol synthesis can be performed by only one enzyme in the 
fasciculata, CytP450n3, whilst conversion of DOC to B can be performed by three 
enzymes in two different zones of the adrenal cortex. In the basal, untreated state 
this key biosynthetic step is impaired compared with normal subjects.
In patients with GSH CytP450n3 synthesises F, but in the basal state F synthesis 
is impaired, as is the conversion of DOC toB. One possible explanation for the high 
basal S:F and DOC:B ratios is an excess of a pseudosubstrate which can compete 
with the usual precursor for the active site of the enzyme. For example 18- 
hydroxyDOC, 18-oxocortisol or 18-hydroxycortisol are all present in high 
concentrations and might inhibit the efficiency of 110-hydroxylation. Precedents for
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pseudosubstrate inhibition are found in cases of classical 21-hydroxylase 
deficiency (Hornsby, 1989). Following ACTH, the marked increase in the local 
release and synthesis of 11-deoxycortisol and DOC, the normal enzyme substrates 
may overcome the pseudosubstrate inhibition in the case of corticosterone but not 
cortisol synthesis. No plasma measurements of 18-hydroxyDOC, 18-oxocortisol or 
18-hydroxycortisol are available in this study but will be performed in the future to 
assess this possibility.
An alternative explanation may be that the relative amount of S to F and DOC to B 
conversion performed by each enzyme may be altered in GSH. Clearly the activity 
of the normal CYP11B2 gene product (CytP450aido) will be suppressed by the 
mineralocorticoid excess state produced by aldosterone excess consequent upon 
the expression of the chimeric CYP11B1/B2 gene product in GSH. Therefore F and 
B synthesis will only be performed by CytP450nB (F and B) and the chimeric gene 
product (B only) in the zona fasciculata.
ACTH levels are not elevated in GSH (Connell et al, 1986, New et al, 1973). In 
GSH, basal untreated S:F and DOC:B ratios are high. It has been suggested that 
the zona fasciculata is the major site of in vivo corticosterone synthesis (Tan and 
Mulrow, 1979), but in vitro both CytP450nB and CytP450aido have equal 
corticosterone synthetic capacity (Kawamoto et al, 1992). Therefore, in the basal 
state there may be a relative deficiency of F and B synthetic capacity due to 
impaired basal activity of CytP450nB due to unknown factors, whilst activity of the 
chimeric gene is relatively low. When ACTH is administered there is an increase in 
the synthesis and release of DOC and B by the chimeric gene product sufficient to 
compensate for the basal deficiency. However, ACTH stimulation of CytP450nQ 
leads to an incresae in S:F ratio because F synthesis is still impaired.
The impaired activity of CytP450nB may result from altered expression of 
CYP11B1 and gene transcription in the zona fasciculata or impaired 
responsiveness to ACTH. All patients with GSH in this study possessed the -340C 
allele of the CYP11B2 promoter region polymorphism which alters DNA binding to 
the SF-1 region in vitro (White et al, 1994). CYP11B1 also has a SF-1 binding 
region and sequences in the promoter region specific for other regulatory species 
such as cAMP (Parker and Schimmer, 1993). It is possible therefore, that 
polymorphisms exist which affect the expression of the CYP11B1 gene product in 
GSH and essential hypertension and result in impaired CytP450nQ function. 
Similarly, other gene conversion events related to the primary unequal 
recombination may have altered important regions of the promoter which impair the
151
expression of CYP11B1 in GSH. Alternatively, as both CytP450nB and the 
chimeric gene product are expressed within the mitochondria there may be 
competition for available adrenodoxin and electron transport systems which results 
in an impaired basal activity of both enzymes. Following ACTH, selective activation 
of the chimeric gene may occur with exacerbation of the 11 6-hydroxylase activity 
of CytP450n3 and enhaced B synthesis.
Molar plasma B:ALDO ratio was low in the untreated GSH patients compared with 
normal controls, and rose signifcantly following ACTH whereas the B:ALDO ratio in 
normotensive controls fell following ACTH (not statistically significant). ' * 
Aldosterone synthesis in GSH presumably occurs in the zona fasciculata and is 
performed by the chimeric CYP11B1/B2 gene product. This is confirmed by 
observations in patients with GSH of tandem increases in aldosterone and 18- 
hydroxycortisol following ACTH (Connell et al, 1986). ACTH will increase 
aldosterone synthase activity in this case and should increase aldosterone 
biosynthesis. This is confirmed when the basal and post-ACTH aldosterone 
concentrations are examined. However, the incremental rise in aldosterone 
concentration following ACTH is approximately three-fold whereas the rise in 
corticosterone concentration is almost 13 times. The equivalent changes in 
normotensive controls were 3- and 6-fold increases respectively. Therefore it would 
appear that in GSH aldosterone synthase activity, i.e. 18-hydroxylation of 
corticosterone and other 17-hydroxy- and 17-deoxycorticosteroids, is impaired 
compared with normotensive controls when assessed by B:ALDO ratio. The 
explanation for this observation is not clear but in vitro expression studies of 
chimeric cDNA plasmids have shown that basal B:ALDO ratios are of a similar 
order to that seen in these patient studies (approximately 2-4) (Pascoe et al,
1992a) and that aldosterone synthase activity of the chimeric cDNA is relatively 
less than that of CYP11B2 (approximately 1/3 of the activity of CYP11B2 cDNA in 
vitro) (Miyahara et al, 1992). Thus, ACTH may increase the supply of precursor 
corticosterone but conversion to aldosterone may be limited by saturation of the 
aldosterone synthase activity of the chimeric gene product resulting in apparent 
inhibition of the synthetic capacity of the enzyme. It may be possible to assess this 
by using 18-hydroxycortisol measurements across the ACTH infusion as an index 
of the activity of the chimeric gene product compared to that of CytP450n&. 
Therefore, variation in enzymatic activity may offer a plausible explanation for the 
disordered aldosterone synthase activity in GSH.
Patients with essential hypertension and Conn's syndrome exhibited evidence of 
impaired CytP450nB function as shown by the S:F ratios, both basally and
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following ACTH, and the high DOC:B ratio after ACTH in the Conn's syndrome 
group. Similar findings have been reported previously and suggest that in both 
conditions 116-hydroxylation is impaired. Aldosterone synthase activity did not 
change following ACTH in these patients and the B:ALDO ratio was low suggesting 
relatively unimpaired aldosterone synthase activity.
In summary, patients with GSH exhibit signs of primay aldosterone excess which 
are abolished following glucocorticoid administration. Patients who inherit the 
condition from their mothers develop higher plasma aldosterone concentrations 
and blood pressure levels than those inheriting the condition from their father. The 
composition of the chimeric gene appears to have no effect on blood pressure 
levels or plasma aldosterone concentrations in affected individuals. There is 
evidence of impaired 11 6-hydroxylation of 17-hydroxy- and 17- 
deoxycorticosteroids in patients with GSH. Basal S:F and DOC:B ratios were 
elevated in patients with GSH. ACTH produced a rise in S:F ratio but a fall in 
DOC:B ratio. The impaired 1113-hydroxylation activity may reflect pseudosubstrate 
inhibition of the 116-hydroxylase enzymes or altered gene expression in the 
adrenal cortex of patients with GSH. Similarly, aldosterone synthase activity may 
be impaired in GSH compared with normal subjects. The low basal B:ALDO ratios 
rise following ACTH, principally due to an excessive rise in corticosterone 
concentrations, reflecting impaired aldosterone synthetic capacity of the chimeric 
gene product.
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Chapter 7
LEFT VENTRICULAR MASS IN GLUCOCORTICOID-SUPPRESSIBLE 
HYPERALDOSTERONISM
7.1 Introduction
Left ventricular hypertrophy is an important consequence of arterial hypertension 
and its presence is an important predictor of subsequent mortality from stroke, 
ischaemic heart disease and sudden cardiac death (Stokes et al, 1989). The basic 
mechanisms underlying the development of left ventricular hypertrophy are unclear 
but studies of animal models of mineralocorticoid-dependent hypertension suggest 
an important role for aldosterone in the development of myocardial fibrosis and left 
ventricular remodelling (Weber et al, 1992). For example, Brilla et al. (Brilla et al, 
1993b) have shown that reactive accumulation of collagen within the 
intramyocardial arteries and neighbouring interstitial space occurs in both the 
pressure overloaded hypertrophied left ventricle as well as the normotensive, non 
hypertrophied right ventricle of rats with arterial hypertension due to either primary 
or secondary hyperaldosteronism. In addition, it has been shown that 
spironolactone, an aldosterone antagonist, can prevent the occurrence of 
myocardial fibrosis in doses which are insufficient to lower blood pressure in the 
same models (Brilla et al., 1993a). However, the role of aldosterone in the 
development of left ventricular fibrosis and hypertrophy in man remains unclear. A 
post-mortem study of five patients with adrenal adenomata demonstrated the 
presence of perivascular fibrosis in the coronary and systemic arteries in a similar 
distribution to that seen in animal models of mineralocorticoid-dependent 
hypertension (Campbell et al, 1992).
Patients with GSH are exposed to abnormally high plasma aldosterone levels from 
birth, and possibly also in utero, and most eventually develop hypertension. 
Therefore, these patients should be at high risk of developing left ventricular 
hypertrophy and myocardial fibrosis if the observations in animal models are 
applicable to man.
To determine whether prolonged hyperaldosteronism in GSH has effects on left 
ventricular mass, 11 patients with GSH and ten control subjects were studied by 
echocardiography.
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7.2 Subjects and Methods
7.2.1 Subjects
Eleven subjects with GSH (6 males) and ten unaffected normotensive controls (6 
males) with no family history of hypertension were studied.
Three hypertensive subjects with GSH had received glucocorticoid therapy prior to 
echocardiography (Dexamethasone 0.25mg daily) for a median of six months 
(range 3 months, 6 months and 2 years).
7.2.2 Genotvoing
Patients with GSH were identified by genotyping based on a Southern blot of 
Bam HI digested DNA prepared from peripheral leucocytes as described in Chapter 
3.
7.2.3 Biochemical measurements
Measurements of plasma potassium, aldosterone and renin concentrations were 
performed on patients and controls at 9am following overnight recumbency 
(patients) or 90 minutes of supine rest (controls). No patients or controls were 
receiving any glucocorticoid, hypotensive or diuretic drugs at the time of the 
examination.
Plasma assays were performed in a single batch for each group as described in 
2.6.1-3.
7.2.4 Echocardiographic measurements
Echocardiograms were performed by the same person in all 11 patients and 10 
controls. Measurements were obtained from echocardiograms in a blinded fashion 
by two observers as described in 2.5.6. Height and weight were recorded at the 
time of echocardiography and left ventricular mass determined as described in 
2.5.6.
7.2.5 Statistics
Differences in blood pressure, plasma aldosterone, renin and potassium 
concentration and left ventricular mass measurements between the two groups 
were assessed by the Mann-Whitney U-test.
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7.3 Results
The two groups were matched for age range and sex distribution: median age of 
subjects was 27 years (Range 6-59 years, males=6), and the median age of the 
control subjects was 29 years (Range 20-54 years, males=6).
7.3.1 Blood pressure and biochemical analyses
Patients with GSH had elevated blood pressures, plasma aldosterone 
concentrations and suppressed plasma active renin concentrations compared to 
the normotensive subjects (Table 7.3 a).
Mean Blood 
Pressure 
(mmHg)
Renin
(mU/ml)
Aldosterone
(pmol/l)
Potassium
(mmol/l)
GSH 119(9) 1.0 (0.4) 766(111) 4.07 (0.12)
GSH-HT 133(7) 1.7 (0.3) 796 (164) 3.93 (0.16)
GSH-NT 78 (6)* 1.0 (0.1) 712(175) 4.28 (0.15)+
Controls 86 (4)* 23 (2.5)* 305 (34)* 4.16(0.11)
GSH - GSH patients, n=11; GSH-HT - GSH patients with elevated blood pressure 
GSH-NT - GSH patients with normal blood pressures 
Results are expressed as mean ± s.e.m.
* p<0.0001 for comparison between GSH-HT patients and GSH-NT and controls
*  p<0.001 for comparison between Controls and all GSH patients groups 
t  p=0.057 for comparison between GSH-HT and GSH-NT
Table 7.3 a Blood pressure and biochemical data on GSH patients and controls.
Subjects with GSH were subdivided into patients with GSH and hypertension, 
those patients whose resting pressure was <160 mmHg systolic or <90 mmHg 
diastolic, (GSH-HT) (n=7) and patients with GSH without hypertension (GSH-NT), 
(n=4). Plasma active renin and aldosterone concentrations in GSH-HT and GSH- 
NT were not significantly different from each other but plasma potassium in the 
GSH-NT group tended to be higher in the GSH-HT group (p=0.057).
7.3.2 Left ventricular mass index
The left ventricular mass index determined by echocardiography of subjects and its 
relation to mean arterial blood pressure is shown in Table 7.3 b.
The left ventricular mass index of subjects with GSH was not significantly different 
from each other or from the control group (GSH - 99.7 +/- 7.7 gram/m2 vs. 100.3 
+/- 5.4 gram/m2, p=0.76).
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Mean Blood Pressure 
(mmHg)
Left ventricular mass index 
(gram/m2)
GSH 119 (9)f 99.7 (7.7)4:
GSH-HT 133(7) 100(10.1)4:
GSH-NT 78 (6)* 99.2 (13.6)4:
Controls 86(4)* 100.3 (5.4)4:
GSH - GSH patients, n=11; GSH-HT - GSH patients with elevated blood pressure 
GSH-NT - GSH patients with normal blood pressures 
Results are expressed as mean ± s.e.m.
* p<0.0001 for comparison between GSH(all patients) GSH-HT and other groups, 
t  p<0.001 for comparison between GSH(all patients) and GSH-NT and control groups 
t  p= not significant for comparison between all groups.
Table 7.3 b Comparison of left ventricular mass index in patients with GSH and controls
Left ventricular mass index was non-significantly different when patients were sub­
divided on the basis of blood pressure; GSH-HT -100.0 +/-10.1 gram/m2, GSH- 
NT - 99.2 +/-13.6 gram/m2, Control 100.3 +/- 5.4 gram/m2, p=0.63. In addition, 
neither age at diagnosis nor duration of hyperaldosteronism before diagnosis of 
GSH had any demonstrable effect on left ventricular mass index.
However, a statistically significant positive correlation between basal plasma 
aldosterone concentration and LVMI in patients with GSH (Spearman rank 
correlation coefficient, r=0.66, p<0.03) (Figure 7.3 a).
7.4 Discussion
Echocardiography allows the accurate identification of left ventricular hypertrophy 
in patients with hypertension, a group at high risk of developing serious 
complications such as stroke, cardiac failure and sudden death (Stokes et al,
1989). Reversal of left ventricular hypertrophy can be achieved using a number of 
anti-hypertensive agents (MacMahon, 1994).
There is now a large body of animal data, predominantly in rat models of 
mineralocorticoid dependent hypertension in favour of a pathogenetic role for 
aldosterone in the development of myocardial fibrosis and left ventricular 
remodelling (Brilla et al, 1993a, Brilla et al, 1993b, Weber et al, 1992).
Observations in rats with mineralocorticoid hypertension suggest that myocardial 
fibrosis can occur in both left and right ventricles in the presence of arterial 
hypertension (Brilla et al, 1993a, Brilla et al, 1993b). In these models the right 
ventricle is exposed to normal pressures and it is suggested that the fibrosis occurs
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Figure 7.3 a Correlation between plasma aldosterone concentration and 
Left ventricular mass index in patients with GSH.
as a direct result of mineralocorticoid action on the cardiac fibroblasts rather than 
an effect of pressure-overload mechanisms. Therefore, the aldosterone receptor 
antagonist, spironolactone may have an important and specific role in the 
prevention and treatment of aldosterone-induced myocardial fibrosis (Brilla et al, 
1993a, Brilla et al, 1993b). Administration of spironolactone in doses that do not 
lower blood pressure prevents the development of myocardial fibrosis such that left 
ventricular hypertrophy occurs in the absence of significant collagen accumulation. 
If spironolactone is given in high doses which prevent mineralocorticoid-induced 
hypertension, both myocardial fibrosis and left ventricular hypertrophy are 
prevented. Left ventricular hypertrophy reflects an increase in cardiac myocyte 
mass whereas myocardial fibrosis may have no effects on LVMI but may affect 
cardiac function. For example, cardiac fibrosis is an important determinant of 
ventricular diastolic function in animal models of ventricular hypertrophy, 
particularly in association with hypertension of renal origin (Swales, 1994). Fibrosis 
may also contribute to sudden death in patients with normal gross cardiac anatomy 
by acting as a substrate for the development of re-entrant ventricular arrhythmias 
or areas of focal arryhthmogenic myocardial ischaemia. Biopsy of ventricular 
muscle from patients with grossly normal hearts and life-threatening arrhythmias 
showed areas of intramyocardial fibrosis (Strain et al., 1983).
Clinical information in human subjects on the effects of prolonged primary 
hyperaldosteronism is limited. In a post-mortem study of five patients with adrenal 
adenomata, the presence of perivascular fibrosis in the coronary and systemic 
arteries in a similar distribution to that seen in animal models of mineralocorticoid- 
dependent hypertension was reported (Campbell et al, 1992). Such patients 
usually have marked hyperaldosteronism and hypertension and usually also have 
associated left ventricular hypertrophy. Pre-existing left ventricular hypertrophy in 
these patients can be reversed upon treatment of the hyperaldosteronism, either 
by removal of the adenoma or by the administration of aldosterone antagonists 
(Pringle et al., 1988).
Furthermore, studies of patients with essential hypertension in association with left 
ventricular hypertrophy suggest a positive correlation between plasma aldosterone 
concentration and left ventricular mass index (Duprez et al., 1993). In the study of 
hypertensive subjects, the mean arterial pressure of hypertensive subjects was 
similar to that observed in the patients with GSH but plasma aldosterone levels 
were within the normal range. The mean left ventricular mass index of the patients 
with essential hypertension was significantly greater than in the subjects with GSH,
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but both groups showed a similar correlation between plasma aldosterone 
concentration and left ventricular mass index.
It is clear therefore that primary aldosterone excess in man can cause 
hypertension, left ventricular hypertrophy and myocardial fibrosis. The relationship 
among these features is variable and may be influenceded by factors other than 
aldosterone. Thus, the plasma aldosterone concentrations seen in patients with 
GSH are only modestly elevated compared to those seen in the majority of cases 
of Conn's syndrome (Ferriss, 1992), and may in themselves be insufficient to 
provoke significant pressure- mediated LVH. Previous observations suggest that 
blood pressure in many patients with GSH is only modestly elevated and may 
require 2-3 decades to develop despite the presence of hyperaldosteronism 
(Jamieson et al, 1994). Therefore, it may require the interaction of the genetically- 
determined hyperaldosteronism and other factors, either genetic or environmental, 
such as salt intake, to provoke significant LVH in patients with GSH. However,
GSH patients may have myocardial fibrosis present, even at this level of 
aldosteronism, which could be detected by myocardial biopsy. Detection of 
myocardial fibrosis would confirm the observations in animal studies of 
aldosterone-dependent, hypertrophy-independent myocardial fibrosis.
The measured LVMI in our patients with GSH was not significantly raised 
compared with the normotensive controls. This may reflect the relatively small size 
of our sample. Alternatively, as aldosterone may have predominant effects in 
producing cardiac fibrosis rather than pressure-mediated hypertrophy, which 
cannot be detected by conventional transthoracic echocardiography, this may be 
the principal consequence in GSH. Thus, significant LVH may not occur because 
pressure-dependent effects are not prominent in these patients in distinction to 
those patients with adrenal adenomata (Ferriss, 1992).
The literature on GSH consists of case reports; systematic evaluations of 
cardiovascular risk are not available. It is thought that there is an increased risk of 
premature stroke in these patients, although the reasons for this are unclear 
(Connell et al, 1986, New and Peterson, 1967). In addition, severe renal 
impairment as a consequence of GSH has been reported (Lee et al, 1982).
Because of the relative rarity of GSH and the geographical isolation of many of our 
affected subjects, the numbers studied were limited. However, the results of these 
observations suggest that, genetically determined, prolonged elevation of plasma 
aldosterone concentrations does not necessarily lead to left ventricular 
hypertrophy. However, plasma aldosterone concentrations do have a definite effect
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on left ventricular mass index as shown by the positive correlation between plasma 
aldosterone concentration and left ventricular mass. Other factors, however, may 
be important in determining the absolute level of blood pressure attained and the 
risk of subsequent end-organ damage.
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Chapter 8 
CONCLUSIONS
Until recently, diagnosis of GSH relied on the accurate documentation of primary 
aldosterone excess and demonstration of its complete reversal following 
glucocorticoid administration. This process requires frequent visits for blood 
sampling and the need to take dexamethsone for 1 month. Elevated urinary 
excretion of 18-hydroxylated cortisol derivatives has been shown to identify reliably 
the affected relatives of index cases of GSH (Rich et al, 1992). This method 
requires an accurate 24 hour urine collection and a readily available assay, 
features which may limit its applicability to patients unable to provide accurate 
urine collections, for example young children, or patients remote from a major 
endocrine centre. In addition to the relatively cumbersome technical aspects of 
these approaches, they rely to a greater or lesser extent on the presence of a 
proband whose relatives can be screened for GSH rather than being applicable to 
wider clinical practice for detection of the disorder in the general hypertensive 
population.
The development of the molecular genetic method which can be used to diagnose 
GSH from a single blood sample or from placental tissue is a significant advance in 
the detection of GSH. This method is 100% specific and sensitive for GSH (Lifton 
et al, 1992). In addition, these studies have demonstrated that hypertension is not 
a sine qua non of the condition in childhood or the second decade. Similarly 
plasma potassium measurements are a poor indicator of hyperaldosteronism in 
GSH. However, given the strong family history of hypertension and related 
problems in all the kindreds, patients under 25 years of age or those with a strong 
family history of hypertension or premature cerebrovascular disease GSH should 
always be considered as a possible cause of hypertension and action taken to 
exclude or confirm its presence.
The discovery of a potential influence of the parental origin of the chimeric gene on 
plasma aldosterone concentration and blood pressure is novel and intriguing. As 
discussed there are a number of lines of evidence to suggest that hypertension 
may have its origin, or at least its potential course, modified in utero. The origin of 
this programming effect is unclear but may arise from fetal vascular effects of 
intrauterine mineralocorticoid excess or a genomic effect, i.e. imprinting. Further 
studies in an animal model to assess the effect of maternal mineralocorticoid 
excess on offsprings blood pressure are planned.
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The nucleotide sequences of the chimeric genes are in keeping with the previously 
published data. Similarly the lack of apparent variation in clinical phenotype in 
individuals with differing chimeric genes is not surprising when the effects of 
nucleotide changes on the predicted amino acid structure of the chimeric gene 
product are examined.
The discovery of a polymorphism in the promoter region of CYP11B2 and its 
linkage to GSH is interesting. This polymorphism and the gene conversion 
involving intron 2 of CYP11B1 and B2 indicate a possible mechanism whereby the 
formation of a chimeric gene might occur. Preliminary unpublished data suggest 
that the intron 2 duplication is in linkage disequlibrium with -340C only in whites, 
not black subjects, thus reinforcing the suggestion of a Celtic bias in the origin of 
GSH (PC White, personal communication). The presence of the intron 2 gene 
conversion would explain the observed data on the structure of the chimeric genes. 
As yet no chimeric CYP11B1/B2 gene in patients with GSH containd exon 2 from 
CYP11B2 (Jamieson et al., 1995, Lifton et al, 1992, Miyahara et al, 1992, Pascoe 
et al, 1992a). This would suggest that the presence of the gene duplication, whilst 
facilitating the formation of chimeric genes also limits the composition of the gene 
to a minimum of exons 1-2 from CYP11B1 and the remainder from CYP11B2. 
Other data on the origin of aldosterone synthase activity in the CYP11B2 gene 
product may explain why there is a limit to GSH activity of chimeric genes (Pascoe 
and Curnow, 1994). When exon 5 of a chimeric gene originates from CYP11B1 
aldosterone synthase activity of the chimeric gene product is abolished (Pascoe et 
al, 1992a). Thus it would appear that the genes causing GSH are likely always to 
contain exons 1-2 from CYP11B1, exon 5 from CYP11B2 and a variable portion of 
intron 2-4 from CYP11B1 and B2.
Impaired 11 B-hydroxylase activity is a feature of essential hypertension. These 
studies have demonstrated the presence of impaired 11B-hydroxylation in GSH 
also. The basis for this apparent deficiency is unclear but may arise from 
pseudosubstrate inhibition of 11 B-hydroxylase enzymes in the adrenal cortex, or 
altered expression of the genes encoding enzymes with 11 B-hydroxylase capacity, 
i.e. CytP450n3, CytP450aido, and the CYP11B1/B2 chimeric gene product.
There are clear similarities between essential hypertension and GSH in this regard 
and the abnormalities underlying impaired 11 B-hydroxylation in both conditions 
may have a similar etiology.
End-organ damage is the cause of mortality and morbidity in hypertension. Left 
ventricular hypertrophy is a significant independent risk factor for sudden death.
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Animal studies and in vitro observations on cardiac fibroblasts suggest that 
aldosterone may be an important mediator of myocardial fibrosis. Thus aldosterone 
excess may have adverse effects on cardiac remodelling, particularly if present 
from childhood. Studies in this thesis were unable to show an effect of aldosterone 
excess on absolute left ventricular mass index (LVMI) in patients with GSH, 
although LVMI was correlated with plasma aldosterone concentration. However, 
these studies did not address the role of such aldosterone excess on the fibrous 
tissue content of the ventricles or the coronary arteries of patients with GSH, sites 
of prominent aldosterone-induced myocardial fibrosis.
A international registry of cases of GSH has been established in Harvard Medical 
School, and British cases of GSH are logged by the Blood Pressure Group, 
Department of Medicine and Therapeutics, Western Infirmary, Glasgow. The 
establishment of such registers will allow data from centres world wide to be 
pooled and important questions about GSH to be answered. For example, how 
great is the effect of parental inheritance of GSH on phenotype and what other 
factors interact to alter the phenotype; are there prominent effects of aldosterone 
on LVMI or myocardial fibrosis in patients with GSH; do individuals inheriting 
chimeric genes which differ significantly in composition, e.g. exon 1-2 or exon 1-4 
from CYP11B1, exhibit any phenotypic differences?
Furthermore, a gradual increase in awareness of GSH will undoubtedly lead to an 
increase in diagnoses of GSH aided by the simplicity and reliability of the molecular 
genetic method. This makes possible accurate assessment of population 
prevalence of the condition.
Since commencing the writing of this thesis a further kindred has been discovered 
and is in the process of being characterised. The work carried out in this thesis has 
characterised the basic clinical and genetic features of our local kindreds with GSH 
and will act as a catalyst for further work on this and related topics such as:
1) The need to establish the population prevalence of GSH in target 
populations, e.g. hypertension clinic, Isle of Lewis population
2) A further examination of the role of intrauterine influences on blood pressure 
in GSH by the use of animal models and the detailed analysis of birthweight data 
and adult blood pressure in patients and offspring with and without GSH
3) Study of the effects of mineralocorticoid exposure in utero on myocardial 
fibrosis in the offspring of aldosterone-treated rats.
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APPENDIX I
Genomic DNA solutions
Cell Lysis Buffer
Nuclei Lysis Buffer
RNAse enzyme 
Sodium acetate 
Phenol/Chloroform
0.32M Sucrose 
10mMTRIS
5mM Magnesium Chloride 
1% Triton X-100 
pH 7.5
10mM TRIS 
0.4M Sodium Chloride 
2mM EDTA 
pH 2.8
100^g/ml
3M
50:50, pH 7.5, 0.1% hydroxyquinolone
TE buffer
Loading Buffer 
20xSSC
Denaturation Buffer 
Neutralisation Buffer
Depurination buffer 
Sephadex
Prehybridisation Buffer 
(100ml)
Salmon sperm DNA 
SDS
10mM TRIS 
10mM EDTA 
pH 7.5
30% Glycerol
0.25% Bromophenol Blue
3M Sodium Chloride 
0.3M Sodium Citrate 
pH 7
0.5M Sodium Hydroxide 
1.5M Sodium Chloride
0.5M Tris- HCI 
3M Sodium Chloride 
pH 7.5
0.25M Hydrochloric Acid
30g Sephadex 
500 ml 2X SSC
30ml 20X SSC 
10ml 50X Denhardts 
5ml 10% SDS 
1.2ml Denatured
Sonicated Salmon Sperm (50pg/100ml) 
10mg/ml sonicated 
10% Solution
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Proteinase K
Saturated Sodium Chloride 
Ethanol
Ethidium Bromide
10|ig/ml
Approximately 6M 
95%
10mg/ml
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APPENDIX II
Molecular Biology Reagents 
Restriction enzymes
Concentration Recognition Site
50U/(il GAGATCC
CCTAGAG
Storage Buffer
10mM Tris-HCI, 300mM KCI, 0.1 mM EDTA, 1mM DTT,
0.5mg/ml BSA, 50% glycerol, pH 7.4
10X Reaction Buffer
60mM Tris-HCI, 60mM MgC^, 1M NaCI, 10mM DTT, pH7.4
Concentration Recognition Site
10U/pl GGACC
CCAGG
Storage Buffer
10mM Tris-HCI, 300mM NaCI, 0.1 mM EDTA, 1mM DTT, 
0.5mg/ml BSA, 50% glycerol, pH 7.4
10X Reaction Buffer
100mM Tris-HCI, 100mM MgCI2, 0.5 M NaCI, 10mM DTT, pH7.9 
DNA Polymerase Enzyme
Taq polymerase: 2-5U/(il 
Storage Buffer
50mM Tris-HCI, 100mM NaCI, 0.1 mM EDTA, 5mM DTT,
50% glycerol, Triton X-100, pH 8.0
10X Reaction Buffer
100mM Tris-HCI, 2.5mM MgC^, 500 mM KCI,
Triton X-100, pH 9.0
Nucleotides:
dATP, dCTP, dGTP, dTTP: 0.2 mM
Enzyme
BamHI:
Enzyme
Haelll:
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Oligonucleotide labelling
T4 Polynucleotide kinase: 5-10pU/ml
10X Reaction Buffer
700 mM Tris-HCI, 100mM MgCI2, 50mM DTT, pH 7.6 
DNA labelling for Southern Blotting
Random Primer Labelling Kit (Gibco-BRL Life Technologies)
Klenow Enzyme (Large fragment of DNA Polymerase I): 3U/jil 
Storage Buffer: 100mM K3 PO4 , 10mM 2-mercaptoethanol, 50% glycerol
Random Primers Buffer Mixture: 0.67M HEPES, 0.17M Tris-HCL,
17mM MgCl2, 33mM 2-mercaptoethanol, 1.33mg/ml BSA,
18 OD26o units/ml oligodeoxyribonucleotide primers (hexamers) 
pH 6.8
Nucleotides:
dATP, dGTP, dTTP: 0.5 mM in 3mM Tris-HC, 0.2 mM Na2EDTA 
Purification of PCR products
GELase: 1 U/pl
Reaction Buffer:
40mM bis(2-hydroxyethyl)imino-tris(hydroxymethyl)methane,
1mM EDTA, 40mM NaCI, pH 6.0
Storage Buffer: 50mM Tris-HCI, 0.1 mM EDTA, 0.1M NaCI, 0.1%
Triton X-100, 50% (w/v) glycerol, pH 7.5
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DNA Sequencing
DNA Sequencing Kit (Sequenase Version 2.0)
Storage Buffer: 13 U/pl in 20mM KP04> pH 7.4, 1mM DTT,
0.1 mM EDTA, 50% glycerol
Enzyme Dilution Buffer: 10 mM Tris-HCI, pH 7.5, 5 mM DTT,
0.5 mg/ml BSA
Sequenase Buffer (5X): 200mM Tris-HCI, pH 7.5,
100mM MgCl2, 250 mM NaCL
Labelling Mix (5X): 7.5pM dGTP, 7.5 pM dCTP, 7.5 pM dTTP
Termination Mixes (5X):
ddG: 80 pM dGTP, 80 pM dATP, 80 pM dCTP, 80 pM dTTP,
40 pM ddGTP, 50 mM NaCI
ddA: 80 pM dGTP, 80 pM dATP, 80 pM dCTP, 80 pM dTTP,
40 pM ddATP, 50 mM NaCI
ddT: 80 pM dGTP, 80 pM dATP, 80 pM dCTP, 80 pM dTTP,
40 pM ddTTP, 50 mM NaCI
ddC: 80 pM dGTP, 80 pM dATP, 80 pM dCTP, 80 pM dTTP,
40 pM ddCTP, 50 mM NaCI
Stop Solution: 95% formamide, 20 mM EDTA, 0.05% Bromophenol blue
0.05% Xylene Cyanol FF
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APPENDIX III
Oligonucleotides used in this thesis
Oligonucleotide Sequence 51 > Site Use
1 TTTGAATTCTCGAAG
GCAAGGCACCAG
CYP11B1 5' UTR 
(♦)
PCR of chimeric 
CYP11B1/B2 gene
2X CTCGGATCCCAGCTC
TCAGCTCCCAA
CYP11B2 Intron 2 
(-)
PCR of chimeric 
CYP11B1/B2 gene
3A GC AG A AAAT CCCT CC 
CCCCTA
CYP11B1 Intron 2
M
PCR of chimeric 
CYP11B1/B2 gene
5 GACACGT GGGCGCC 
GTGTGA
CYP11B1 Inton 5 
(•)
PCR of chimeric 
CYP11B1/B2 gene
5N T GGAGCAT GGAT CC 
CCACACA
CYP11B2 Intron 5 
(•)
PCR/ Sequencing 
chimeric CYP11B1/B2 
gene
6A GT CT AACCCT GCAGC 
TGTGT
CYP11B1 Intron 5
M
PCR of chimeric 
CYP11B1/B2 gene
CC AATCTAGATTTGTGC
AGGAGCTGGCTGG
CYP11B2 3'UTR 
(-)
PCR of chimeric 
CYP11B1/B2 gene
3 AC AAGG AGGAT GCC 
ATA
CYP11B1/2 Intron 2
M
Sequencing chimeric 
CYP11B1/B2 gene
4 GGACTGAAGGGAGT 
GTG
CYP11B1/2 Intron 3
M
Sequencing chimeric 
CYP11B1/B2 gene
2523 TT CGG AT CCT CCCT C 
CACCCTGTTC
CYP11B2 S' UTR (-) PCR of CYP11B2 
promoter region
2524 TTTGTCGACATGTGT
TCAAAACCCACA
CYP11B2 5' UTR 
(*)
PCR of CYP11B2 
promoter region
2360 AT CCAAGGCCCCCT C 
TCAT
CYP11B2 5' UTR 
(+)
ASO Probe
2361 ATGAGAGGGAGCCT
TGGAT
CYP11B2 5' UTR 
(-)
ASO Probe
Key:
PCR - polymerase chain reaction amplification, ASO Probe - allele specific oligonuceotide 
probe, UTR - untranslated region of gene, either 51 or 3'.
(+) or (-) - sense of oligonucleotide, i.e. (+) elongates the sense strand 5' to 3' and (-) 
elongates the antisense strand 5* to 3'
Calculation of oligonucleotide concentrations
The concentration of an oligonucleotide of known sequence can be calculated 
when the molecular weight (MW) of the oligonucleotide and the quantity 
synthesised is determined.
MW = [(A x 312.2) + (G x 328.2) + (C x 288.2) + (T x 303.2)] - 61.0 
Where A, G, T, and C are the number of each base in the sequence
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The quantity synthesised is determined from the optical density (OD) reading. OD 
is the amount synthesised in 1ml volume. An OD reading of 1.00 corresponds to 
approximately 37mg/ml of oligonucleotide.
Concentration = ( OD x 0.037/MW) x 106
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APPENDIX IV
Nucleotide Sequences of CYP11B1 and CYP11B2
Listed below are the nucleotide sequences for CYP11B1 and CYP11B2 obtained 
from the Human Genome databank.
Accession numbers for the sequences are as follows:
CYP11B1: 5‘ flanking region and exon 1 D10169, D90428, X55765
Exon 1 and 2 M32863, J01540
Exon 3 -8 M32878, J01540
Exon 9 M32879 J01540
CYP11B2: 5' flanking region and exon 1 D10170, D90429
Exon 1 and 2 M32864, J05140
Exon 3-8 M32880, J05140
Exon 9 M32881 J05140
Exons are indicated by bold type. The position of oligonucleotides listed in 
appendix III are indicated by bold letters above the relevant sequence bounded by 
double < » ; the double »  indicates the sense of the oligonucleotide, e.g. < oligo 
1 »  indicates that oligo 1 is a sense oligo.
CYP11B1
TTTTCTAGTTCTTTTAATTGTGATGTTAGGGTGTCAGTTTTGGATCTTTCCTGCTTTCTC 
1 ------------------+ ----------------- + ------------------+ ------------------ + ------------------+ ------------------ + 60
TTGTGGGCATTTAGTGCTATAAATTTCCCTCTACACACTGCTTTGAATGTGTTCCAGAGA 
6 1 ----------------- +----------------- + ------------------+ ------------------ + ------------------+ ------------------ + 120
TTCTGGTATGCTGTGTCTTTGTTCTCGTTGGTTTCAAGAACATCTTTATTTCTGCCTTCA 
1 2 1 ------------------+----------------- + ------------------+ ------------------ + ------------------+ ------------------ + 180
TTTTGTTACGTACCCAGTAGTCATTCAGGAGCAGGTTGCTCAGTTTCCATGTAATTGAGC 
1 8 1 ------------------+ ----------------- + ------------------+ ------------------ + ------------------+ ------------------ + 240
GGTTTTG AGTGAGTTTC TTAATC CTG AGTTCTAGTTTG ATTGC AC TAAAATTTTTAAAAA 
241 ----------------- + ----------------- + ------------------+ ------------------ + ------------------+ ------------------ + 300
GTAAAAAAAATACATGTGGTTTAATACAATTCATGCCAACTCATTCCCTCGTTTTTTGCT 
301 ----------------- +----------------- + ------------------+ ------------------ + ------------------+ ------------------ + 360
AT AAAC C TTGC AAGG AG ATGAATAATC C AAGGCTC TTGG ATAAG ATAAGGGC C CC ATCC A 
361 ----------------- + ----------------- +------------------+ ------------------ + ------------------+ ------------------ + 420
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421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
TCTTGCTCCTCTCAGCCCTTGGAGGAGGAGGGAGAGTCCTTTTCCCCTGTCTACGCTCAT 
---------+--------- +---------+--------- +--------- +--------- + 480
GCACCCCCAATGAGTCCCTGCCTCCAGCCCTGACCTCTGCCCTCGGTCTCTCAGGCAGAT 
----------------- + ------------------+ ----------------- + ------------------ + ------------------+ ------------------ + 540
< Oligo 1 >>
CCAGGGCCAGTTCTCCCATGACGTGATCCCTCTCGAAGGCAAGGCACCAGGCAAGATAAA 
 +---------+--------- +-------- +--------- +--------- + 600
AGGATTGCAGCTGAACAGGGTGGAGGGAGCATTGGAATGGCACTCAGGGCAAAGGCAGAG 
 +---------+--------- +-------- +--------- +--------- + 660
GTGTGCATGGCAGTGCCCTGGCTGTCCCTGCAAAGGGCACAGGCACTGGGCACGAGAGCC 
---------+--------- +--------- +-------- +--------- +--------- + 720
GCCCGGGTCCCCAGGACAGTGCTGCCCTTTGAAGCCATGCCCCGGCGTCCAGGCAACAGG 
---------+--------- +--------- +-------- +--------- +--------- + 780
TGGC TGAGGC TGC TGCAGATC TGGAGGGAGC AGGGTTATGAGGAC C TGC ACC TGGAAGTA 
---------+--------- +--------- +-------- +--------- +--------- + 840
CACCAGACCTTCCAGGAACTGGGGCCCATTTTCAGGTAAAGCCCTCCCTGGCCCTCGCTG 
----------------- +------------------+-------------------+ -----------------+ ------------------ + ------------------ + 900
GAACACCCAGTGCCCTGCCCTTGCTGCCCAGGACCCTGCCGGGCACTCAGCACTGCCATT 
----------------- + ------------------+ -------------------+ -----------------+ ------------------ + ------------------ + 960
CCCAGCAGGTCCCGGCACTCTGCATCCTTTGGAAGAGGGAAGATCGAGCACGTGCTGTCT
I-------------------h-------------------+ ----------------- h---------------------1-------------------1- 1020
GTGCGCTGCAGGGCAGGGCATGTGCAGAGCAAATGGGAGCTCGGCTGCAGAGAGGGCAGG 
 + ----------------- + -------------------+ -----------------+ ------------------ + ------------------ + 1080
ACTCAGAGGCACTGAAGTTAAGAGGTTCCGGGCAGTCAGCAAGAGGGCGTTTAGCTGTGA 
----------------- + ------------------+-------------------+ -----------------+ ------------------ + ------------------ + 1140
AGCCGCTAATCCAGGAGAGGGGAGGGTGGACAGGAGACACTTTGGATTGGGACTGCAGGG 
------------------ 1--------------------  + -------------------1------------------- h--------------------(- 1200
TGGGGCCAGCAGGGACTAGACCCCGTCCAGCAGGGCCTCCTGCTTGGCCCCACAGGTACG 
 +---------+--------- +-------- +--------- +--------- + 1260
ATTTGGGAGGAGC AGGC ATGGTGTGTGTGATGC TGC C GGAGGAC GTGGAGAAGC TGC AAC 
---------+--------- +--------- +-------- +--------- +--------- + 1320
AGGTGGACAGCCTGCATCCCCACAGGATGAGCCTGGAGCCCTGGGTGGCCTACAGACAAC 
---------+--------- +--------- +-------- +--------- +--------- + 1380
ATC GTGGGC AC AAATGTGGCGTGTTC TTGC TGTAAGC GGCGAGC TGAGAGC TGGGAGC AG
----------------- +------------------+-------------------+ -----------------+ ------------------ + ------------------ + 1440
GGTGGGC AGC C TGGGTGTAGGGGGG AGGCGAGAG AGGC AGG AAAAGC TTG AC AAC AGGGG 
----------------- + ------------------+ -------------------+ -----------------+ ------------------ + ------------------ + 1500
< Oligo 3A >>
TC AGTTC C TTTC TTGC AGAAAATC CCTCCCCCC TAC TAC AGGG AGGGC C CGC ATGGGTG A 
----------------- + ------------------+ -------------------+ -----------------+ ------------------ + ------------------ + 1560
GGTGGTGCCAGACTTGGGGCGCCAGGTCCCGGGAATGACCTCAGTTACCCTGTCAGCACC 
----------------- h-------------------- 1--------------------+ ------------------1--------------------- 1------------------ + 162 0
173
TGTGGGCAGAAGCTACCATCTCATCCCTGCTTAGACCTGAGTGGCCTTTGTCCAGCACCT 
1621  +  +  +  +  +  + 1680
GGAGGCCGTCTGAGAAAAGGCTGCAGCTCGAACACAAACAGGCAGCTTCTACCAGGGCCC 
1681 ----------------- + ------------------+ ------------------+ ------------------+ ------------------+ ------------------- + 1740
CCAGTCAGCTCCCTGCAGGCCGATTCCCCTTGGGACAAGGAGGATGGGATACGGGTCAGG 
1741 ----------------- + ------------------+ ------------------+ ------------------+ ------------------+  + 1800
GCCTGTGTTTTGCTGGGGCGGCCTCACAAGCTCTGCCCTGGCCTCTGTAGGAATGGGCCT 
1801 -........+......... +--------- +--------- +------- + ---........ + 1860
GAATGGCGCTTCAACCGATTGCGGCTGAATCCAGAAGTGCTGTCGCCCAACGCTGTGCAG 
1861 --------- +--------- +--------- +--------- +--------- +----------+ 1920
AGGTTCCTCCCGATGGTGGATGCAGTGGCCAGGGACTTCTCCCAGGCCCTGAAGAAGAAG 
1921 --------- +--------- +--------- +--------- +--------- +----------+ 1980
GTGCTGCAGAACGCCCGGGGGAGCCTGACCCTGGACGTCCAGCCCAGCATCTTCCACTAC 
1981 --------- +--------- +--------- +--------- +--------- +----------+ 2040
ACCATAGAAGGTGTGGGCCACATGGGTTGATCCAGCCTCAGAGACCCTGGAGTGGCCAGG 
2041 ------------------+------------------+ ------------------+ ------------------+ ------------------+ ------------------- + 2100
GACGGGGATGGGGG ACTG AAGGG AGTGTGGGGAGGC AGC C AGG AGGCCCGGTTC C C TTGT 
2 1 0 1 ----------------- +------------------+ ------------------+ ------------------+ ------------------+ ------------------- + 2160
GCTCAGCAGTGCATCCTCCCCGCAGCCAGCAACTTGGCTCTTTTTGGAGAGCGGCTGGGC 
2161  + ----------------- + --------+  + ----------------------------+ ------------------- + 2220
CTGGTTGGCCACAGCCCCAGTTCTGCCAGCCTGAACTTCCTCCATGCCCTGGAGGTCATG 
2221    +---------+--------- +--------- +--------- +----------+ 2280
TTCAAATCCACCGTCCAGCTCATGTTCATGCCCAGGAGCCTGTCTCGCTGGACCAGCCCC 
2281 ---------+--------- +-----—---+--------- +--------- + + 2340
AAGGTGTGGAAGGAGCACTTTGAGGCCTGGGACTGCATCTTCCAGTACGGTGAGGCCAGG
2341 ----------------- +------------------+------------------+------------------+ ------------------+------------------- + 2400
GACCCGGGCAGTGCTATGGGGAAGGACACCATCGGGCCCCCAATTTCTCCCTCTCCACCA 
2401 ----------------- + ------------------+ ------------------+------------------+ ------------------+ ------------------- + 2460
CCCAGTGGGGAATGGAGGCCACAGGGAGGGGTCGGGGATTCCTCACCGTCCTGCCAGGGA 
2461 ----------------- + ------------------+ ------------------+ ------------------+ ------------------+ ------------------- + 2520
GATTGGTGTGAGGCTGGGGCTGGGCTGGGCTGATCCGGAGAATTTGGGATGAGAGCAGGG 
2521 ----------------- +------------------+ ------------------+ ------------------+ ------------------+ ------------------- + 2580
AGACTTGGTGCTGGGCTAGCTGGCAGGAGGAGGACACTGAAGGATGTTTCCCAGCACCAA 
2581 ----------------- + ------------------+ ------------------+ ------------------+ ------------------+ ------------------- + 2640
AGTC TG AGGGCTGC C TC C CGCTC CC CGG ATAGGCGAC AAC TGTATCC AGAAAATC TATC A 
2641 ----------------- + ------------------+ ------------------+ ------------------+------------------+------------------- + 2700
GGAAC TGGC C TTC AGCC GC C C TC AAC AGTAC AC C AGC ATC GTGGC GGAGC TC C TGTTGAA 
2701 ....... +-------+--------- +--------- +--------- +----------+ 2760
TGC GGAAC TGTC GCCAGATGC CATC AAGGC C AAC TC TATGGAAC TC AC TGC AGGGAGCGT 
2761 ---------+--------- +--------- +--------- +--------- +----------+ 2820
GGACACGGTCAGGCCGGCAACCAGCCCCACCCAGAGAGGGTGATGCCAAGCCTGCCTCCC 
2821  f------------------- h-------------------h------------------ + ------------------+ ------------------- + 2880
174
<< O lig o  5 >
AGGCACTGCCTGCCAATGTCACACGGCGCCCACGTGTCCCATGCCCAGGCTATGGGCCCC 
2881 ----------------- + ------------------ + ------------------+ ------------------+ ------------------+ ------------------ + 2940
ACATTTCTTACTTGGGATTGTGATGTGATAAACACGTTTGCAGGTTGCCATGGTTGGAAT 
2941 ----------------- + ------------------ + ------------------+ ------------------+ ------------------+ ------------------ + 3000
GGGGGGTTCCTTTCCTTCTGTGGAGGACTCAGGGAAACGGGGTTTGGATGGGCATTAGGA 
3001 ----------------- + ------------------ + ------------------+ ------------------+ ------------------+ ------------------ + 3060
TTTGAAGTCTTGGGCTCTGTCGTGCTCAGGGTATGCATGTCTGCACCCCTCACAGGGAGG 
3061 ----------------- + ------------------ + ------------------+ ------------------+ ------------------+ ------------------ + 3120
< O l ig o  6A
TTGTCCTGGGAGGGGTGTCCCGGGGGCTGAGTCCTCCTGTGCAAGGTCTGACCCTGCAGC 
3 1 2 1 ------------------ + ------------------+ -----------------+ ------------------+ ------------------+ ------------------ + 3180
> >
TGTGTCTCCTGCAGACGGTGTTTCCCTTGCTGATGACGCTCTTTGAGCTGGCTCGGAACC 
3181 ----------------- + ------------------- + -----------------+------------------+------------------+ - - -  + 3240
CCAACGTGCAGCAGGCCCTGCGCCAGGAGAGCCTGGCCGCCGCAGCCAGCATCAGTGAAC 
3241 ---------+----------+-------- +--------- +--------- +--------- + 3300
ATCCCCAGAAGGCAACCACCGAGCTGCCCTTGCTGCGTGCGGCCCTCAAGGAGACCTTGC 
3301 ----------------- +------------------- +-----------------+------------------+------------------+ ------------------ + 3360
GGTGGGTGCTGGCTGAGGCCTCCCTGTGGCCCTGGCCCTGCTGGAGAGTCAGCCCCCACT 
3361 ----------------- + ------------------- + -----------------+ ------------------+ ------------------+ ------------------ + 3420
GGGTGGTTGCAGACAGAATCTGGGCTATAAACACCTACCCAGCAGCCATCCTGACTGCTC 
3421 ----------------- + ------------------- + -----------------+ ------------------+ ------------------+ ------------------ + 3480
TCTCGCGTCAAGGACAGGGAGCTCTTCTTCCTCTGGAATCCCTCTTCAACGCCCTGGGGA 
3481 ----------------- + ------------------- + -----------------+ ------------------+ ------------------+ ------------------ + 3540
TTAACGTGGGGGCATGTCCTTCTGCGCTCGGGGCTGCTTAAGTTAGGGGAGGTTTGGCCG 
3541 -----------------+ ------------------- + -----------------+ ------------------+ ------------------+ ------------------ + 3600
GGCTCAGCAGGTGCAAGGAAGCACTTCCTACACCTGGGCTTCCCATGGATCTGGGACCTC 
3601 -----------------+ ------------------- + -----------------+ ------------------+ ------------------+ ------------------ + 3660
TGCGGGGTCTTCGGTAGGAAGGGTGCAGAGAGCACAGGAACCCCATCCCAGCTGAGACCC 
3661 ---------+----------+-------- +--------- +--------- +--------- + 3720
TTTCTATGGATGCCCCCACCTCCAGGCTCTACCCTGTGGGTCTGTTTCTGGAGCGAGTGG 
3721 ---------+----------+-------- +--------- +--------- +--------- + 3780
CGAGCTCAGACTTGGTGCTTCAGAACTACCACATCCCAGCTGGGGTGAGTGAGCCCCACA 
3781 ---------+----------+-------- +--------- +--------- +--------- + 3840
CCCTCGAGCTGAGAACCTCCCTCCCCAGTCATTCCCTGATCCCCGCTCTGCTCCGTCCGC 
3841 ---------+----------+-------- +--------- +--------- +--------- + 3900
AGACATTGGTGCGCGTGTTCCTCTACTCTCTGGGTCGCAACCCCGCCTTGTTCCCGAGGC 
3901 ---------+ + --------- +--------- +--------- +--------- + 3960
CTGAGCGCTATAACCCCCAGCGCTGGCTAGACATCAGGGGCTCCGGCAGGAACTTCTACC 
3961 ---------+----------+-------- +--------- +--------- +--------- + 4020
ACGTGCCCTTTGGCTTTGGCATGCGCCAGTGCCTTGGGCGGCGCCTGGCAGAGGCAGAGA
175
4021
4081
4141
4201
4261
4321
4381
4441
4501
4561
4621
4681
4741
4801
4861
4921
4981
5041
5101
5161
5221
4080
4140
4200
4260
4320
4380
4440
4500
4560
4620
4680
4740
4800
4860
4920
4980
5040
5100
5160
5220
TGCTGCTGCTGCTGCACCATGTGAGCAGGCCCGGGGAATTCTGGGCCTGGGCTGTAAGGT 
 + ------------ + -----------+ ----------- + ------------ + ----------- +
GGGGCTGGTCAGGAATGAAACAGGTTGGAGGCCAGGCTGCTGTTCCCCCTTCAGCATAAT 
 + ------------+ -----------+ ----------- + ------------ + ----------- +
CTCTGCAACTTTGAGGGTCTGAGAAGGCTGCACCACGTCGATGGGCTGCGGACCAAGCCA 
 + ------------+ -----------+ ----------- + ------------ + ----------- +
GATGGAAACCCGGCTTCTGTCCTAGGTGCTGAAACACCTCCAGGTGGAGACACTAACCCA 
 + ----------- + ---------- +-----------+----------- +---------- +
AGAGGACATAAAGATGGTCTACAGCTTCATATTGAGGCCCAGCATGTGCCCCCTCCTCAC 
 +----------- +---------- + -----------+ ----------- +---------- +
CTTCAGAGCCATCAACTAATCACGTCTCTGCACCCAGGGTCCCAGCCTGGCACCAGCCTC 
 + ------------ + -----------+ ----------- + ------------ + ----------- +
CCTTTCTGCCTGACCCCAGGCCACCCCTCTTCTCTCCCACATGCACAGCTTCCTGAGTCA 
 + ------------ + -----------+ ----------- + ------------ + ----------- +
CCCCTCTGTCTAACCAGCCCCAGCACAAATGGAACTCCCGAGGGCCTCTAGGACCAGGGT 
 + ------------------------ +  - - --------------------------+ --------------------------- + ---------------------------- + --------------------------+
TTGCCAGGCTAAGCAGCAATGCCAGGGCACAGCTGGGGAAGATCTTGCTGACCTTGTCCC 
 +--------------+------------ +------------- +--------------+-------------+
CAGCCCCACCTGGCCCTTTCTCCAGCAAGCACTGTCCTCTGGCAGTTTGCCCCCATCCCT 
 + --------------------------------- + ------------------------------ + -------------------------------- + --------------------------------+ -------------------------------- +
CCCAGTGCTGGCTCCAGGCTCCTCGTGTGGCCATGCAAGGGTGCTGTGGTTTTGTCCCTT 
 + ------------+ -----------+ ----------- + ----------- + ------------+
GCCTTCCTGCCTCTAGTCTCACATGTCCCTGTTCCTCTTCCCCTGCCAGGGCCCCTGCGC 
 + -------------+ ------------+ ------------ + ------------ + ------------ +
AGACTGTCAGAGTCATTAAGCGGGATCCCAGCATCTAGAGTCCAGTCAAGTTCCCTCCTG 
 + ------------ + -----------+ ----------- + ----------- + ------------+
CAGCCTGCCCCCTAGGCAGCTCGAGCATGCCCTGAGCTCTCTGAAAGTTGTCGCCCTGGA 
 + ------------ + -----------+ ----------- + ----------- + ------------+
ATAGGGTCCTGCAGGGTAGAATAAAAAGGCCCCTGTGGTCACTTGTCCTGACATCCCCAT 
 + ------------ + -----------+ ----------- + ----------- + ------------+
TTTCAAGTGATACAACTGAGTCTCGAGGGACGTGTGTTCCCCAGCTGATCGTGTCAGCCT 
 + ------------+ -----------+ ----------- + ----------- + ------------+
CATGCCCCTGGCCTCATCTTTCATGGACCAGGCCTTGTTCCAGGAGTGGGCGTTGGGTCC 
 + ------------ + -----------+ ----------- + ----------- + ------------+
TCTGCTTCCTGTGCTGTCCCCTGGGGAAGGTCCCAAGGATGCTGTCAGGAGATGGAAGAG 
 +--------- +-------- +--------- +--------- +--------- +
TCATGTGGGGTGGGAACCTGGGGTGTGGTTCCAGAAATGTTTTTGGCAACAGGAGAGACA 
 + ------------ + -----------+ ----------- + ----------- + ------------+
GGATTGGGCCAACAAGGACTCAGACGAGTTTTATTGACTATTCTCTGACA 
----------------- + ------------------- + -----------------+ ------------------+  + 5270
176
CYP11B2
Oligo 2524 >>
’TGTC TACATGTGTT CAAAACCCAC AGCATGTTGA CCACCAGGA GGAGACCCCAT
---+ ---------+ ---------+ ---------+ ---------+ ---------+
51 GTGACTCCAG GGCCCCTGGT TGATAACAAC GTATCGAGAT TCCTCACATG
---------+ ---------+ ---------+ ---------+ ---------+
101 GAACCAGTGC GCTTCTGTGG TGGAGGGTGT ACCTGTGTCA GGGCAGGGGG
---------+ ---------+ ---------+ ---------+ ---------+
151 TACGTGGACA TTTTCTGCAG TTTTTGATC A ATTTTGCAAT GAACTAATCT
---------+ ---------+ ---------+ ---------+ ---------+
201 CTGGTATAAA AATAAAGTCT ATTAAAAGAA TCCAAGGGGC CCTCTCATCT
---------+ ---------+ ---------+ ---------+ ---------+
251 CACGATAAGA TAAAGTCCCC ATCCATTTTG CTCCTCTCAG CCCTGGAGAA
---------+ ---------+ ---------+ ---------+ ---------+
301 AGGAGAGGCC AGGTCCCACC ACCTTCCACC AGCATGGACC CCCAGTCCAG
---------+ ---------+ ---------+ ---------+ ---------+
351 ACCCCACGCC TTTTCTCAGC ATCCTCAGAC CAGCAGGACT TGCAGCAATG
---------+ ---------+ ---------+ ---------+ ---------+
401 GGGAATTAGG CACCAGACTT CTCCTTCATC TACCTTTGGC TGGGGGCCTC
---------+ ---------+ ---------+ ---------+ ---------+
451 CAGCCTTGAC CTTCGCTCTG AGAGTCTCAG GCAGGTCCAG AGCCAGTTCT
---------+ ---------+ ---------+ ---------+ ---------+
501 CCCATGACGT GATATGTTTC CAGAGCAGGT TCCTGGGTGA GATAAAAGGA
---------+
<<
---------+ ---------+
Oligo 2523
---------+
>
---------+
551 TTTGGGCTGA ACAGGGTGGA GGGAGCATTG GAATGGCACT CAGGGCAAAG
---------+ ---------+ ---------+ ---------+ ---------+
601 GCAGAGGTGT GCGTGGCAGC GCCCTGGCTG TGCCTGCAAA GGGCACGGGC
---------+ ---------+ ---------+ ---------+ ---------+
651 ACTGGGCACT AGAGCCGCTC GGGCCCCTAG GACGGTGCTG CCGTTTGAAG
701 CCATGCCCCA GCATCCAGGC AACAGGTGGC TGAGGCTGCT GCAGATGTGG
751 AGGGAGCAGG GTTATGAGCA CCTGCACCTG GAGATGCACC AGACCTTCCA
801 GGAGCTGGGG CCCATTTTCA GGTAAAGCCC TCCCTGGCCC TCGCTGGGAA
851 CACCCAGATC CCTCCCCCTG CTGCCCAGGA CACTGCCAGG CACTCAGCAC
---------+
901 TGCCATTCCC AGCAGGTCCC GGCACTCTGC ATCCTTTGGA GGATGGGGAA
---------+ ---------+ ---------+ ---------+ ---------+
951 GGAGTGCAGC ACATGCTGGT CTGTGGTGCT GCCAGGGCAG GGGATAGTGC
177
1001
1051
1101
1151
1201
1251
1301
1351
1401
1451
1501
1551
1601
1651
1701
1751
1801
1851
1901
1951
---------+ ---------+ ---------+ ---------+ ---------+
AGAGAAAACC CCAGCTCACT GCAGAGAGGG CAGGACTCAG AAGCACTAAA
---------+ ---------+ ---------+ ---------+ ---------+
GTTGAAAGGT TCCAGGGAGC CAGCAGGAGG GCTTTAGCTG TGAAGCCGCT
---------+ ---------+ ---------+ ---------+ ---------+
AATCCAGGAG CAGGGAGGGT GGACAGGAGA CACTTTGGAT TGGGACTGCA
---------+ ---------+ ---------+ ---------+ ---------+
GGGTGGGGCC ACGAGGGACA TGACCCCGTC CAGCAGGGCC TCCTGCTTGG
---------+ ---------+ ---------+ ---------+ ---------+
CCCCACAGGT ACAACTTGGG AGGACCACGC ATGGTGTGTG TGATGCTGCC
---------+ ---------+ ---------+ ---------+ ---------+
GGAGGATGTG GAGAAGCTGC AACAGGTGGA CAGCCTGCAT CCCTGCAGGA
---------+ ---------+ ---------+ ---------+ ---------+
TGATCCTGGA GCCCTGGGTG GCCATCAGAC AACATCGTGG GCACAAATGT
<< Oligo 2X >
GGCGTGTTCT TGTTGTAAGC GGCGAGTTGG GAGCTGAGAG CTGGGAGCAG
---------+ ---------+ ---------+ ---------+ ---------+
GGTGGGCAGC CTGGGTGTAG GGGGGAGGCG AGAGAGGTAG GACCCAAAAG
---------+ ---------+ ---------+ ---------+ ---------+
CACATCTGCC CTGGGCCCCT GTGGTGGGCA GTGAGGGTGA GCACCCGGCC
---------+ ---------+ ---------+ ---------+ ---------+
CAGAGGACGG CCATCCTGTG GGGTCGCGTC TGCACTGTGG GTTGGGGAAG
---------+ ---------+ ---------+ ---------+ ---------+
CAGGGCGGTG GTGGAGAAAT GGGCAGGGGC ACCTCTGCAG AGAAGACGCA
---------+ ---------+ ---------+ ---------+ ---------+
GAGCAATGAG CCCTTCTGTG TAGTGAGAAC CCGCTCTGCA CCAACCTCGG
---------+ ---------+ ---------+ ---------+ ---------+
CGGCTGCTTT CTCTTGCGGT CTGGGGACTC TCCTTCCCAT AGGTCAGAAA
---------+ ---------+ ---------+ ---------+ ---------+
ACTGAGGCCC TGAGAAGGGG ACTTCCACTG GCCCAGGTCA CAGGCTGAGT
---------+ ---------+ ---------+ ---------+ ---------+
ACTGAGCCTG GTGTTCGCCG GGGCCACAGC CTCCCTCAGG GCGCTCAGGG
---------+ ---------+ ---------+ ---------+ ---------+
TCCCTGCAGA ACAGGGGTCA CCTCCTTTCT TGGAGAAAAG CCCTACCCTG
---------+ ---------+ ---------+ ---------+ ---------+
TTACTACAGG GAGGGCCTGC ATGGGTGAGG TGGTGCCAGA CTTGGGTCGC
---------+ ---------+ ---------+ ---------+ ---------+
CAGGTCCCAG GAATGACCTC AGTTACCCTG TCAGCACCTG TGGGCAGAAG
---------+ ---------+ --------------- + --------------- + --------------- +
CTACAGTCTC ATCCCTGCTT AGACCTGAGC GGCCTTTGCC CAGCACCTGG
--------------- + --------------- + --------------- + --------------- + --------------- +
178
2001
2051
2101
2151
2201
2251
2301
2351
2401
2451
2501
2551
2601
2651
2701
2751
2801
2851
2901
2951
3001
AGGTCGCTCT GAGAAAAGGT CTGCAGCTCG AACACAAACA GGCAGCTTCT 
 +  +  +  +  +
ACCAGGGCCC CAGTCACTCC TGCAGGCCGA TTCCCCTTGG GTACAAGGAG
GATGGGATAC GGGGTCAGGG CCTGTGTCTT GCTGGGGCGG CCTCACAAGC
TCTGCCCTGG CCTCTGTAGG AATGGGCCTG AATGGCGCTT CAACCGATTG
CGGCTGAACC CAGATGTGCT GTCGCCCAAG GCCGTGCAGA GGTTCCTCCC
GATGGTGGAT GCAGTGGCCA GGGACTTTTC CCAGGCCCTG AGGAAGAAGG
---------+ ---------+ ---------+ ---------+ --------------- +
TGC TGCAGAA CGCCCGGGGG AGCCTGACCC TGGACGTCCA GCCCAGCATC
TTCCACTACA CCATAGAAGG TGTGGGCCAT GCGGGAAGGT CCAGCCCCAG
AGACCCTGGA GTGGCCAGGG ATGGGGATGG AGGACTGAAG GGAGTGTGGvj
GAGGCAGCCA GGAGGTCCGG GGCTGCCTTG TGCTCAGCAG TGCATCCTCC
CCGCAGCCAG CAACTTAGCT C TTTTTGGAG AGCGGCTGGG CCTGGTTGGC
--------------- + --------------- + --------------- + --------------- + --------------- +
CACAGCCCCA GTTCTGCCAG CCTGAACTTC CTCCATGCCC TGGAGGTCAT
GTTCAAATCC ACCGTCCAGC TCATGTTCAT GCCCAGGAGC CTGTCTCGCT
GGATCAGCCC CAAGGTGTGG AAGGAGCACT TTGAGGCCTG GGACTGCATC
TTCCAGTACG GTGAGGCCAG GGACCCGGGC AGTGCTATGG GGAAGGGACA
CCATGGGGGC CCAATTTCTC CCTCTCCACC ACCCAGTGGG GAATGGAGGC
CACAGGGAGG GGTCGGGGAT TCCTCACCTT CCTGCCGGGG AGATTGGTGC
GAGGCTGGGG CTGGGCTGGG CTGATCCGGA GAATTTGGGA TGAGAGCAGG
GAGATTTGGG TGTCGGGGCA GTCTCGGCAG GAGGAGGACA CTGAAGGATG
CTTCCCAGCA CCAAGATCTA GGGCTGTCCC CTGCTCCCTG TACAGGTGAC
AAC TGTATCC AGAAAATCTA CCAGGAACTG GCCTTCAACC GCCCTCAACA
--------------- + --------------- + --------------- + --------------- + --------------- +
179
3051
3101
3151
3201
3251
3301
3351
3401
3451
3501
3551
3601
3651
3701
3751
3801
3851
3901
3951
4001
4051
CTACACAGGC ATCGTGGCAG AGCTCCTGTT GAAGGCGGAA C TGTCAC TAG
---------+ ---------+ ---------+ ---------+ ---------+
AAGCCATCAA GGCCAACTCT ATGGAAC TCA CTGCAGGGAG CGTGGACACG
---------+ ---------+ ---------+ ---------+ ---------+
GTCAGGCCAG CAACCAGCCC CACCCAGAGA GGGTGATGCC AAGCCCTGCC
---------+ ---------+ ---------+ ---------+ ---------+
TCCCAGCACT GCCTGCCAAT GCCACACGGC ACCCACGTTC CCCATCCCCA
---------+ ---------+ ---------+ ---------+ ---------+
GGCTACAGGC CCCACATTTC TGTTGCCCTC AGCCTTCCCC CTCCTTTGTT
---------+ ---------+ ---------+ ---------+ ---------+
AAGGGATGAG ATTTGCAGGG GAGGGGAAAT GTGAGCTCCC CCTCACATGA
+
<< Oligo 5N >
+
GACTGAGTTT GCAGTTACCT GTGTGGGGAT CCATGCTCCA GGCTGGAAGA
---------+ ---------+ ---------+ ---------+ ---------+
AAGTTGGATG AGGCCCTGGA CACACAGCAG CTCTGTCCCC ACTGGAAAGC
---------+ ---------+ ---------+ ---------+ ---------+
TCTGGGTGTA CAAGGAGAAG GAGGGTTGAG AGGCAGCTGG AGGACTCCAC
---------+ ---------+ ---------+ ---------+ ---------+
TGGGCACCCT TCCCAGTGTG CCCGGTCACC TTGGGCCAGA AATGTACATG
---------+ ---------+ ---------+ ---------+ ---------+
CATGGGAGGG CAGGGTTGTG GGGAAGGCAG CAGCACGGGC TCCAGCCAGT
---------+ — ---------+ ---------+ ---------+
GCAGAGGGGC CTGTGGGTGC ACAGTGGGGA GAACTCAATG GAAGCAGAGG
---------+ ---------+ ---------+ ---------+ ---------+
GAGCTGGGGC TCCAGAACTC CCAGGATGAT GCTGAGGTCT GGCCCCCTTT
---------+ ---------+ ---------+ ---------+ ---------+
TCTAAGGTGG CTGTGAGAAC CCGCCTGAAG AGGCTGCAGG GGACCTGGGC
---------+ ---------+ ---------+ ---------+ ---------+
CTTGGTGGAG ATGGGGGTC A GCTTTGCGTG AAGAAGTCAG GGAATCTGGC
---------+ ---------+ ---------+ ---------+ ---------+
CCAAGTGGTC ATCAAGGTTT CAGATCCGGC GTCCCAGGGC TCTGTCGTGC
TCAGGGCATG GATGTCTCCA CCCCTCAGAG GGAGGTTGTC CTGGCTGGGG
---------+ ---------+ ---------+ ---------+ ---------+
TGTCCCGGGG GCTGAGTCCT CCTGTGCAAG GTCAGACCCT GCAGACATGG
CTTCTGTAGA CAGCGTTTCC GTTGC TGATG ACGCTCTTTG AGCTGGCTCG
---------+ ---------+ ---------+ ---------+ ---------+
GAACCCCGAC GTGCAGCAGA TCCTGCGCAA GGAGAGCCTG GCCGCCGCAG
CCAGCATCAG TGAACATCCC CAGAAGGCAA CCACCGAGCT GCCCTTGCTG
180
4101
4151
4201
4251
4301
4351
4401
4451
4501
4551
4601
4651
4701
4751
4801
4851
4901
4951
5001
5051
5101
CGGGCGGCCC TCAAGGAGAC CTTGAGGTGG GTGCTGGATG AGGCCTCCCT
GTGGCCCTGG CCCCCTGCTG GAGAGCAGCC CCCACTGGGT GGTGGCAGAC
--------------- + --------------- + --------------- + --------------- + --------------- +
AGAATCTGGG GCTGATAAAC AGCGTCACCC AGCAGCCCAT TCCCCTGCAC
--------------- + --------------- + --------------- + --------------- + --------------- +
CTGCTCTTCC TCCCCCTCAA GGTCTGGGAG CTCTTCTTCC TCTGAATCCC
--------------- + --------------- + --------------- + --------------- + ----------------+
TCTTCAACAC CCTGGGGATT AACGTGGGGC ATGTCCTTCT GCGCTTGGGG
--------------- + --------------- + --------------- + --------------- + --------------- +
CTTCTCAAGT TAGGGGAGGT TTGGCTGGGC TCAGCAGGTG CAAGGAAGCA
--------------- + --------------- + --------------- + --------------- + --------------- +
CTTCGTCACG ACCTGGGCTT CCCATGGGCC AGGGAGCTGT GCGGGGTCTT
--------------- + --------------- + --------------- + --------------- + --------------- +
CGGTAGGAAG GGTGCAGAGA GCACAGGGAG CCCCATCCAG CTGAGGACCC
TTTCTGTGGA TGCCCCCACC TCCAGGCTCT ACCCTGTGGG TCTGTTTTTG
GAGC GAGTGG TGAGCTCAGA CTTGGTGCTT CAGAACTACC ACATCCCAGC
TGGGGTGAGT GAGCCCCCAC ACCCCTCGAG CTGAGAACCT CCCTCCCCAG
TCATTCCCTG ATCCCTGCTC TGCACCGTCC GCAGACATTG GTACAGGTTT
TCCTCTACTC GCTGGGTCGC AATGCCGCCT TGTTCCCGAG GCCTGAGCGG
TATAATCCCC AGCGCTGGCT AGACATCAGG GGCTCCGGCA GGAAC TTGCA
--------------- + --------------- + --------------- + --------------- + --------------- +
CCACGTGCCC TTTGGCTTTG GCATGCGCCA GTGCCTCGGG CGGCGCCTGG
CAGAGGCAGA GATGCTGCTG CTGCTGCACC ACGTAAGCAG GCCTGGGCCC
CTTCAGCATA ATTGTTGCAC CTGGGACGAT GGGAGGAAGC TGCCCCAGGT
CCATGGGCTA CTGACCAGGC CTGATGGAAA CCCAGCCTCT GTCCTAGGTG
CTGAAGCGCT TCCTGGTGGA GACACTAACT CAAGAGGACA TAAAGATGGT
CTACAGCTTC ATATTGAGGC CTGGCACGTC CCCCCTCCTC ACTTTCAGAG
--------------- + --------------- + --------------- + --------------- + --------------- +
CGATTAACTA GTCTTGCATC TGCACCCAGG GTCCCAGCCT GGCCACCAGC
--------------- + --------------- + --------------- + --------------- + --------------- +
181
5151
5201
5251
5301
5351
5401
5451
5501
5551
5601
5651
5701
5751
5801
5851
5901
5951
6001
TTCCCTCTGC CTGACCCCAG GCCACCTGTC TTCTCTCCCA CGTGCACAGC
<< Oligo CC >
TTCCTGAGTC ACCCCTCTGT CCAGCCAGCT CCTGCACAAA TGGAACTCCC
---------+ ---------+ ---------+ ---------+ ---------+
CAGGGCCTCC AGGACTGGGG CTTGCCAGGC TTGTCAAATA GCAAGGCCAG
---------+ ---------+ ---------+ ---------+ ---------+
CGCACAGCTG GAGCGATCTT GCTGCAGGCC TGCCTTGTCC CCAGCCCCAC
---------+ ---------+ ---------+ ---------+ ---------+
CTGGCCCCTT CTCCAGCAAG CAGTGCCCTC TGGACACTTG ACTCTACTCC
---------+ ---------+ ---------+ ---------+ ---------+
TCCCAGCGCT GGCTCCAGGC TCCTCATGAG GCCATGCAAG GGTGCTGTGA
---------+ ---------+ ---------+ ---------+ ---------+
TTTTGTC C C Z DTTGCCTTCC TGCFINDCTA GTCTCACATG TCCCTGTCCC
---------+ ---------+ ---------+ ---------+ ---------+
TCTCGCCCTG GCCAGGGCCT CTGTGCAGAC AGTGTCAGAG TCATTAAGCG
---------+ ---------+ ---------+ ---------+ ---------+
GGATCCCAGC ATCTCAGAGT CCAGTCAAGT TCCCTCCTGC AGCCTGACCC
---------+ ---------+ ---------+ ---------+ ---------+
CAGGCAGCTC GAGCATGCCC TGAGCTCTCT GAAAGTTGTC ACCCAGAAAT
---------+ ---------+ ---------+ ---------+ ---------+
ACGATCCTGC AGGGTAGACT AAAAAGGCCC CTGTGGTCAC TTATACTGAC
---------+ ---------+ ---------+ ---------+ ---------+
ACATTTTAAG TGATACAACT GAGTCTCGAG GGGCGTGTGT TCCCCAGCTG
---------+ ---------+ ---------+ ---------+ ---------+
ATCATGTCAG CCTCATGCCC CAGGCCTCGT CTTTCATGGA CCAGGTCTTG
---------+ ---------+ ---------+ --------------- + --------------- +
TTCAAGCAGC GAGTGTTGGG TCCTCTGCTT CCTGAGCTGT CCCCTGGAAA
--------------- + --------------- + --------------- + --------------- + --------------- +
AGGTCCCGAG GATGCTGTCA GGAGATGGAA GAGTCATGTG GGGTGGGAAC
--------------- + --------------- + --------------- + --------------- +
CTGGGGTGTG GTTCCAGAAA TGTTTTTGGC AACAGGAGAG AC AGGATTGG
--------------- + --------------- + --------------- + --------------- + --------------- +
GCCAACAAGG ACTCAGATGA GTTTATTGAC TCATTCCTCT GGAAGATACG
CAGC
+
182
CYP11B2 promoter region
The 5'-untranslated flanking region of CYP11B2 containing the -340C/T 
polymorphism is listed below. The sequence strands -340C and -340T denote the 
sequence between -452 to -383 containing either a C or T at -340. Restriction sites 
for the enzyme Haelll are marked in bold at the site i.e. GGCC.
< Oligo 2524 >>
TTTGTC TACATGTGTT CAAAACCCAC AGCATGTTGA CCACCAGGA GGAGACCCCAT GTGACTCCAG
GGACCCTGGT TGATAACAAC GTATCGAGAT TCCTCACATG GAACCAGTGC GCTTCTGTGG TGGAGGGTGT 
ACCTGTGTCA GGGCAGGGGG TACGTGGACA TTTTCTGCAG TTTTTGATCA ATTTTGCAAT GAACTAATCT 
-340C
Haelll site 
< >
CTGGTATAAA AATAAAGTCT ATTAAAAGAA TCCAAGGGGC CCTCTCATCT CACGATAAGA TAAAGTCCCC
A
-340T C/T polymorphism
A
CTGGTATAAA AATAAAGTCT ATTAAAAGAA TCCAAGGGGT CCTCTCATCT CACGATAAGA TAAAGTCCCC
Haelll site 
< >
ATCCATTTTG CTCCTCTCAG CCCTGGAGAA AGGAGAGGCC AGGTCCCACC ACCTTCCACC AGCATGGACC
CCCAGTCCAG ACCCCACGCC TTTTCTCAGC ATCCTCAGAC CAGCAGGACT TGCAGCAATG GGGAATTAGG
Haelll site 
< >
CACCAGACTT CTCCTTCATC TACCTTTGGC TGGGGGCCTC CAGCCTTGAC CTTCGCTCTG AGAGTCTCAG
GCAGGTCCAG AGCCAGTTCT CCCATGACGT GATATGTTTC CAGAGCAGGT TCCTGGGTGA GATAAAAGGA
<< Oligo 2523 >
TTTGGGCTGA ACAGGGTGGA GGGAGCATTG GAATG
Start >
Haelll digest of the PCR product results in products of the following sizes:
-340T -340C
324 245
138 138
88 88
69
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APPENDIX V
Data for patients studied in this thesis
A) Patients with GSH
Mean arterial 
blood pressure 
(mm Hg)
Serum
potassium
(mmol/l)
Plasma active 
renin 
concentration 
(uU/ml)
Plasma
aldosterone
concentration
(pmol/ll)
Normal range 3.6-5.1 5-50 140-500
Individual
1-11-1 155 3.4 1 904
1-11-2 124 3.6 1 971
1-111-1 94 3.9 1 666
1-111-2 76 4.6 1 662
1-III-3 70 4.4 4 452
2-11-1 120.5 4.2 1503
2-111-1 124 3.7 3 1288
2-III-2 139 4.4 1 1266
2-IV-1 82 4.2 0 688
2-IV-2 80 4.6 1 648
3-1-1 136 4.2 1 596
3-11-1 144 3.7 1 1100
4-11-1 153 2.8 1 2466
4-111-1 113 3.0 1 971
4-III-2 113 3.4 2 956
5-1-1 120.5 3.6 4 583
5-11-1 170 3.3 1 1248
5-II-2 155 2.8 1 832
5-II-3 115 3.9 1 1806
Data at presentation, n=19.
Individuals are identified by their kindred identifier as described in figure 3.3 a
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B) ACTH infusion data
Below are listed the steroid biochemical data obtained from the ACTH infusion 
studies carried out in Chapter 6.
1) Plasma aldosterone response to ACTH
Time
(mins)
0 15 30 45 60 75 90
GSH 17.8 33.3 41 61 70.3 76.3 57.1
4.4 7.2 6.9 11.8 10.9 10.3 9.1
NT 9 6.8 12 21.2 23.4 32.4 28.2
2.2 2.1 2.5 4.0 2.6 5.2 4.4
HT 11.4 12.8 16.1 20.9 27.6 33.9 33.3
1.9 2.0 2.6 3.8 4.0 5.4 4.8
Conn's 35.7 28 32 50.7 70 88.7 82
4.9 8.3 7.4 10.3 18.6 15.9 18.4
Data are mean ± s.e.m. Units are ng/dl. To convert to pmol/l - divide by 0.0361
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension,
Conn - patients with aldosterone-secreting adenomata
2) Plasma corticosterone response to ACTH
Time
(mins)
0 15 30 45 60 75 90
GSH 97.4 218.7 367.3 612 783.3 999.3 1315
51 67 95 136 110 178 145
NT 266 218 478 790 1076 1483 1344
159 73 76 157 99 282 254
HT 227 242 380 646 847 942 1111
80 62 100 152 200 200 179
Conn's 293 274 351 722 972 1061 1286
130 175 134 113 65 50 39
Data are mean ± s.e.m. Units are ng/dl. To convert to pmol/l - divide by 0.0346
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension,
Conn - patients with aldosterone-secreting adenomata
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3) Plasma 11-deoxycorticosterone response to ACTH
Time
(mins)
0 15 30 45 60 75 90
GSH 11 17.7 26.7 33.3 50.7 54.7 84.9
2.9 5.0 7.6 11.2 16 14.8 16.8
NT 6.8 8.2 9.4 16.4 17.2 16.6 21.6
2.1 1.3 2.3 4.1 4.1 4.3 7.0
HT 7.6 8.4 9.5 14.3 20.3 21.3 23.9
2.0 1.8 1.8 2.8. 5.1 4.7 4.6
Conn's 16.7 19 16 37 56.7 53.3 63
0.3 3.6 2.6 13 17 19.1 20.8
Data are mean ± s.e.m. Units are ng/dl. To convert to pmol/l - divide by 0.033
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension,
Conn - patients with aldosterone-secreting adenomata
4) Plasma 11 -deoxycortisol response to ACTH
Time
(mins)
0 15 30 45 60 75 90
GSH 37.6 51.3 120.3 145.7 181.3 204 230
7.9 11.8 47 25 11 6 14
NT 22.8 28 37.6 61.6 55.2 73.2 74.8
11 12.5 8.0 16.4 17.6 16.7 14.7
HT 32.8 41.9 53 110.8 109 118.5 168.5
11.1 12 17.4 26.8 24 25 31.5
Conn's 47.3 38.7 78.3 128.3 277 202.3 265
7.6 7.5 26.7 25.3 79 59 66.7
Data are mean ± s.e.m. Units are ng/dl. To convert to pmol/l - divide by 34.6
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension,
Conn - patients with aldosterone-secreting adenomata
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5) Plasma cortisol response to ACTH
Time
(mins)
0 15 30 45 60 75 90
GSH 285 426 491 570 639 721 747
26 49 54 59 59 70 35
NT 368 387 561 656 753 788 793
28 30 37 33 46 40 33
HT 402 454 548 654 763 783 838
31 35 48 48 45 43 42
Conn’s 414 452 498 602 680 719 803
5 51 23 19 48 55 50
Data are mean ± s.e.m. Units are nmol/l.
GSH - patients with GSH, NT - normotensive controls, HT - patients with essential hypertension, 
Conn - patients with aldosterone-secreting adenomata
C) Left ventricular mass data
Patient LVIDd
(cm)
PWTd
(cm)
IVSTd
(cm)
LVM
(gram)
Height
(cm)
Weight
(kg)
BSA
(m2)
LVMI
(g/m 2)
2-IV-1 4.14 0.80 0.72 104.02 141 33 1.15 90.61
2-IV-2 4.05 0.82 0.70 99.69 110 19 0.76 131.46
2-11-1 4.10 0.80 0.71 101.10 158 54 1.54 65.78
2-111-1 5.21 1.02 1.09 252.10 182 75 1.96 128.75
2-III-2 4.83 0.88 1.07 197.85 167 60 1.67 118.25
1-11-1 4.30 1.10 1.20 205.89 178 80 1.98 103.97
1-11-2 5.19 1.08 1.11 264.33 179 77 1.96 135.11
1-111-1 5.08 0.98 0.90 206.19 180 82 2.83 72.83
3-1-1 3.25 0.86 0.99 89.59 166 68 1.76 50.99
3-III-2 4.56 0.95 1.13 195.84 179 72 1.90 103.00
3-11-1 4.80 1.00 1.10 217.46 177 88 2.05 105.88
LVIDd - diastolic left ventricular internal diameter, PWTd - diastolic posterior left ventricular wall 
thickness, IVSTd - diastolic ventricular septal thickness, LVM - leftventricular mass, BSA - body 
surface area, LVMI - left ventricular mass index.
Echocardiographic measurements for calculation of left ventricular mass in 11 
patients with GSH (Chapter 7).
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